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ABSTRACT 
Enzymes are exceptional biocatalysts capable of performing a wide range of 
reactions in all kinds of organisms. Some of them seem to work in rather mysterious 
ways, but science as evolved much since the first days when they were discovered and 
now there are several methods, both experimental and computational, that can be 
employed to study such remarkable molecules. 
For this manuscript, we focused mostly on enzymes that are involved in the 
synthesis of other molecules, either fatty acids, cholesterol or aspartate. In common they 
have the fact that the study of their structure, mechanism of reaction and active site can 
help in the development of drugs that can be used in the treatment of some disease. 
These studies were done using theoretical and computational methods, which, albeit 
being fairly recent, have some advantages over experimental methods, such as the fact 
that they are capable of characterizing transition states. With the development of 
technology to the level it is currently, so did these methods evolve and keep evolving, 
thus allowing us to perform more accurate calculations in a smaller amount of time. 
Using computational methods, we have studied several enzymes and concluded 
that nowadays these methods enable us to collect a wide array of data that would take 
a lot longer to gather by other methods. We were able to test and explore several different 
things, such as what is the reaction mechanism of the enzyme L-asparaginase, what 
residues of the interface of HMG-CoA-R are important to the formation of the tetramer 
or how the KS module begins the synthesis of a fatty acid molecule. 
The results obtains throughout these studies can be used in future works to 
develop new drugs to fight diseases like hypercholesterolemia and cancer, by either 
searching for different molecules to inhibit the enzyme or engineering a protein we know 
has some effect against that disease in order to improve it. 
 
Keywords: Enzymatic catalysis, HMG-CoA Reductase, lipids, cholesterol, 
QM/MM methodology, density functional theory, molecular modeling, quantum 
mechanics. 
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RESUMO 
As enzimas são biocatalizadores extraordinários capazes de realizar uma grande 
variedade de reacções químicas nos mais diversos organismos. Algumas parecem 
mesmo funcionar de forma mística, mas a ciência também foi evoluindo desde que estas 
foram descobertas e actualmente temos à nossa disposição variados métodos; tanto 
experimentais como computacionais, que pode ser utilizados para estudar estas 
moléculas notáveis. 
Neste manuscrito focamo-nos especialmente em enzimas envolvidas na síntese 
de outras moléculas: ácidos gordos, colesterol ou aspartato. O ponto comum entre elas 
é que o estudo da sua estrutura, mecanismo de reacção e centro activo pode ajudar no 
desenvolvimento de novos medicamentos passíveis de ser utilizados no tratamento de 
algumas doenças. Estes estudos foram feitos recorrendo a métodos teóricos e 
computacionais, os quais, apesar de serem significativamente recentes, apresentam 
algumas vantagens comparativamente aos métodos experimentais, tais como o facto 
de serem capazes de caracterizar estados de transição. Com o desenvolvimento 
tecnológico que se tem verificado actualmente, estes métodos também vieram a evoluir, 
o que nos permite realizar cálculos cada vez mais precisos num espaço de tempo cada 
vez menor. 
Usando métodos computacionais, foi-nos possível estudar diversas enzimas e 
concluir que actualmente estes métodos permitem-nos chegar a uma variedade de 
informações diferentes, as quais iriam levar muito mais tempo a recolher com outros 
métodos. Foi-nos, desta forma, possível testar e explorar diversas coisas diferentes, tais 
como o mecanismo de reacção da L-asparaginase, quais os resíduos da interface da 
enzima HMG-CoA-R são fundamentais para a formação do tetrâmero ou de que forma 
o módulo KS inicia a síntese de uma molécula de ácido gordo. 
Os resultados obtidos através destes estudos pode vir a ser usados no futuro para 
desenvolver novos medicamentos que nos permitam combater doenças como a 
hipercolesterolemia ou o cancro, usando estratégias como a procura de moléculas 
diferente capazes de inibir uma determinada enzima, ou melhorando uma enzima que 
já tenha actividade contra essa doença de forma a torna-la mais eficaz.  
 
Palavras-chave: Catálise enzimática, HMG-CoA Reductase, lípidos, colesterol, 
metodologia QM/MM, teoria do funcional da densidade, modelação molecular, mecânica 
quântica.
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CHAPTER 1 
FATS – THE GOOD, THE BAD AND THE UGLY 
1.1. The Biochemical Importance of lipids 
Life as we know exists possibly due to a lot of independent coincidences that we 
cannot currently explain. It assumes many forms, some as simple as a single cell and 
other so complex that, even now, after so much scientific progress, we can still look and 
wonder how such amazing beings and structures came into existence. In spite of all the 
different forms of life that we know about today, we can still find something common in 
all of them, like the fact that all living organism must have some kind of genetic material, 
be it in the form of DNA or RNA, and a lipid membrane separating the inside environment 
from the outside. 
All living organisms known today are carbon based, which means that the 
molecules that make up most of these beings have a carbon backbone. Most organic 
molecules essential for the correct functioning of a cell are composed of carbon, 
including protein, lipids, carbohydrates and nucleic acids. 
Proteins can be compared to small organic machines capable of preforming a wide 
array of tasks in the cell. They can be quite different from one another, and yet they are 
all composed of the same blocks: amino acids. These small molecules bind together to 
form bigger molecules and depending on the amino acid content of a protein, their forms 
and function also change. Protein function spans from simple tasks, such as allowing 
certain molecules or atoms to cross the cell membrane, to other much more complex, 
like producing energy or carrying organelles or vesicles inside the cell. Protein can also 
be broken down to provide energy, but this occurs only as a last resort, since cells 
typically have other methods of obtaining energy. 
Carbohydrates are thus called because they are made up of carbon, oxygen and 
hydrogen, and the ratio of oxygen to hydrogen is usually 1:2, like in water. In the cells, 
the major function of carbohydrates is to provide energy. They are the preferred energy 
source for many organisms, such as bacteria, and can either be used instantaneously 
or, in the case of mammals for example, stored in the form of glycogen. In humans, 
glucose is the primary source of energy used by the brain, and other indigestible 
carbohydrates, also called dietary fiber, help to regulate the gastrointestinal tract. 
Nucleic acids are also some of life’s most important molecules. They include both 
DNA and RNA, and without them it would be impossible for organisms to survive. Nucleic 
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acids are composed of smaller units called nucleotides, which can be assembled into 
huge macromolecules and carry all the information for protein assembly and the genetic 
instructions used in the development, functioning and reproduction of all known living 
organisms. RNA is a less stable molecules that is used as an intermediate between the 
DNA and the protein assembling mechanisms. Even though both DNA and RNA are 
composed of only four different nucleotides (cytosine, guanine and adenine and thymine 
in the DNA, whereas in RNA thymine is replaced by uracil), the different arrangements 
of this nucleotides in groups of three, called codons, forms the entire genetic code. 
Last, but not the least, we have the lipids, a much wider and diverse class of life 
molecules. Lipids include molecules such as fats, sterols, fat-soluble vitamins, mono-, 
di- and triglycerides, amongst many others. One of the few thigs all of them have in 
common is that they are either hydrophobic or amphiphilic. The amphiphilic nature of 
some lipids allows them to form vesicles that can be used to store and transport other 
cellular components. This dual nature enables them also to form the cell membranes 
that are so important for life sustenance, as they enclose the inside of the cell and 
separate the cytoplasm from the outside medium. Lipids can perform a myriad of other 
functions in the cells. They are used to store energy, anchor proteins to the membrane, 
help the folding of other membrane proteins, function as co-factors, among others. 
 
Table 1- Different types of lipids, organized in different categories according to their chemical structure, with 
some of their functions and examples. 
Lipid Category Functions Examples 
Fatty Acids Energy storage Oleate, stearoyl-CoA 
Glycerolipids Energy storage Di- and triacylglycerols 
Glycerophospholipids 
Cell membrane building 
blocks 
Phosphatidylcholine, 
phosphatidylserine 
Sphingolipds Cell protection Sphingomyelin 
Sterol Lipids 
Varied (ex: cell membrane 
structure, hormones) 
Cholesterol, bile acids 
Prenol Lipids 
Varied (ex: antioxidants 
agents) 
Farnesol, geraniol 
Saccharolipids Cell membrane structure Lipopolysaccharide 
Polyketides Varied (ex: antibiotic) Tetracycline, aflatoxin B1 
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Lipids can be divided in different categories according to their chemical structure 
(Table 1). Having into account that lipids can be very different from one another, they 
can also be grouped according to their function. In the following sections, we will further 
discuss their most important functions in the cells and in mammals. 
 
1.2. Fatty acids 
Maybe their best known function, being used as cell fuel is a very important task 
that lipids perform in many organisms. Fatty acids are the basic precursors of most lipids. 
Contrarily to proteins and nucleic acids, lipids do not have a monomers that come 
together in order to form large macromolecules. Instead, they start as a smaller lipid, 
usually fatty acids, that are joined to others but in small number (mostly 2 or 3 at a time) 
by a glycerol molecule. This gives rise to different classes of lipids, such as 
glycerophospholipids or triglycerides. Fatty acids can also be metabolized into other 
lipids.1 
 
 
Figure 1 – Structure of the palmitic acid as an example of the dual nature of fatty acids. In orange is represented 
the large aliphatic (hydrophobic) chain and in blue the carboxylic head group (hydrophilic). 
 
Fatty acids are composed of a long hydrocarbon chain attached to a carboxyl 
group. This causes the fatty acids to be amphiphilic in nature, having a hydrophilic head 
group and a lipophilic tail end (Figure 1). Their length can vary within the cells, but the 
most common fatty acids in the cells have either 14, 16, 18 or 20 carbon atoms. For 
storing energy, three fatty acid molecules are combined with glycerol, they form 
triacylglycerides, which are stored as fat droplets in the adipose cells. Whenever the 
organisms are in need of energy, and in response to hormones such as adrenaline, 
triacylglycerides are hydrolyzed in the cytosol and release the fatty acids into the blood. 
These, in turn are taken up by the cells and oxidized to CO2 to yield energy. 
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Even though the hydrophilic head of fatty acids is always the same, a carboxylic 
group, their lipophilic end can change in both size and saturation. Some other less 
conventional fatty acids can even have branched chains or contain carbon rings. Most 
naturally occurring fatty acids have a length that ranges from 12 to 24 carbons in a linear 
configuration. Double bounds are also frequent in some structures, and usually occur 
between the ninth and tenth carbon in monounsaturated fatty acids, and in the case of 
polyunsaturated fatty acids the other double bounds usually form between C-12 and C-
13, and C-15 and C-14. Double bounds rarely occur conjugated in polyunsaturated fatty 
acids (alternating between single and double bonds, as in –CH=CH–CH=CH–) but are 
frequently separated by a methylene group (as in –CH=CH–CH2–CH=CH–). Other 
common characteristic present in most naturally occurring unsaturated fatty acids is the 
fact that the double bonds are usually in the cis configuration. Trans fatty acids are a 
product of fermentation in the rumen of certain animals, and can be obtained in dairy 
products. 
The physical properties of fatty acids depend mostly on both their length and 
degree of saturation. 1 For example, solubility is dependent on the number of carbons in 
the structure; the larger the number, the less soluble the fatty acid is. This is easily 
understandable, since the only part of the fatty acid that is hydrophilic is the carboxylic 
group. If the chain is small enough, the fatty acid can have some solubility in water. 
However, since the carbon chain is completely hydrophobic, the larger it is, the smaller 
its solubility. 
Other property that varies greatly amongst fatty acids is their melting point. This 
property is not so much related to the length of the carbon chain but rather to its 
saturation degree. It is evident that the larger the fatty acid the higher its melting point 
will be, since larger molecules have a bigger contact area and therefore the number of 
Van der Waals interactions will also be bigger. On the other hand, in the case of saturated 
versus unsaturated fatty acids, if both have the same number of carbons, the saturated 
one will have the higher melting point. This too relates to the Van der Waals energy, but 
in this case it has to do with their ability to be packed. Saturated fatty acid are much more 
flexible and can therefore be packed much more neatly and tightly, forming almost 
crystalline arrangements (Figure 2a). Unsaturated fatty acids, contrarily, have a more 
rigid structure, resulting from the bend imposed by the double bond (Figure 2b). This 
results in their inability to form connections as tight as their saturated counterpart, 
meaning that the energy needed to melt them will be smaller.  
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Figure 2 – Representation of how the saturation level of fatty acids affects the way they are packed. (a) Saturated 
fatty acids can be packed more tightly and neatly, whereas when unsaturated fatty acids are also present (b) the 
bend in their structure makes it more difficult for them to organize in a neat structure. 
 
1.2.1. Fatty Acids as an Energy Source 
Fatty acids constitute the major source of energy in many tissues, and especially 
in the heart muscle. In humans, the oxidation of fatty acids is quantitatively more 
important than that of glucose, as a source of ATP. The reason for this is that fats are 
stored in a much more reduced form that carbohydrates. 
The conversion of fatty acids into energy (ATP) is called β-oxidation and occurs in 
the mitochondria2-3. A similar process occurs in the peroxisomes, although in this case it 
is not coupled to ATP production and is used as a means of shortening very long fatty 
acids (20+ carbon long) before these can be relocated to the mitochondria where β-
oxidation proceeds as usual (Figure 3). Since peroxisomes lack respiratory chain, 
contrarily to mitochondria, the energy produced during oxidation is dissipated as heat. 
Despite this major difference, both oxidative processes are basically identical, and are 
mediated by similar enzymes. They begin with the esterification of the fatty acid molecule 
to coenzyme A (CoA) in the cytosol, forming fatty acyl CoA. This initial reaction requires 
energy, meaning that a molecules of ATP is hydrolyzed to AMP. Next, the fatty acyl CoA 
is relocated to either the mitochondria or the peroxisome, where it undergoes several 
cycles of four reaction each. During each cycle the fatty acyl CoA is shortened by two 
carbons, which are converted into acyl CoA and the remaining fatty acyl CoA, with the 
generation of NADH and FADH2. 
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This process is repeated sequentially until all the fatty acid has been used. The 
complete oxidation of an 18-carbon fatty acid yields eight molecules of NADH and eight 
of FADH2 as well as nine molecules of acyl-CoA. The acyl-CoA produced during β-
oxidation then undergo the citric acid cycle and are oxidized to CO2. The FADH2 and 
NADH produced during both the citric acid cycle and the β-oxidation of fatty acids are 
used to create a proton-motive force, which in turn powers the synthesis of ATP. It is 
through this whole process that the cells create energy through lipids. 
 
 
Figure 3 – Schematic representation of the oxidation of fatty acids in both mitochondria and peroxisomes 
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1.2.2. Fatty Acids as Precursors to other Lipids 
1.2.2.1. Triacylglycerides 
As stated previously, lipids can take up many forms and play many different roles 
in the organism. Fatty acids are probably the most versatile of lipids, as they can be 
easily modified and transformed into different kinds of lipids or some other molecule. 
Fatty acids can bind to a molecule of glycerol to form triglycerides (Figure 4). The 
bond formed is an ester linkage in which three fatty acids are connected to a single 
glycerol. Triglycerides can contain only one type of fatty acid, in which case they are 
referred to as simple triglycerides, or they can be composed of a mix of different fatty 
acids.  
 
 
Figure 4 – Simplified representation of how a triglyceride is formed from three free fatty acid and a glycerol 
molecule.  
 
Triglycerides are mostly non-polar, because the polar carboxylates from fatty acids 
and the polar hydroxyls from glycerol are both bond in the ester linkage. This renders 
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the triacylglycerides practically insoluble in water. In mammals and other vertebrates, the 
triglycerides are stored in special cells called adipocytes, which in turn form adipose 
tissue. Since they are not soluble in the aqueous cytoplasm, stored fats form big droplets 
that occupy most of the adipocyte cell. 
Most organisms use fats as a form of stored energy because they present several 
advantages in comparison to polysaccharides: they are dehydrated, which means they 
can be stored without the organism having to carry around the extra weight of the water, 
which is needed in the case of polysaccharides, and also the oxidation of one gram of 
fat yields more than the double of the energy produced by the oxidation of one gram of 
carbohydrates1. For this reasons triacylglycerides are the primary molecule for storing 
energy, whereas carbohydrates are mostly used as a quick source of metabolic energy. 
For animals living in cold climates, these stored fats have the additional function of 
insulator, preventing the body from losing too much heat. 
 
1.2.2.2. Phospholipids and Glycolipids 
Another type of lipids that can be obtain from fatty acids are phospholipids and 
glycolipids. These types of lipids are vital for all organisms, as they are the main 
constituents that compose cell membranes. Although different in structure, both 
phospholipids and glycolipids have similar characteristics, and they both also contain 
one or more types of fatty acids in their structure. 
Cell membranes are very complex systems that separate the cells cytoplasm from 
the external medium, while still allowing for the transference of compounds from the 
inside to the outside and vice-versa, as well as carrying out other important functions. 
They comprise some very different components, although, in a simplistic way, they can 
be seen as composed essentially of a double layer of phospholipids. 
Membrane lipids are amphiphilic, which means that one of their ends is polar and 
hydrophilic and the other one is non-polar and lipophilic (Figure 5). It is this dual nature 
of membrane lipids that gives biological membranes their characteristic architecture, the 
double layer of lipids. Being amphiphilic, membrane lipids tend to interact in a way so 
that their lipophilic ends interact with each other and are oriented to the middle of the 
membrane, whereas the hydrophilic ends interact with the water in the environment or 
the aqueous cytoplasm. Membranes act as a barrier to prevent the passage of polar 
molecules from one side of the membrane to the other, and this architecture is indeed 
very efficient at accomplishing this task. 
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Figure 5 – Illustration of how phospholipids are arranged to form a phospholipid bilayer. Their head groups 
(polar) are oriented towards the outside so they can interact with the medium, while their tails (apolar) are on the 
inside and interact with each other to reduce unfavorable interactions. 
 
Membranes from most organisms are composed primarily of two different types of 
lipids: phospholipid and glycolipids (Figure 6). In phospholipids the polar head group is 
connected to the non-polar tail by a phosphodiester linkage. On the other hand, the 
hydrophobic head is composed of a simple sugar or a complex oligosaccharide. 
 
 
Figure 6 – Division of the different types of lipids that mainly compose the biological membranes of most 
organisms. 
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Phospholipids can be further divided in two different classes: glycerophospholipds, 
if they are derived from a glycerol molecule, or sphingolipids, if they are derived from 
sphingosine. Glycerophospholipids have two fatty acids attached to the first and second 
carbon of the glycerol molecule through an ester linkage. This constitutes the non-polar 
part of the phospholipid. The polar head is bound to the last carbon from glycerol and it 
comprises a highly polar or charged alcohol (some examples are choline and 
ethanolamine) linked via a phosphodiester linkage. At neutral pH, the hydrophilic head 
group can be either neutral, positively or negatively charged, which contributes to some 
of the properties of the cellular membrane. The fatty acids that constitute the lipophilic 
tail can vary significantly and can sometimes be specific for different organisms or 
tissues, but in general the C1 from glycerol contains either a C16 or C18 saturated fatty 
acid and the C2 contains a C18 or C20 unsaturated fatty acid. 
Contrarily to glycerophospholipds, sphingolipids do not derive from glycerol but 
rather from sphingosine (Figure 7). Sphingosine is an amino alcohol that contains a large 
aliphatic chain. Carbons C1, C2 and C3 of sphingosine are structurally similar to those 
of glycerol. The long aliphatic chain is attached to C3 and play the same role a fatty acid 
would play in a glycerophospholipid. C2 is connected to a nitrogen which is able to bond 
to a fatty acid through an amide linkage. Finally, C1 can bind different compounds. In the 
case of phospholipids, C1 binds choline through a phosphodiester linkage. The choline 
then becomes the polar head group of the phospholipid, whereas the aliphatic chain of 
sphingosine and the fatty acid constitute the hydrophobic tail group. 
 
 
Figure 7 – Sphingolipid structure: the blue part represents the sphingosine molecule, the yellow is a fatty acid 
that binds the nitrogen atom of the sphingosine and the X (green) can be different modifications (either a hydroxy 
or a variety of carbohydrate or phospholipid structures) 
 
Instead of choline, C1 can also bind one or more sugars directly to the –OH. This 
compounds are called glycosphingolipids and occur largely on the outer face on the 
plasma membrane. Since glycosphingolipids do not contain phosphate but they do 
comprise a hydrocarbon molecule they belong to the glycolipids group. 
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A different type of glycolipids is the galactolipids. These are predominant in plant 
cells and have one or two galactose residues connected to the C3 of a glycerol molecule 
by a glycoside linkage. Galactolipids are found mostly on the inner membrane of the 
chloroplast. 
 
1.2.3. Fatty Acid Synthesis 
While we can obtain a many fatty acids through the food we eat, our body and that 
of many organisms is also capable of synthetizing them from smaller molecules. Fatty 
acid synthesis is a rather complex process that requires various steps that occur 
cyclically. Even though the chemistry behind fatty acid synthesis is more or less 
conserved in all organisms, the enzymes that catalyze them can be somewhat different. 
For example, fatty acid synthesis in bacteria is catalyzed by several different enzymes, 
whereas in mammals it is accomplished by a single enzyme called fatty acid synthase 
(FAS)4. 
The process of fatty acid synthesis always begins with the same two molecules, 
acetyl and malonyl. Only one acetyl molecule is needed for the synthesis of one fatty 
acid, while the number of malonyl varies according to the final number of carbons in the 
fatty acid. Both acetyl and malonyl used in the biosynthesis of fatty acids derive from 
acetyl-CoA and malonyl-CoA respectively. NADPH is also needed to function as a 
reducing agent during this process. The complete reaction catalyzed by FAS is 
summarized in the following equation: 
 
Acetyl-CoA + 7 Malonyl-CoA + 
14 NADPH + 14 H  
Palmitic Acid + 7 CO2 + 8 CoA 
+ 
14 NADP+ + 6 H2O 
 
The mammalian FAS and the reaction catalyzed by it will be further discussed in 
chapter 7. 
 
1.3. Cholesterol: a Vital Molecule 
The cholesterol molecule is of vital importance to almost all forms of life known to 
date, especially for animals. However, due to its association with several heart diseases, 
cholesterol is currently perceived as a somewhat bad compound that needs to be 
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avoided at all costs. The truth is, in fact, that without cholesterol, life has we know it would 
not be possible. 
Cholesterol (Figure 8) is the major sterol present in animal tissues. It is amphiphilic, 
having both a hydrophobic hydrocarbon body and a hydrophilic head group which 
includes a hydroxyl group. Since it belongs to the sterol group, cholesterol is a structural 
lipid and can be found in the cellular membrane of most eukaryotic cells. It contains a 
steroid nucleus that consists of four fused rings, three of which have six carbons and one 
with five, a feature shared between all sterols. This nucleus is also characterized for 
being almost planar and rigid. 
In mammals, cholesterol plays a vital role and is considered an essential 
component for the proper functioning of our cells. Its roles range from component in cell 
membranes to precursor of several steroid hormones1. 
 
 
Figure 8 – Structure of the cholesterol molecule. 
 
The importance of cholesterol in cell membranes can be assessed by comparing 
the fluidity of membranes with more or less cholesterol. The polar head group of 
cholesterol interacts with the similar head group of the phospholipids, while the nonpolar 
group interacts with their hydrophobic tails. Since cholesterol is somewhat rigid, 
membranes with larger cholesterol content will tend to be more rigid and packed, while 
those with less cholesterol will be more fluid. Cholesterol is also important in other 
membrane processes, such as endocytosis1. 
In addition to being a structural component of membranes, cholesterol is also a 
precursor of natural steroid hormones produced in our body. These include hormones 
produced in the adrenal gland, male sex hormones and female sex hormones. The 
adrenal gland is located just above the kidneys and its main role is to produce and 
release two classes of hormones: corticosteroids and catecholamines (epinephrine and 
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norepinephrine). From these only the first is derived from cholesterol and it can be further 
divided into two other classes: mineralocorticoids and glucocorticoids. 
Mineralocorticoids, like aldosterone, are hormones related to the reabsorption of such 
ions as Cl-, Na+ and HCO3- by the kidney, therefore regulating the concentration of 
electrolytes in the blood. On the other hand, glucocorticoids, like cortisol, affect above all 
the metabolism of carbohydrates in the body, regulating the metabolism of glucose. 
Furthermore, sex hormones produced by male and female sex glands are also derived 
from cholesterol. These can be divided into androgens, such as testosterone, which are 
responsible for the development of male characteristics, and estrogens and 
progestogens, which are responsible for the development of female characteristics 
among other functions1. 
Other fates of the cholesterol molecule in our bodies are as precursor in the 
synthesis of bile salts and also in the synthesis of vitamin D1. 
Cholesterol present in our bodies derives from two different sources: it can either 
be synthesized de novo within our cells, or it can be obtained through ingestion of certain 
foods, such as beef and pork meat, eggs and cheese. Although many people regularly 
eat these foods, there really is no absolute need to ingest them for the sole purpose of 
obtain more cholesterol, since our own cells are capable of producing enough quantity 
of this molecule for everything our body needs5-6. Nonetheless, whether or not there is 
dietary intake of cholesterol, its levels are maintained through regulation of both 
synthesis and absorption, which means that when low quantities of cholesterol are 
ingested, absorption and synthesis will be up-regulated. Likewise, if dietary intake is high, 
its excretion will be increased7. 
Currently, cholesterol has gained a bad reputation next to the great majority of 
people, especially because of its association with cardiovascular diseases. According to 
the World Wealth Association (www.who.int), in the top 10 leading causes of death 
(worldwide) in 2008, ischemic heart disease (IHD) was number one, accounting for 
12.8% of total deaths, followed by stroke and other cerebrovascular disease as number 
two (10.8%). Since both of these diseases are associated with hypercholesterolemia, it 
is easy to understand why this molecule has such bad name. 
In a more direct way, cholesterol is related to atherosclerosis8, which is one of the 
main causes of both IHD, stroke and cerebrovascular diseases. Atherosclerosis is 
nothing more than the accumulation of fatty materials, such as cholesterol, on the walls 
of arteries. It is a complex process which involves a chronic inflammatory response on 
the walls of arteries to oxidized low-density proteins (LDL). LDL are very rich in 
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cholesterol and cholesteryl esters and, when oxidized, they are toxic to the cells on the 
walls of blood vessels, triggering an inflammatory response. This leads to a pathogenic 
accumulation of cholesterol in blood vessels and the formation of atherosclerotic 
plaques, resulting in the constriction of blood vessels8. Atherosclerosis occurs when the 
amount of cholesterol in the blood, due to either unregulated synthesis or considerable 
ingestion of cholesterol rich foods, exceed the amount need for the production of 
steroids, bile acids and membranes. 
 
1.3.1. Biosynthesis of Cholesterol and the Role of HMG-
CoA 
The biosynthesis of cholesterol is a complex process, heavily regulated at several 
points throughout its progression. Some of the intermediaries can be diverted and used 
as precursors in the biosynthesis of other compounds or perform themselves certain 
functions on the body9. This process requires numerous enzymes, some of which are 
accounted amongst the most regulated enzymes known, as is the case of 3-hydroxy-3-
methylglutaryl-CoA reductase (HMG-CoA-R)10. 
The first step in the synthesis of cholesterol is the formation of mevalonate from 
acetate (Figure 9)1. It begins with the condensation of two acetyl coenzyme A (acetyl-
CoA) molecules to form acetoacetyl-CoA, a process catalyzed by the enzyme thiolase. 
Next, HMG-CoA synthase catalyzes the reaction between acetoacetyl-CoA and another 
molecule of acetyl-CoA in order to form HMG-CoA. The final step in the synthesis of 
mevalonate is accomplished by the enzyme HMG-CoA reductase and it is not only the 
committed step of this whole process but also the rate-limiting one. The HMG-CoA is 
reduced to mevalonate by the enzyme with the aid of two NADPH. 
The subsequent step in the biosynthesis of cholesterol comprises the conversion 
of mevalonate into two activated isoprenes (isopentanyl-5-pyrophosphate and 
dymethylallyl pyrophosphate). Following a series of successive condensations of 
activated isoprenes, a 30 carbon molecule will be formed: squalene. Squalene is the 
biochemical precursor of all steroids, and despite being a linear compound, its structure 
can still be linked to that of the cyclic steroids. In order to form cholesterol, squalene has 
to endure a succession of changes, being initially converted to lanosterol, a 4 ring 
compound, which is finally transformed into cholesterol after about 20 reactions. 
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Figure 9 – Diagram of the mevalonate pathway, first step in the biosynthesis of cholesterol. 
 
Since cholesterol biosynthesis is an energetically expensive and complex process, 
it is only natural to assume that it is also carefully regulated. In order for this to happen, 
there are several checkpoints throughout the biosynthesis of cholesterol. In mammals, 
its regulation is controlled by both intracellular cholesterol concentration and hormones 
(insulin and glucagon)10. Perhaps the most important of all these checkpoints is the 
conversion of HMG-CoA to mevalonate, a step catalyzed by HMG-CoA-R, as mention 
before. The importance of this enzyme to the mevalonate pathway has been evaluated 
through various experimental works, including that of Chappell (1995) in which, after 
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introducing a constitutively expressed HMG-CoA-R gene from a hamster into tobacco 
plants, the activity of the enzyme became unregulated and the accumulation of sterols 
increased 3- to 10-fold11. Because of this reason, and some others about to be 
discussed, this enzyme has been subject to many studies, made with the intention to 
assess not only its importance on the biosynthesis of steroids, and above all cholesterol, 
but also to understand how it works and is regulated. 
 
1.3.1.1. Structure of HMG-CoA Reductase 
Isoprenoids, the main product of the mevalonate pathway, are of major importance 
in a lot of different organisms, from bacteria to plants and animals12. For this reason, 
many of these organisms also have similar enzymes that perform analogous reactions. 
 
 
Figure 10 – Structure of the tetramer of HMG-CoA reductase. 
 
HMG-CoA-R can be found in both eukaryotes and prokaryotes, including mammals 
and plants. From sequence analysis it was possible to divide different HMG-CoA 
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reductases in two classes. Class I enzymes comprise those from eukaryotes and the 
majority of archaea while class II enzymes are found in prokaryotes and some archaea13. 
Although the amino acid sequence of the catalytic portion is well conserved within each 
classes, the same cannot be said when classes are compared between themselves, with 
identities ranging between 14 to 20%14. 
In bacteria, the enzyme is soluble in the cytoplasm15, whereas in all other 
eukaryotic organisms it is inserted in the membrane of the endoplasmic reticulum and 
has a transmembrane domain (residues 1 to 339 in humans) and a cytosolic domain 
(residues 460 to 888 in humans), where the active site is located, connected to each 
other by a linker region (residues 340 to 459). Prokaryotic HMG-CoA-R lacks both the 
transmembrane domain and linker. 
The tridimensional structure for the catalytic domain human HMG-CoA-R (Figure 
10) has been solved for the first time in 2000 by Istvan et al16. Currently there are over 
20 structures for the human enzyme available on the Protein Data Bank website, totaling 
27 if we also count those from other organisms. They include not only structures from 
the enzyme alone but also complexes between HMG-CoA reductase and HMG-CoA, 
NADP+ and different statins (Table 2). 
 
Table 2 – Current known HMG-CoA reductase crystal structures available in the Protein Data Bank. The table is 
ordered by increasing resolution. 
PDB Year Resolution (Å) Size Ligand(s) PDB Year Resolution (Å) Size Ligand(s) 
2R4F 2008 1.70 441 RIE 3CCW 2008 2.10 441 4HI 
3CCZ 2008 1.70 441 5HI 3CCT 2008 2.12 441 3HI 
1DQA 2000 2.00 441 
HMG, CoA, 
NADP 
1HWK 2001 2.22 467 ADP, 117 
2Q6B 2007 2.00 441 HR2 3BGL 2008 2.22 441 RID 
2Q6C 2007 2.00 441 HR1 1HWJ 2001 2.26 467 ADP, 116 
2Q1L 2007 2.05 441 882 1HWI 2001 2.30 467 ADP, 115 
3CD7 2008 2.05 441 882 3CDB 2008 2.30 441 9HI 
3CDA 2008 2.07 441 8HI 1HW9 2001 2.33 467 ADP, SIM 
1DQ8 2000 2.10 467 HMG, CoA, DTT 3CD5 2008 2.39 441 7HI 
1HW8 2001 2.10 467 ADP, Compactin 3CD0 2008 2.40 441 6HI 
1HWL 2001 2.10 467 ADP, FBI 1DQ9 2000 2.80 441 HMG 
 
From the structures resolved until now we can see that human HMG-CoA 
reductase is a tetramer produced by four identical monomers. The monomers form 
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dimers in which each subunit is coiled around the other in an intricate way (Figure 11). 
Each enzyme contains four active sites, two in each dimer, and they are made up of 
residues from both subunits. The monomer (Figure 12) itself can be divided in three 
different domains: a small, helical amino-terminal N-domain (residues 460 to 527), a 
large central L-domain that binds HMG-CoA (residues 528 to 590) and a small carboxyl-
terminal S-domain that binds NADPH (residues 591 to 682). 
The dimer interfaces are extensive and all domains of the monomer participate in 
the interactions that join both subunits together. However, the most broad interactions 
are located in the three following regions17: 
 The loop that connects the L-domain and the S-domain (residues 682 to 
694), called the cis-loop. 
 The region in the L-domain where an intramolecular β-sheet is formed. The 
two strands of this β-sheet are characterized by a highly conserved 
sequence (ENVICX3I/LP) 
 A four α-helix bundle (two from each monomer) formed by helixes Lα6 and 
Lα7, which fold in an antiparallel fashion with the corresponding helixes 
from the neighboring subunit. 
 
 
Figure 11 – Structure of one dimer of HMG-CoA reductase. 
 
Despite the fact that the HMG-CoA reductase tetramer was only observed on 
crystallized structures of the catalytic domain alone, other experiments suggest that this 
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configuration is maintained even in the full-length human HMG-CoA reductase, 
containing both catalytic and membrane domains16.  
 
 
Figure 12 – Illustration of the monomer of HMG-CoA reductase, with evidence on the different domains. In red is 
represented the N-domain, in orange the L-domain and in yellow the S-domain. It is also possible to see the 
binding site for both NADPH (upper right) and HMG-CoA (lower left). 
 
The membrane domain of HMG-CoA reductase is not very conserved in 
eukaryotes, contrarily to the catalytic portion. In humans, the membrane spanning region 
forms 8 helixes that are inserted in the membrane. Mammalian enzymes contain a 167-
residue segment which is sensitive to sterols. This segment has a sequence identity of 
approximately 25% with other enzymes that are influenced by cholesterol18. 
 
1.3.1.2. Active Site Architecture and Catalytic Mechanism 
of HMG-CoA Reductase 
The active site of HMG-CoA reductase is formed by residues of two different 
subunits, which form a dimer when bound together. In the same active site, HMG-CoA 
binds to the L-domain of one monomer, while NADPH binds to the S-domain of the other. 
The formation of the tetramer does not appear to be involved in the substrate binding. 
Multiple interactions are formed between the L-domain of one monomer and the 
HMG-CoA moiety. The CoA portion of the substrate binds in an extended conformation. 
FCUP 30 
New Therapeutic Strategies to Lower Blood Stream Cholesterol Levels through the Inhibition of HMG-CoA Reductase  
 
The ADP portion of CoA interacts with a positively charged pocket near the enzyme 
surface. Residues Ser565, Asn567, Arg568, Lys722, Ser865 and His866 are involved in 
the binding of CoA (Figure 13A). There is, however, one residue from the neighboring 
subunit (Tyr479) which interacts with CoA. The side chain of Tyr479 stacks against the 
adenine base in van der Waals interactions while the hydroxyl group makes a hydrogen 
bond with the 3’-phosphate of the ribose moiety. 
 
 
Figure 13 – Representation of the active site of HMG-CoA-R (A), the binding site for HMG-CoA (B) and NADPH 
(C). Each subunit of the dimer is colored differently (pink and blue). 
 
NADPH binds essentially to the S-domain of the other subunit. Residues Ser626, 
Arg627, Phe628, Asp653, Met655, Gly656, Met657, Asn658, Val805 from one monomer 
and residues Asn870 and Arg871 from the neighboring one form the binding pocket were 
NADPH binds (Figure 13B). The diphosphate group is stabilized by the conserved 
sequence element DAMGMN. 
The HMG binding pocket is located between the L- and S- domain and residues 
from both subunits contribute to the binding. This is also the catalytic site. HMG make a 
sort of a bridge between HMG-CoA and NADPH. The binding pocket of HMG is formed 
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by residues Ser684, Asp690, Lys691, Lys692 and Asp767 from one subunit and Glu559, 
Lys735, Asn755, Leu853 and His866 from the other (Figure 13C). 
 
 
Figure 14 – Currently accepted catalytic mechanism of HMG-CoA reductase. The catalytic residues are Lys691, 
Glu559 and His866. 
 
The side chains of both Lys691 and Glu559 are ideally positioned in the active site 
to participate directly in the reduction of HMG-CoA. Negatively charged intermediates 
can be stabilized by the positive charge of Lys691. The proximity between one of the 
side chain oxygens of Glu559 and the carbonyl oxygen of HMG may suggest that this 
residue is protonated. After the binding of NADPH, His866 can make a hydrogen bond 
with the CoA thiol, which is consistent with the role proposed for this amino acid in the 
currently accepted mechanism, where histidine donates a proton to the thioanion19. The 
proposed mechanism is represented in Figure 14. 
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1.3.1.3. Regulation of HMG-CoA Reductase 
HMG-CoA reductase is one of the most regulated enzymes in our organism10. Its 
regulation can be achieved in four different ways: transcription of the enzyme’s gene20-
21, translation of its mRNA22, degradation of the functional enzyme23 and modulation of 
its activity24. 
Transcription of HMG-CoA reductase gene is controlled by the transcription factor 
sterol regulatory element-binding protein 2 (SREBP-2)25. It regulates the levels of mRNA 
in response to sterols. Initially, SREBP-2 binds itself to the SREBP cleavage activating 
protein (SCAP) in the endoplasmic reticulum or in the nuclear envelope to form the 
complex SCAP-SREBP, which is sensitive to sterol levels. When the concentration of 
cholesterol in the cell is high enough, proteins Insig-1 and Insig-2 bind to the SCAP 
portion of the complex, preventing its movement from the reticulum to the Golgi. 
However, if the levels of cholesterol in the cell are low, these two proteins allow activation 
of the complex and its translocation to the Golgi, where the SREBP will be sliced in two 
positions. This cleavage releases the N-terminal basic helix-loop-helix domain, which is 
now free to enter the nucleus and behave as a transcriptional factor and is able to 
recognize certain sequences of DNA called sterol-regulatory elements. When this 
transcription factor binds them, it promotes the transcription of the HMG-CoA reductase 
gene. 
The regulation of the degradation of HMG-CoA reductase involves the membrane 
portion of the enzyme26 and is induced by a non-sterol metabolite derived either from 
mevalonate alone or mevalonate and another sterol10. Once again, protein Insig-1 has 
an important role to play27. In this case, when levels of cholesterol are high enough, both 
SCAP and HMG-CoA reductase compete in order to bind Insig-1. If HMG-CoA reductase 
binds to Insig-1, Lys248 (human HMG-CoA reductase) will be ubiquitinated and the 
protein is then quickly degraded through an ubiquitin-proteasome mechanism28. 
The catalytic activity of HMG-CoA reductase can be modulated by 
phosphorylation29. Next to His 866, one of the active site residues, there is a serine 
residue (Ser872), which can be phosphorylated. The phosphorylation of this residue 
leads to the decrease of the catalytic activity of HMG-CoA reductase by decreasing the 
affinity of the enzyme to NADPH30. The position of the serine, so close to the catalytic 
histidine, is well conserved in superior eukaryotes, which suggests that the 
phosphoserine can interfere with the ability of histidine to protonate coenzyme A thianion 
before it is released from the active site31. Alternatively, it is supposed that the 
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phosphoserine can also prevent the closure of a C-terminal region which is thought to 
trap the substrate in the active site and facilitates catalysis. The subsequent 
dephosphorylation of the serine completely restores the catalytic activity of HMG-CoA 
reductase29. 
 
1.3.2. Statins: the most Common HMG-CoA Reductase 
Inhibitors 
In order to try to diminish the escalading number of deaths caused direct or 
indirectly by high levels of blood cholesterol, scientists started to investigate the best way 
to help reduce these levels32. They soon found out that controlling the ingestion of 
cholesterol containing food was not enough to control its concentration in the blood33 and 
so they had to resort to other approaches, such as bile-acids sequestrants, nicotinic acid, 
fibrates and probucol. Still, the efficiency of these medications was limited and the search 
for better cholesterol lowering drugs ensued. When, in mid-‘70s, compactin, the first 
HMG-CoA reductase inhibitor was discovered by Endo and coworkers, the drug was 
tested for its efficiency as a cholesterol lowering medicine34-35. As the results were 
favorable, development of new and improved statins rose and soon after it became the 
most used treatment for high levels of blood cholesterol36. 
Statins (Figure 15) are potent competitive inhibitors of HMG-CoA reductase37 and 
can be divided in two types, based on their structure38. Type I statins (lovastatin, 
pravastatin and simvastatin) are natural fungal products and type II statin are fully 
synthetic. All statins share an HMG-like moiety, covalently linked to a rigid hydrophobic 
group. When administered, the HMG-like moiety of mevastatin, simvastatin and 
lovastatin is in an inactive form, which is later hydrolyzed in vivo by cellular enzymes 
(esterases)39. Structurally, type II statins are characterized by the presence of larger 
hydrophobic regions and attached fluoro-phenyl groups40. 
The ability of statins to inhibit HMG-CoA reductase arises from the HMG-like 
moiety, which competes with HMG-CoA to bind to the HMG bind site of the enzyme. 
Though the hydrophobic part of statins is different from the coenzyme A portion of the 
substrate, these non-polar groups also contribute to blocking the access of HMG-CoA to 
the active site. The affinity of the enzyme for statins is slightly higher than its affinity for 
the substrate41. 
Even though statins are widely used nowadays as the major drug against high 
cholesterol levels, there are still some side effects linked to them. These include skeletal 
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muscle-related toxicity (myalgias, rhabdomyolysis), cataracts, vascular lesions in the 
central nervous system and testicular degeneration42-43. 
 
 
Figure 15 – Structure of some statins. 
 
Since different statins seem to cause different side effects, it has been suggested 
that these variations are caused by the singular chemical structure of the non HMG-like 
part. These structural differences can cause them to bind to unwanted targets, alter 
associated downstream metabolic pathways and produce unsafe side products44. While 
some of these can cause beneficial (pleiotropic) effects (plaque stabilizing, anti-
inflammatory and antithrombotic effects, etc.45) others can be adverse and even lethal 
(rhabdomyolysis). Fatalities due to rhabdomyolysis lead to the withdrawal of one of the 
statins (cerivastatin) from the market in 200146. Still, in spite of the possibly of such 
serious side effects, this did not preclude atorvastatin from being the most profitable drug 
in the world over the last 8 consecutive years (with sales over 8 billion Euros each year), 
which demonstrates the great need of drugs that lower the blood concentration of 
cholesterol. 
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CHAPTER 2 
COMPUTATIONAL METHODS 
2.1. Protein Structure and Model Building 
In order for computational biochemists to do their job, they need to have a model 
of the system they wish to work on. In our case, the objects of our studies were always 
enzymes. Protein and enzyme models are stored in an online database call Protein Data 
Bank (PDB)47. This is the biggest website were one can go to and search for the 
tridimensional structure of a given protein, as well as other systems such as viral capsids 
and mitochondria. With the advance of X-ray crystallography, Nuclear Magnetic 
Resonance (NMR) and electron microscopy, matched with the progress made in 
molecular biology, the number of protein structure in PDB has grown exponentially over 
the last few years (Figure 16). 
 
Figure 16 – Graphical representation of the number of structures on the Protein DataBank website, and how it as 
changed over the years. 
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Currently there are over 100.000 structures archived in this website (exactly 
128.783 at the time this page was written, at the beginning of April 2017) and each week 
more structures are added. Approximately 89% of these were obtained through the use 
of X-ray crystallography, 10% through NMR and 1% through electron microscopy, hybrid 
techniques and others. 
PDB structures have a collection of all the atoms of a given object (protein, DNA, 
RNA, etc.) and their coordinates in the tridimensional space. When opening one of this 
files, one can view how that molecule is composed and how its atoms are arranged in 
space. 
After choosing which object we are going to study, we should first check PDB (and 
other similar databases) to see if there are tridimensional structures available for that 
protein. If multiple structures exist, we must first evaluate each one of them to see which 
structure best suits our study. Usually we tend to favor structures with better resolution 
and, if possible, with substrates, products or analogs in the active sites. These 
compounds give us a lot of information about the configuration of the protein when its 
active site is full, since it can be very different when there is no molecule in it. Also, the 
fewer modifications a structure has in relation to the native protein, the better. Finally, 
one should also be aware that frequently the protein in PDB is not that of the species 
one wants to study. For the most part we want to study human proteins, but sometimes 
they are not available. In these cases, we must search for a protein from a similar species 
(for example, of another mammal) and check if both amino acid sequences are similar, 
with special focus on the active site residues. If the sequences are very similar and the 
active site residues are conserved, then we usually assume that both proteins work in 
the same way, and so the results obtained for one can be extrapolated to the other. In 
more difficult cases there is always the option of modeling the protein using solved 
structures with high sequential similarity. This method, however, should be avoided and 
used only if it is absolutely necessary, because we can never be 100% certain that the 
final structure resembles, indeed, the actual real structure of that protein. Also, we must 
conduct further experiments that help us validate the final structures, such as using 
molecular dynamics to see if denaturation does not occur over time. 
Another problem with using protein models, especially when these are obtained 
through X-ray crystallography, is that some atoms do not appear in the structure. In the 
case of X-ray crystallography, atoms with low electron density do not show up on the 
diffraction pattern, which means that their position cannot be assessed. This is more 
noticeable for hydrogen atoms, which rarely appear in PDB structures. They must be 
added after the structure is chosen and downloaded from the database. 
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There are several computer programs and online servers that automatically add 
missing hydrogens to protein, however such subject is not that trivial. For most atoms, 
the number of hydrogens and their position can be easily inferred, but there are some 
cases in which it may be difficult to know in which position an hydrogen must be added 
(for instance, if it makes a hydrogen bridge or not) and the worst case scenario is when 
we are not sure whether a residue is protonated or not. For this last case, which is usually 
common in amino acids with multiple ionization states (histidine, lysine, arginine, 
glutamate and aspartate), it is important to know the optimum pH of the protein and check 
(again, using online servers) the pKa for each of these amino acids in the protein 
environment. Then, depending on the results and, whenever possible, using results 
already published, we can decide whether or not to protonate a given residue. It is worth 
noting, though, that these algorithms are not 100% accurate and therefore the results 
given by them should not be followed blindly but regarded more as suggestions than 
actual truth about the protonation state of the amino acids. Oftentimes visual inspection 
is also a good tool to help ascertain which protonation state is more likely. 
Sometimes mutations are added to the protein prior to crystallization, and these 
are the residues that ultimately appear on the structure. This is done for various reasons, 
sometimes to help the protein crystallize or to prevent catalysis from happening, which 
means that the substrate becomes trapped on the active site and we can examine the 
way it binds to the protein. Mutated residues must be modified into the wild type ones 
too before using the model. For small modifications like this, it is easy to revert the amino 
acid back to the one encountered in the wild type enzyme by simply using an editing 
software, such as GaussView48, and modify the atoms one by one. 
Another common problem that exists in downloaded structures is when there are 
residues of the protein missing. This is due to the way X-ray crystallography works: some 
unordered parts of the protein (most frequently, loops) might not crystalize correctly and, 
therefore, do not have a diffraction pattern that allows for their unambiguous resolution. 
These missing parts must be added subsequently to the model. This case is a bit harder 
to address than the one before, since the parts missing can be long. In this case, a better 
approach is to superimpose the structure with another that has the missing parts in it and 
simply copy and paste the atoms to our model. If no other similar protein is available, we 
can try modeling it using protein with a similar structure. In either of these cases, it is 
wise to follow up with a small molecular dynamics to try and see if the protein does not 
lose its integrity. 
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2.2. Molecular Mechanics 
After we have completed the model of the object we want to study, be it a protein, 
DNA, protein-ligand complex, or any other option, then we can finally start researching 
several different things about it. Computational biochemistry is such a vast area, with so 
many different techniques, that nowadays one can study virtually anything, especially 
with the fast development of computers and processors. One of the most versatile 
computational methodologies that enables us to analyze and calculate different 
characteristics of a protein is molecular mechanics49-50. 
Molecular mechanics is a means to simplify a system of atoms and calculate its 
different properties using classical (or Newtonian) mechanics. It describes the model 
using a force field, which is a combination of a general equation for the energy as a 
function of the atomic coordinates, and a set of parameters that are needed to adapt the 
equation to the specific molecular system under study. The development of molecular 
mechanics began when computers were not powerful enough to treat a very large 
system with quantum mechanics. These calculation required very high computational 
power, which was not available at the time. With molecular mechanics, these systems 
can be described using the laws of classical mechanics. In molecular mechanics the 
smallest unit we can treat is the atom, however if we want to speed up our calculations 
we can form units composed of united atoms or even whole residues. These approaches 
allow us to speed up our calculations at the cost of atomic precision. With the ever 
growing computational power, today we do not need to perform these types of 
calculations for the systems we normally study. Still, in cases where we have a protein 
with a very high molecular weight, the use of these coarse graining methods can be 
helpful. In this work, we will focus only on atomistic models, since our models were 
manageable in a reasonable time frame using this approach. 
 
2.2.1. Force fields 
As it was stated previously, force fields are an essential part of molecular 
mechanics. They are used to derivate the total energy of the system in a given 
conformation. Several types of force fields exist and are used depending on the type of 
system and simulation time. In this work, we used exclusively the AMBER (Assisted 
Model Building with Energy Refinement) force field51 to characterize proteins. For ligands 
we used GAFF52 (General AMBER Force Field) to describe them, since this force field 
FCUP 39 
New Therapeutic Strategies to Lower Blood Stream Cholesterol Levels through the Inhibition of HMG-CoA Reductase  
 
has all parameters to characterize almost all organic molecules composed of C, N, O, H, 
S, P, F, Cl, Br and I. 
A force field is basically a mathematical expression and a set of parameters that 
enable the description of the dependence of the energy of a system on the coordinates 
of its particles. Most molecular systems are too complex to be treated with quantum 
mechanics, so we resort to using simple classical functions that represent it as a group 
of atoms connected by harmonic (elastic) forces and a set of parameters obtain through 
either experimental (X-ray and electron diffraction, NMR, spectroscopy, etc.) data or 
quantum calculations on smaller models. Although there are currently many different 
force fields in literature, which are used depending on complexity of the system and the 
level of accuracy we want to obtain, typical they are defined using the following 
expression: 
Vt =  ∑ Vbonds  + 
n−bonds
b=1
 ∑ Vangles  + 
n−angles
a=1
 ∑ Vdihedrals + 
n−dihedrals
d=1
 ∑ Vee
n−nbpairs
p=1
+  ∑ VLJ
n−nbpairs
p=1
  
(1) 
In which the first term is the sum of the potential energy associated with bond 
stretching, the second corresponds to angle bending, the third to dihedral torsions and 
the last two relate to the non-covalent interactions, electrostatic and Van der Waals 
interactions, respectively.  
In molecular mechanics, bond stretching is often represent as a harmonic function. 
Covalent bonds are described as springs that either elongate or shorten and therefore 
their potential energy can be calculated using Hooke’s Law. This means that, in the force 
field general equation (equation (1) the term Vbonds takes the following form: 
𝑉𝑏𝑜𝑛𝑑𝑠 =  𝑘𝑟 (𝑟 − 𝑟𝑒𝑞)
2 
(2) 
Where kr is the bond force constant, req is the length of the bond in equilibrium and 
r is the current bond distance. The force constant is inferred from infrared or Raman 
spectra, while r is obtained from either X-ray diffraction experiments or quantum 
mechanics calculations. 
One of the major drawbacks of molecular mechanics is the fact that it cannot deal 
with breaking and formation of new bonds, and we are therefore unable to study chemical 
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processes. This is due to the fact that this approximation is incorrect for bond 
displacements bigger than 10%, which is a problem that derives from the fact that the in 
a harmonic potential the energy keeps growing as the bond length increases. If we were 
to use, for example, the Morse potential (or some other which, as the distance increases, 
the energy levels), the breaking of chemical bonds could be simulated. However, the 
parameterization for these types of potential is rather complex and must be done for 
each individual case, while the results are not always accurate. For this reason, most 
force fields use a harmonic function instead, since for near equilibrium conformations, 
the results obtained with these potential are acceptable. 
The energy associated with angle distortion is also estimated using a harmonic 
approximation. Therefore, we can calculate Vangles using the following expression: 
𝑉𝑎𝑛𝑔𝑙𝑒𝑠 =  𝑘𝜃 (𝜃 − 𝜃0)
2 
(3) 
In this case, kƟ is the force constant, Ɵ0 is the angle at the equilibrium configuration 
and Ɵ is the current angle. The quadratic approximation is fairly good to calculate the 
potential energy of angles, but it has also two weaknesses: it is not accurate for 
calculating energies when the angle is very different from the standard configuration and 
it does not account for cases in which a molecule can have several equilibrium angles, 
as it happens it many organic molecules. Nevertheless, this approximation is used rather 
frequently and it presents good results in most of the cases.  
For dihedral torsion, it becomes more difficult to establish an expression that can 
accurately calculate the potential energy associated with this type of interaction. 
Torsional energy relates to the energy variation associated with the rotation of the bond 
between two atoms, B and C, in the four atom sequence ABCD, which are sequentially 
bound. The problem with dihedrals is that they are periodic, and so, in order to calculate 
their energy we must use the ensuing expression: 
𝑉𝑑𝑖ℎ𝑒𝑑𝑟𝑎𝑙𝑠 =
𝑉𝑛
2
 [1 + 𝑐𝑜𝑠(𝑛𝑛 𝜙 −  𝛾)] 
(4) 
Vn represents the height of the energy barrier, n is the number of minima or maxima 
that exist between 0 and 2π, ɸ is the current dihedral angle, and γ is the phase. Torsion 
parameters are often calculated using ab initio methods and then refined with the help 
of experimental approaches, such as vibrational spectra. In macromolecules, such as 
proteins, where there is a large number of dihedrals, these motions must be defined 
more precisely than angle bending or bond stretching, since dihedrals are necessary to 
ensure the correct degree of rigidity of the molecule and to reproduce the major 
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conformational changes. Some force fields also employ an extra variable to account for 
improper torsions, which corresponds to the energy associated with the rotation of a 
bond in which the four atoms analyzed are no necessarily bond sequentially. Improper 
torsions are important to ensure the planarity of sp2 atoms. 
As for the non-covalent interactions, we have two different terms, one for 
calculating the potential energy associated with electrostatic interactions, and another 
for Van der Waals interactions. 
Electrostatic potential energy is related to the electronegativity of the different 
atoms that compose a molecule. Electronegativity is a chemical property that represents 
how much tendency an atom has to pull an electron towards itself. Therefore, atoms with 
more electronegativity tend to pull electrons from other atoms of the molecule, thus 
creating an uneven distribution of electrons in chemical bonds and the formation of an 
electric dipole. The electrostatic potential energy is calculated by assigning a specific 
partial charge to each nucleus and using Coulomb’s law, which states that the electrical 
force between two particles depends on the magnitudes of the charges of each particle 
and on the distance between them. The relationship between all this quantities can be 
expressed by the following mathematical expression: 
𝑉𝑒𝑒 =  
𝑞1𝑞2
4𝜋𝜀0𝑟
 
(5) 
in which q1 and q2 represent the partial charges of each atom, ε0 is the vacuum 
permittivity and r the distance between both atoms. Through this expression we can see 
that the energy associated with the electrostatic potential is directly proportional to the 
partial charges of the atom and inversely proportional to the distance between then, 
meaning that the further apart the atoms are the smaller (in absolute terms) the energy 
associated with this potential.  
The last contribution that is usually taken into account when calculating the energy 
of a system is that of the Van der Waals interactions. In order to accurately simulate the 
behavior of pairs of atoms at a certain distance, the equation used to calculate the Van 
der Waals energy must account for two things: the repulsion felt by the atoms when their 
respective orbitals superimpose (due to Pauli’s exclusion principle) and the attraction 
created by London dispersion forces, in which the instantaneous uneven distribution of 
electrons in an atom can create a temporary dipole which, in turn, create another induced 
dipole in a nearby atom. Van der Waals forces vary very quickly with the distance 
between both atoms being very repulsive when they are really close. However with the 
increase in the distance between them, the atom start to attract each other, until the point 
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when they no longer feel one another. This behavior can be described mathematically 
through the Lennard-Jones potential (also known as the 6-12 potential): 
𝑉𝐿𝐽 =  4𝜀 [(
𝑟𝑚
𝑟
)
12
 −  (
𝑟𝑚
𝑟
)
6
] 
(6) 
In this expression ε represents the minimum potential energy reachable, rm is the 
distance at which this minimum potential is reached and r is the current distance between 
the atoms. The Lennard-Jones potential is rather good at simulating the Van der Waals 
forces felt between two atoms since the positive factor (power 12) models the repulsion, 
the negative factor (power 6) models the attraction and the first can be obtain by just 
squaring the second, which saves computing time. 
Most force fields use only these five terms in order to calculate the total energy of 
the system. However, depending on the force field, other terms might also be employed 
in addition to the one described. These are called cross-terms and usually vary 
depending on the force field, and can describe, among other properties, the coupling 
between bending, stretching and torsion energies. These terms are often added to 
correct the calculated energies and render results more accurate.  
For this work we used mainly the AMBER force field. AMBER is an “all-atom” force 
field, which means that the smallest unit it considers is the atom. With this force field, all 
of the atoms of the system are explicit and treated according to their place on the 
structure. However, protons and electrons are implicitly taken into account by parameters 
that describe the atoms (atomic charge and van der Waals radius). 
 
2.2.2. Energy Minimization 
When performing energy minimization calculations, one tries to reach the structure 
of the system that has the smallest possible energy, i.e. the one which correlates to a 
minimum on the potential energy surface49-50. In proteins it is rather difficult to find the 
absolute minimum, since it would require a very large amount of time to explore the 
whole of the potential energy surface, which in the case of proteins, due to the many 
degrees of freedom that it contains, is relatively big. For this reason, when minimizing 
finding a protein structure with minimum energy we have to settle for a local minimum. 
Furthermore, for proteins there are a lot of degenerate local minima, which means that 
at room temperature, a protein is never found at an absolute minimum, quite the 
opposite, since in the case of proteins we can have different local minimum with an 
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abundant population. Therefore, using a local minima as a starting point for the following 
calculations is sufficient. 
AMBER employs two different algorithms to search for a local minimum structure: 
steepest descent and conjugate gradient. The steepest descent algorithm is useful when 
the geometry of the system is very far from a local minimum and it is ensured that it will 
converge to a minimum. As the coordinates of the system are changed, the gradient (the 
derivative of the potential energy) is calculated, and the algorithm moves the system in 
the direction that contradicts the gradient. It the case of a one dimensional system, the 
algorithm takes the following form:  
𝑥𝑖+1 = 𝑥𝑖 − 𝜀𝛻𝑉(𝑥𝑖) 
(7) 
where xi+1 is the new position of the system, xi is the previous position, ε is the 
magnitude of the step taken towards the minimum and ∇V(xi) represents the magnitude 
of the potential energy function at the previous position. One of the flaws of this method 
is that, since it uses only the current gradient, the direction followed by the path tends to 
be somewhat erratic, changing with each iteration and creating a zig zag pattern. This 
pattern is particularly noticeable when the system is already close to a minimum. Since 
this weakness translates into a loss of performance during the minimization, AMBER 
also employs the conjugate gradient algorithm. The difference between both algorithms 
is that, contrarily to steepest descent, conjugate gradient uses not only the gradient from 
the current step but it conjugates it with gradients from other previous steps. For this 
reason, the path followed by this algorithm is much more focused after some iterations, 
which allows for convergence to be reached in very few steps after a certain point. 
 
2.2.3. Molecular Dynamics: 
The minimization of a system allows us to detect a structure in which it will be more 
stable (have more negative potential energy). However, most of the times, we do not 
wish to find out which conformation is the most stable, but rather see how the system 
evolves as time goes by and which set of enzyme conformations are the most occupied 
at physiological temperature. In order to achieve this, we must employ molecular 
dynamics, in which the potential energy function is used together with the Newton 
equations of motion49-50, 53. The conjugation of both allows us to simulate the behavior of 
our molecular system through the course of a time lapse. 
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To “kick-start” our model into motion, we must first assign random initial velocities 
to each atom, which is done according to a Maxwell-Boltzmann distribution, and taking 
into account the expected temperature of the system. At this stage, we need to calculate 
the acceleration for each particle in order to know their position after a certain time has 
elapsed. From Newton’s second law of motion we know that: 
𝐹𝑖 = 𝑚𝑖𝑎𝑖  
(8) 
which means that the force acting upon an atom i of the system is equal to the 
product of the mass of that atom (mi) and its acceleration (ai). The acceleration can also 
be represented as the second order derivative of position with respect to time, meaning 
that another way to represent ai is: 
 
𝑎𝑖 =
𝑑2𝑟𝑖
𝑑𝑡2
 
(9) 
Combining equations (8 and (9 we get a final expression, which is used in 
molecular dynamics to calculate the trajectory of each particle of the system.  
𝐹𝑖 = 𝑚𝑖
𝑑2𝑟𝑖
𝑑𝑡2
 
(10) 
Each atom will move according the force F being applied to it. In order for the 
trajectory to be calculated along a time scale, we need the initial positions of the atoms, 
which can acquired by X-ray crystallography, NMR and other methods. The most difficult 
term to calculate in molecular dynamics is the acceleration, which cannot be calculated 
analytically for systems bigger than two atoms, since it is dependent on all atoms of the 
system. The solution found for this problem is to solve it numerically, which can be done 
using one of several integration algorithms. AMBER uses the Leap-frog algorithm, which 
takes the following form: 
𝑣 (𝑡 +
1
2
𝛿𝑡) = 𝑣 (𝑡 −
1
2
𝛿𝑡) + 𝑎(𝑡)𝛿𝑡 
(11) 
𝑟(𝑡 + 𝛿𝑡) = 𝑟(𝑡) + 𝑣 (𝑡 +
1
2
𝛿𝑡) 𝛿𝑡 
(12) 
With the Leap-frog algorithm, the velocities of the particles are calculated based 
on their velocities at half-step behind (v( t + ½ δt)) and their acceleration at time t. After 
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these velocities are calculated, their positions can be obtained using equation (12. The 
name for this algorithm comes from the fact that the positions and velocities are 
calculated at interleaved time points in such a way that they “leapfrog” over one another. 
 
2.2.3.1. Molecular Dynamics Parameters 
In molecular dynamics one of the most critical parameters to choose is the time 
step. At each time step, the new positions and velocities for each atom are determined 
from the old ones and the forces being applied to them, so in order to take the least 
computational time possible it would make sense to use a large time step which would 
allow us to scan the movements of the system in a large temporal range while doing the 
least number of calculations possible. The problem with this approach is that calculating 
structures which are temporally far apart can lead to wrong results, since the new atom 
positions and velocities are calculated from the ones of the previous step. If the forces 
are relatively constant during the step, then the results should be accurate, however with 
a large time step we cannot be certain if this is the case, and the calculations will result 
in wrong potential energies and positions for the atoms. To avoid these kinds of errors, 
it is customary to select a time step that is ten times smaller than the fastest vibration in 
the system. In most simulations, these vibrations are the stretching vibrations of the 
hydrogen atoms, which have periods of about 10 fs, meaning that the time step should 
be 1 fs. In order to increase the time step, the SHAKE algorithm54 implemented in 
AMBER can be used, which freezes these vibrations. The second quickest vibrations are 
the stretching of C-C bonds. These have a period of circa 20 fs, which means that we 
can increase the time step to 2 fs. 
It is common practice to add explicit water molecules to the model when studying 
a system through molecular dynamics. TIP3P55 is a water model implemented in the 
CHARMM force field is one of the most frequently used. It is characterized by three point 
charges, one for each of the atoms that compose the molecule, but only one van der 
Waals radius, corresponding to the oxygen atom. Another characteristic of the TIP3P 
water type is that it does not have an angle parameter; instead there is a bond parameter 
between the two hydrogen atoms. These simplifications made to the water molecules 
may seem irrelevant, but they play a crucial role for the simulation. When explicit solvent 
is used, the number of water molecules can surpass that of protein atoms by more than 
ten-fold, which would mean that most of the simulation time would be spent calculating 
the behavior of these molecules. In the case of TIP3P waters, the number of interactions 
calculated during the simulation is decreased significantly, simply by eliminating these 
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two van der Waals parameters. Also, by substituting the angle parameter by a bond 
parameters, the calculation time is reduced, since calculating angles is computationally 
more demanding than calculating bonds. 
Besides the added calculation time needed when using explicit solvent, there are 
other complications that arise from this approach. For instance, the fact that the structure 
of the solvent is not as cohesive as that of the protein itself. If we were to run a normal 
simulation with the water molecules simply surrounding the protein, it would result in the 
loss of some of those molecules, and the distortion of the water cap. Another problem 
comes from the fact that those water molecules closest to the solvent-vacuum interface 
would not be properly feeling the rest of the solvent, which would lead to some incorrect 
results. For this reasons, when using explicit solvent we also employ periodic boundary 
conditions, an elegant solution to deal with the problems described above. With periodic 
boundary conditions, the simulation cell is simply repeated an infinite number of times in 
all three coordinates of the system. The most common shape of the box is a cube, 
however other shapes can be used if one wishes, for example, to reduce the number of 
solvent molecules in the system. 
During the molecular dynamics, it is possible to choose one type of ensemble 
conditions from several that are available to the user. The most commonly used amongst 
them are the microcanonical ensemble (NVE), the canonical ensemble (NVT) and the 
isothermal isobaric ensembles. When using the NVE ensemble, the number of particles 
in the system, the volume of the solvent box and the energy are all kept constant 
throughout the simulation. On the other hand, using NVT conditions allows the energy of 
the system to change while the number of particles, volume of the box and temperature 
of the system are kept constant. Finally, in NPT conditions it is the temperature, pressure 
and number of particles that are kept constant. From the three ensembles presented, 
the NPT is the most similar to a physical aqueous solution in room conditions, and for 
this same reason it is the one most frequently used in molecular dynamics. However, the 
canonical ensemble is still useful in the first stages of the simulation, when we want to 
optimize the molecules of the solvent, since after they are added to the system they are 
not in a relaxed and optimal geometry. If the simulation is run at this point with in NPT 
conditions, the system will most likely expand and form cavities in the solvent, due to the 
fact that the pressure is changeable. Since volume is kept constant in the canonical 
ensemble, the water molecules are able to acquire a relaxed conformation without 
deforming the solvent box. 
During the molecular dynamics simulation, the temperature is kept constant 
through the implementation of a thermostat. These are simply functions which, in some 
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way, alter the velocities of the atoms that are part of the system. Changing these 
velocities simulates an increase or decrease in the temperature of the system, which can 
then be adjusted to the designated value. The thermostat used in Amber is the Langevin 
dynamics algorithm, in which stochastic collision of an adequate force are simulated 
upon the atom. What is expected with this approach is to model the effects of the 
surround environment in the system implicitly. 
There are, however, some issues that arise from the usage of periodic boundary 
conditions. One of the most problematic is the fact that, since theoretically the system is 
infinite, there is also an infinite number of contributions that must be calculated in order 
to obtain the potential energy of the system. Some terms are passive to be calculated in 
only one cell (such as those relating to bonds, angles and dihedrals, which are the same 
in all boxes). There are, nonetheless, terms relating to pairwise non-bonded interaction 
that occur between molecules present in one cell and all the other molecules in the 
repeated cells, up to infinity. In order to avoid these infinite calculations, we must employ 
some approximations.  
We can effectively reduce the number of van der Waals interactions that must be 
calculated in one of the easiest ways possible: simply by limiting the number of atoms 
that interact with each other. This can be done by introducing a cut-off radius around 
each atom, this way the central atom will only interact explicitly with those that are found 
within this distance. This approximation can be easily understood if we take into account 
what was stated earlier: that the energy associated to the van der Waals interactions 
decreases very rapidly as distance increases. However, it is also true that with the 
distance the number of interaction also increases, which means that at large distances 
it is still expected that the contribution of these interactions is still meaningful. Since van 
der Waals interactions are always addictive to the total energy, we can simply add a 
correction factor that accounts for the density of the system, which also considers that it 
is homogeneous after the cut-off distance.  
A different approach must be used when it comes to calculating the contribution of 
electrostatic interactions. For these we employ the Particle Mesh Ewald method, in which 
they are divided into large and small range interactions. Long range interactions, which 
are considered for atoms at a distance larger than 10 Å (this distance is usually the same 
as the cut-off used in the calculation of the van de Waals interactions) are taken into 
account through a summation in Fourier space, whereas small range interactions are 
calculated using the force field equation. The reason why we need a different method to 
calculate the contributions of electrostatic interactions is that, contrarily to the van der 
Waals interactions, these decay in an inverse fashion, quadratic to the force. 
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When building the solvent box around our protein some simple rules must be taken 
into account, especially its size. It is important that the cell is large enough that it hinders 
interactions between two proteins. We want to keep the proteins from seeing one another 
because the simulations are done with the purpose of studying them at low 
concentrations in the solution. For this reason, the size chosen for the solvent box is 
usually that of the cut-off distance for non-bonded interactions, since past this distance 
the interaction are no longer considered explicitly. 
 
2.2.3.2. Parametrization of Ligands and Non-standard 
Residues 
As stated previously, in order to run a molecular dynamics simulation, we first must 
have a parameter file for all atoms of the system. This parameters are dependent on 
several factors, including atom type and which other atoms it is bound to, amongst 
others. If we search through the literature, it is possible to find parameters for a large 
variety of biomolecules; however this list is far from complete. For the most common of 
biological system, such as proteins, nucleic acids, phospholipids and carbohydrates, 
these parameters do exist and are already well documented. But for more specific 
molecules, like substrates or inhibitors, these are most probably not yet available on the 
literature, and so it comes down to the person in need of them to calculated these new 
set of parameters from high level quantum mechanics methods. 
For bond and angle parameters, they are determined by scanning the proper 
coordinates of the molecule. An energy optimization is initially performed in order to 
calculate the equilibrium length and force constant of a bond. Subsequently, this same 
bond is stretched and shrunk, so that an energy profile that should be roughly quadratic 
near the minimum is obtained. The two parameters that most authentically mimic this 
energetic profile are chosen. This protocol is usually only put in practice for out of the 
ordinary systems, such as metallic centers. For molecules that are most common in 
biological systems, it is actually much easier and faster to just attribute new parameters 
for bonds and angles based on structure similarities with other molecules that are already 
parameterized. We first define the atom type of each atom of the system, and then 
parameters are attributed in accordance with GAFF. The parameters for dihedrals are 
oftentimes ignored, since they are difficult to calculate and rather numerous. 
Furthermore, 1-4 interactions are already taken into account approximately by non-
bonded interactions.  
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As for the atomic charges, these, however, cannot be assigned by similarity and 
are dependent on each atom type and the environment in which the molecule is inserted, 
which also changes its polarization. The protocol for calculating the charge parameters 
begins with the minimization of the molecule while it is inserted in the site of interest. 
Usually a QM/MM calculation with electrostatic embedding is preformed, where the high 
layer corresponds to the molecule to be parameterized and the low layer to the enzyme. 
After the minimization is finished, we employ the RESP (Restrained ElectroStatic 
Potential fit) method56 in order to assign the charges to each atom. In a RESP calculation 
the charges are assigned to mimic the electrostatic field cleated by the molecule in the 
QM model. The method is called “restrained” because one can make use of certain 
restrictions when attributing the charges. This can be helpful in some cases, for example, 
when there are equivalent atoms in the molecule that have the same charge or for 
imposing a certain charge on an atom. 
It is also important to bear in mind the conformation of the molecule when 
performing ESP calculations. If the molecule is minimized in vacuum, its configuration 
might be quite different from the one it takes when inserted into the enzyme. Some 
groups might interact with one another and that might interfere with the calculation of the 
charges. For example, if a molecule as opposing charges at either end and is somewhat 
flexible, this groups can interact with each other, which would cause the charge 
calculations to be wrong. It is for this reason that the ESP calculation should ideally be 
done using an ONIOM model, with a high layer that consists of the ligand and a low layer 
that refers to the protein. This way, the charges calculated for the ligand will be perfectly 
in tune with the conformation it adopts when inserted into the enzyme. The limitation of 
the approach is that in case we wish to study a different configuration of the same 
molecule (for example, if it is inserted on a different environment, or if it is in solution) the 
charges calculated will not be correct, and a new ESP calculation might be needed.  
 
2.2.3.3. Relaxation of Structures 
Proteins are very complex structures that can contain a large amount of atoms, 
each of which passible of having an important function for the overall structure. For this 
very reason, when studying enzymes and enzymatic catalysis, it is rather important to 
make sure the structure of our model is in a state similar to that it is expected to have in 
its natural conditions. Ensuring the protein is in such a state is one of the most common 
applications of molecular dynamics in this field. With this method, we expect to stabilize 
the structure of the enzyme, or enzyme-substrate complex, after we perform 
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modifications on the original structure. The need to modify the structure that comes from 
crystallography comes from the fact that it seldom is in the state we intend to study the 
enzyme. More often than not, the structures do not have the right substrate (or they have 
no substrate at all) in the active site, or some mutations has been made on the protein. 
Oftentimes the proteins are not fully crystalized and we need to model parts of it as well. 
In order to carry on with the study of the mechanism, we need to arrange the protein so 
that its structure matches what we are trying to study. Often only minor modifications are 
necessary, such as the transformation of one substrate or amino acid into another, but 
sometimes bigger transformations are needed, especially when parts of the protein are 
missing. In the case of only small modifications, a simple structure minimization might 
be enough to ensure the system is in the correct configuration. However, in the case of 
large modifications, in order to stabilize the structure in the right configuration, larger 
movements of the atoms are required and a simple minimization might not suffice, and 
so it is usually accompanied by a molecular dynamics simulation. 
When running a simulations, the protocol used is usually rather simple and 
straightforward. First, when preparing the input file, the structure is checked to see if 
there are any mistakes. Then, solvent molecules (generally water) are add so that they 
form a box around the protein, leaving at least a 12 Å margin from the surface of the 
protein to the edges of the box. Next, we add counter ions, either sodium or chloride, to 
the system, so that the total charge equals zero, which is a standard requirement of the 
Particle Mesh Ewald method. One should always ensure that, when adding counter ions, 
these do not fall near the active site, otherwise they can disrupt the course of the 
dynamics and the structure of the protein. After all these modifications, the initial 
structure is ready, however before commencing the dynamic simulation, it is usual to run 
an energy minimization calculation using the following protocol: first, the hydrogen atoms 
are minimized, after which follows any substrate or residues that might have been 
modeled. Next, the solvent molecules are minimized and lastly all the whole system. In 
the end of all these minimization calculations, the molecular dynamics can start, first with 
the heating of the system at constant volume (canonical ensemble), and then finally the 
production phase takes place with an isothermal isobaric ensemble. 
An important question one should ask when doing any dynamics is how long 
should it be ran for. This is a rather delicate matter that must be met with care. The 
structure obtained through crystallography is no more than an average of the structures 
found in the crystal. That being said, it is understandable that those structures found 
most frequently will have a bigger contribution to the final structure of the protein, 
whereas those which are found with less frequency having a smaller contribution. What 
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we obtain in the end is a Boltzmann distribution of the system, which is encased in a 
single structure. When performing a molecular dynamics simulation, this correlation 
between the crystallographic structure and the Boltzmann distribution is destroyed, and 
so it is usual to keep the calculation running for the minimum amount of time possible, 
only that required to relax the modified sections of the model. We would hope that 
keeping a small simulation time would not disturb the properties of the system. However, 
as many studies have shown, even a very small simulation can disrupt the initial 
configuration of the system, and this might affect both the pathways and energies that 
are resultant from mechanistic studies. 
After the dynamics, in order to assess whether the modeled part of the system is 
already relaxed or not, we perform an analysis of the root mean square deviation 
(RMSd). If the model is relaxed, we can then use the last structure to build the model 
that will be used in the subsequent studies, or if we find it yet needs to undergo molecular 
dynamics for a bit longer we continue the calculation from this last point. 
 
2.3. Quantum Mechanics 
Quantum mechanics began its history at the start of the 20th century, when the 
earliest molecular and atomic systems were first studied57-60 a. In the beginning, physics 
tried to apply the laws of Classical Mechanics to said systems, only to find that they did 
not always followed these laws, or that they presented certain limitations. Thus, quantum 
mechanics emerged from the need to come up with new theories that could explain the 
results that were obtained when studying atomic scale systems. 
At the core of quantum mechanics sits the Schrödinger equation: 
Ĥ𝛹 = 𝐸𝛹 
(13) 
By solving this equation, we can, theoretically, solve all properties of a system, with 
special regard to its energy. These properties are derived from the motions of electrons 
and nuclei of each atom. For ground-state chemistry studies, such as the enzymatic 
reaction discussed later, the time-independent Schrödinger equation is sufficient 
(equation (13). What this equation states is that if we apply the Hamiltonian operator (?̂?) 
to a certain wave function (𝛹) and the result obtained is itself proportional to 𝛹, then we 
                                                     
a QM theory is well presented and organized in any of these books, hence the lack of specific references in the following 
sections.   
FCUP 52 
New Therapeutic Strategies to Lower Blood Stream Cholesterol Levels through the Inhibition of HMG-CoA Reductase  
 
can conclude that 𝛹 is a stationary state and an eigenstate of H and the proportionality 
constant, 𝐸, is the energy of that same state. 
One of the problems of using the Schrödinger equation is that it is analytically 
unsolvable for systems with two or more electrons. For this same reason, in order to 
calculate energies for these types of system several approximations must be made. 
 
2.3.1. Wave Function Methods 
All properties of a system can hypothetically be derived from the motions of the 
electron and nuclei that compose it. Using the Schrödinger equation it is theoretically 
possible to describe these motions and from them calculate the properties of the system. 
One of the terms of the Schrödinger equation is the Hamiltonian operator (?̂?). 
The Hamiltonian operator includes different terms: those associated with kinetic 
energy, i.e. the movement of the particles, and those associated with potential energy, 
i.e. the Coloumb interactions between the various particles. For a general N-particle 
system, ?̂? becomes the following equation: 
?̂? = ?̂?𝑛 + ?̂?𝑒 + ?̂?𝑛𝑒 + ?̂?𝑒𝑒 + ?̂?𝑛𝑛 
(14) 
Where ?̂?𝑛 is the kinetic energy of nuclei, ?̂?𝑒 the kinetic energy of electrons, ?̂?𝑛𝑒 the 
attraction felt between nuclei and electrons, and finally ?̂?𝑛𝑛 and ?̂?𝑒𝑒 represent the 
repulsion felt between nuclei and electrons respectively. Each of these terms, in turn, 
can also be represented in such a way that the ?̂? takes the following form: 
?̂? = − ∑
1
2𝑀𝐾
𝛻𝐾
2
𝐾
− ∑
1
2
𝛻𝑖
2
𝑖
+ ∑
𝑍𝐾𝑍𝐿
|?̅?𝑖 − ?̅?𝑗|𝐾>𝐿
− ∑
𝑍𝐾
|?̅?𝑖 − ?̅?𝐾|
+ ∑
1
|?̅?𝑖 − ?̅?𝑗|𝐾>𝐿𝑖,𝐾
 
(15) 
𝛻𝑖
2 = (
𝜕2
𝜕𝑥𝑖
2 +
𝜕2
𝜕𝑦𝑖
2 +
𝜕2
𝜕𝑧𝑖
2 +) 
(16) 
For any system with two or more electrons, this equation becomes just too 
complicated to be solved exactly using the knowledge available to us. In order to reach 
an approximate result, some simplification have to be introduced. 
The Born-Oppenheimer approximation is based on the fact that electron are much 
smaller than the nuclei, and that they also move at much faster velocities. We can 
therefore assume that when the nuclei assume a certain position, the electrons will adopt 
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the arrangement with the lowest energy before the nuclei move significantly. In practice, 
what this means is that we can separate the Hamiltonian in two different contributions, 
one part for describing the electronic wave function and another for the nuclear wave 
function. Solving the electronic Schrödinger for different nuclear arrangements leads to 
a potential energy surface (PES), the minima of which determines the equilibrium 
geometries of a molecule. 
 
(17)  
 
 
 
 
(18) (19) 
 
Even with the Born-Oppenheimer approximation, the electronic Schrödinger 
equation remains too complicated to be solved for systems with more than one electron, 
due to mathematical limitations. The main problem with its resolution was the electron-
electron repulsion term. Further approximations were thus needed to solve it. In order to 
deal with this problem, the Hartree-Fock (HF) method, also called the self-consistent field 
(SCF) method, was developed, which is based on the independent particle model, where 
each electron is considered to interact with a constant electronic field created by all the 
other electrons. Each electron is thus related with a one-electron wave function (called 
molecular orbital, MO) which is the combination of a spatial function that depends on the 
coordinate of the electron, and a spin function that depends on its spin. The wave 
function has to satisfy the antisymmetry principle, and must change sign if the 
coordinates of the two electron are interchanged (Pauli principle). An easy way to build 
a wave function that respects this principle is by using a Slater determinant of N one-
electron orbitals (N is the number of electrons). With this, the N-particle problem is 
transformed to a set of one-particle problems: 
𝑓𝑖𝜒𝑖 = 𝜀𝑖𝜒𝑖 
(20) 
where 𝑓𝑖 is an effective one-electron operator (Fock operator), in which the 
electron-electron repulsion is treated as an average. 𝜒𝑖 is the corresponding 
eigenfunction (i.e. MO) and the electron in the MO has the orbital energy 𝜀𝑖. 
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The HF equation is non-linear and must be solved iteratively. This is due to the fact 
that the Fock operators are not independent from one another, and so, in order to 
calculate the energy it is necessary to know the wave function of all electrons. We 
employ, therefore, an iterative method in which we begin by selecting a set of molecular 
orbitals that seem appropriate to the system. The Fock operators for each electron are 
formulated using this initial estimate, and the HF equation can be solved, from which 
results a new set of orbitals. This new set is now going to be used to formulate different 
set of Fock operators, and the whole process repeated until the energy difference 
between two consecutive iterations is smaller than a set value.  
The independent-particle model results in an inherent limitation of the HF method, 
since the motion of all electrons are correlated in a real system. Neglecting correlation 
energy (the difference between the HF energy and the exact non-relativistic ground-state 
energy within the Born-Oppenheimer approximation) leads to large deviations from 
experimental results, which makes the HF method very poor for exploring chemical 
reactions. A number of approaches to correct this weakness, collectively called post-
Hartree-Fock methods, have been developed to include dynamic electron correlation. 
For example, Møller-Plesset perturbation theory61 treats correlation as a perturbation of 
the Fock operator. Configuration interaction (CI)62 and couple cluster (CC)63 are also 
methods that allow to recover most (in the limit, all) of the dynamic correlation energy. 
These approaches improve the level of accuracy but become computationally much 
more demanding, and thus are only suitable for relatively small systems. To investigate 
large systems, such as enzymatic reactions, a less costly method is needed. 
 
2.3.2. Density Functional Theory 
In order to deal with the limitations of the HF method and the computational cost 
of the post-HF methods, a new alternative was devised and the density functional theory 
(DFT) approach was born. DFT methods are an alternative to the wave function methods 
described previously. The basis of DFT is the Hohenberg-Kohn theorem, which shows 
that the total energy of a non-degenerate ground state is a unique functional of the 
electron density of the system, namely 𝐸 = 𝐸[𝜌(𝑟)]. This implies that all properties of the 
system can be deduced from the ground-state density and the determination of the 
complicated many-electron wave function can thus be avoided. However, a fundamental 
difficulty emerges here, that is, the exact functional, i.e. the dependency of the energy 
on the given electron density, is not known. Various approximations and attempts have 
been made. 
FCUP 55 
New Therapeutic Strategies to Lower Blood Stream Cholesterol Levels through the Inhibition of HMG-CoA Reductase  
 
The energy functional can be expressed as follows: 
𝐸[𝜌] = 𝑇[𝜌] + 𝐸𝑒𝑒[𝜌] + 𝐸𝑒𝑛[𝜌] 
(21) 
where T is the kinetic energy, Eee the electron-electron repulsion, and Ene the 
nuclei-electron attraction. In 1965, Kohn and Sham contributed a significant 
development, i.e. the orbital-based scheme, in which independent particles move in an 
effective potential (the non-interacting one electron orbitals are called Kohn-Sham 
orbitals, ɸi). The real system of interacting electrons can thus be described through a 
system of non-interacting particles by expressing the electron density as a sum of the 
squared orbitals. Therefore, the total kinetic energy (T) is divided into two parts, the 
kinetic energy of an N electrons non-interacting system (Ts) and a missing fraction (Tc) 
relative to the real interacting system: 
𝑇[𝜌] = 𝑇𝑠[𝜌] + 𝑇𝑐[𝜌] 
(22) 
The functional of electron-electron repulsion (Eee[ρ]) can be divided into the 
classical Coulomb interaction (J) and a non-classical part containing correlation and 
exchange (Encl[ρ]): 
𝐸𝑒𝑒[𝜌] = 𝐽[𝜌] + 𝐸𝑛𝑐𝑙[𝜌] 
(23) 
The total energy can be written as: 
𝐸[𝜌] = 𝑇𝑠[𝜌] + 𝑇𝑐[𝜌] + 𝐽[𝜌] + 𝐸𝑛𝑐𝑙[𝜌] + 𝐸𝑛𝑒[𝜌] 
(24) 
Then, a definition is done by combining the missing part of the kinetic energy (𝑇𝑐[𝜌]) 
and the correlation and exchange part (𝐸𝑛𝑐𝑙[𝜌]) to form the exchange-correlation 
functional (𝐸𝑥𝑐[𝜌]). The total energy can finally be presented as: 
𝐸[𝜌] = 𝑇𝑠[𝜌] + 𝐽[𝜌] + 𝐸𝑛𝑐𝑙[𝜌] + 𝐸𝑥𝑐[𝜌] 
(25) 
The first three terms can be calculated explicitly. All the problems have now been 
centralized in how to accurately describe the exchange-correlation term, 𝐸𝑥𝑐[𝜌], which 
encompasses all the unknown contributions to the total energy. 
Since the true density is that which corresponds to the lowest energy, the 
variational principle can be used to calculate the energy. Using it together with the 
normalization constraints, minimizing the total energy of a determinant constructed by 
Kohn-Sham orbitals results in the Kohn-Sham equations (similar to the Hartree-Fock 
equation): 
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ℎ̂𝑘𝑠𝜙𝑖(𝑟) = 𝜀𝑖𝜙𝑖(𝑟) 
(26) 
where ℎ̂𝑘𝑠 is the one-electron operator and depends on the electron density. If the 
exact form of the 𝐸𝑥𝑐[𝜌] functional in known, the exact total of the many-electron system 
can be obtained by iteratively solving the equation (26. The accuracy of a DFT method 
lies in how accurate the form of 𝐸𝑥𝑐[𝜌] is. 
Many exchange and correlation functionals have been and are still currently being 
developed. A significant improvement to the accuracy of DFT came from the introduction 
of the gradient and higher derivatives of the electron density in the functional, i.e. 
𝐸𝑥𝑐[𝜌, ∇𝜌]. Later, Becke’s introduction of the exact Hartree-Fock exchange as a part of 
𝐸𝑥𝑐[𝜌, ∇𝜌] successfully leads to the popularity of DFT. The DFT methods including HF 
exchange are referred to as hybrid methods. The predominant hybrid functional used by 
chemists is the B3LYP functional, which is written as a linear combination of HF 
exchange and local- and gradient-corrected exchange and correlation: 
𝐸𝑥𝑐
𝐵3𝐿𝑌𝑃 = 𝑎𝐸𝑥
𝐻𝐹 + (1 − 𝑎)𝐸𝑥
𝑆𝑙𝑎𝑡𝑒𝑟 + 𝑏𝐸𝑥
𝐵88 + 𝑐𝐸𝑐
𝐿𝑌𝑃 + (1 − 𝑐)𝐸𝑐
𝑉𝑊𝑁 
(27) 
The weighting parameter 𝑎 determines the extent of replacement of the Slater local 
exchange (𝐸𝑥
𝑆𝑙𝑎𝑡𝑒𝑟) by the exact HF exchange (𝐸𝑥
𝐻𝐹); 𝑏 control the addition of Becke’s 
gradient-correction to the exchange functional (𝐸𝑥
𝐵88); 𝑐 defines the inclusion weight of 
the LYP correlation (𝐸𝑐
𝐿𝑌𝑃) and the VWN correlation (𝐸𝑐
𝑉𝑊𝑁) functionals. (The difference 
between LYP and VWN is that the first is a gradient-corrected correlation functional, 
whereas the second is a local correlation functional.) The three coefficients were 
optimized by minimizing the average absolute deviation of theory from experiment for 
116 atomic and molecular properties (56 atomization energies, 42 ionization potentials, 
8 proton affinities and 10 first-row total atomic energies). 
An important advantage of the DFT methods, when compared to wave-function-
based methods, is the lower scaling. For DFT methods, the dependency of 
computational time (t) on the number of basis functions (N, which can also be 
approximately considered as the number of electrons) is t ~ Nα (α  3), while α is larger 
for wave-function methods. For example, in the case of HF methods, α = 4. The relatively 
low computational cost makes the DFT methods possible to be applied to large systems. 
However, the employment of these methods is definitely affected by its accuracy, in 
particular the accuracy on geometry and energy.  
Even though DFT seems to be an effective tool with several advantages, it is 
important to notice that it is not perfect and comes with several deficiencies, involving 
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mainly self-interaction errors, near-degeneracy errors and the lack of description of Van 
der Waals interactions. In wave-function methods, the artificial repulsion between an 
electron and itself is effectively canceled by an exchange term. In DFT, Coulombic terms 
are described exactly, but the exchange is described by an approximate functional. 
These terms do not cancel in DFT, leading to so-called self-interaction errors. This error 
artificially stabilizes delocalized transition states and tends to decrease the energy barrier 
heights.  
The near-degeneracy error is due to the inherent description of the wave function 
in as a single determinant (the non-dynamical correlation is lacking). In contrast to the 
effect of the self-interaction error, this one tends to increase the height of the barrier. 
Therefore, there is a substantial cancellation effect between this two errors. In practice, 
the B3LYP functional appears to be built to balance these errors as well as possible. For 
high-electron-delocalization reactions, like hydrogen atom or proton transfer reactions, 
the barriers are usually underestimated since the self-interaction error prevails in these 
cases, while in the case of most other reactions it tends to be overestimated, since the 
near-degeneracy error predominates. 
The third deficiency of DFT is the lack of a description of Van der Waals 
interactions. This deficiency often leads to exaggerated repulsion when the atoms are 
forced close to each other, which usually happens in systems with several large 
substituents or ligands. 
 
2.3.3. Basis Sets 
The quality of the results obtained when solving the Schödinger equation, be it 
using HF methods or DFT methods, depends on the basis sets we use to solve it. Basis 
sets are nothing more than a collection of known functions through the linear combination 
of which we can reproduce an unknown function. This functions usually take a shape 
similar to those of the atomic orbitals. As it would be expected, the more functions one 
uses, the better are the results expected to be. However, this brings about a major 
drawback: the greater the number of functions, the larger the time it takes to compute 
the result. This relationship between time and precision must be considered before 
attempting to make any calculation so that there is a good balance between both 
variables. 
Basis sets can be divided between several different types, although those that are 
mostly used are the Slater-type orbitals (STOs) and Gaussian-type orbitals (GTOs).  
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STOs offer a good description for the electronic density around the atom. 
Nevertheless, it is worth noting that for systems with several atoms, where the atomic 
orbitals are centered in different atoms, the integrals that compose these functions are 
not solvable analytically when there are more than two centers. This limitation restricts 
the use of the STOs. 
GTOs are the most commonly used type of basis sets. Contrarily to STOs, these 
GTOs can be solved analytically for multi-electron integrals, however this types of 
functionals do not provide a good description of the electronic density, particularly for 
distances very near or very far from the nucleus, which demands that we use a larger 
number of Gaussian functions. Despite these limitations, the use of GTOs is preferred to 
STOs because the higher number of functions used is balanced by their mathematical 
simplicity, which lowers the computational cost. The results obtained using GTOs can be 
further improved through the use of a contracted Gaussian basis set, which are 
generated through linear combination of uncontracted Gaussian functions (primitives) 
with fixed coefficients so that they form a smaller set of functions. Contracted GTOs 
enhance the description of orbitals with electrons closer to the nucleus, when compared 
to uncontracted GTOs, but they still do not correctly emulate the real behavior of these 
electrons. However, since the electrons closer to the nucleus do not usually play a major 
role in a chemical sense, this approximation is good enough to describe them without 
compromising the results. 
Even though basis sets present several mathematical advantages, they lack in that 
they are not very flexible, i.e., they are not good at describing the deformation that occurs 
in orbitals when they are near other atoms. In order to give basis sets more flexibility, 
several methods, including polarization functions and diffuse basis functions, have been 
developed. 
Polarization functions are nothing more than a set of Gaussian functions one unit 
higher in angular momentum than what are present in the ground state of the atom, which 
will increasing the flexibility of the basis set in the valence region in the molecule, since 
the electronic density can polarize the orbitals in energetically favorable directions.. This 
method is especially convenient when the distribution of electronic density around the 
nucleus is not isotropic. 
For excited states and anions where the electronic density is more spread out over 
the molecule, some basis functions which themselves are more spread out are needed 
(i.e. GTOs with small exponents). These additional basis functions are called diffuse 
functions and they are normally added as single GTOs. 
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2.4. Hybrid Methods (QM/MM) 
When studying the catalytic mechanism of enzyme, the use of computational 
methods has several advantages over experimental methods. They are faster and 
cheaper, and allow for the characterization of transition states and intermediaries, not 
only structurally but also energetically. However, when using computational methods, we 
must consider that enzymes are systems constituted by thousands of atoms, which make 
the resolution of the Schrödinger equation (or the calculation of the electronic density) 
considerably more complex. In order to determine the energy of such systems we can 
make use of very accurate methods, since that would make the calculation much more 
computationally demanding. Still, considering that when studying enzymatic 
mechanisms one must account for the forming and breaking of bonds, the method used 
must handle electrons explicitly. 
In order to solve this problem, hybrid methods were created, which allow the 
system to be divided in several parts, each of which treated with a different theoretical 
level. If we were to divide the system in three parts, they could each be represented as 
follows: 
 An internal layer, which includes all residues involved directly in the 
catalysis (active site) and the substrate. This layer should be treated with 
the highest theoretical level (for instance, post-Hartree-Fock or DFT), since 
it will in this layer that the change in chemical bonds will happen. 
 An intermediate layer, which contains those residues closest to the active 
site. This layer emulates the short-range interactions between the active 
site and the rest of the enzyme, maintaining its structure and stabilizing it 
during the reaction. This layer should be treated with a medium level of 
theory, using for example a semi-empiric method. 
 An outer layer, which includes the rest of the enzyme, emulating the proteic 
environment and is to be treated using the lowest level of theory, such as 
molecular mechanics. 
Using different levels of theory for different layers will allow us to save time in the 
calculations and include a larger portion of the system. High levels of theory are only 
used for a restricted number of atoms and therefore the running time is shortened. 
However, since we also simulated the atoms that are surrounding the active site, the 
environment in which the reaction takes place resembles more closely that in which 
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reaction takes place in vivo. Overall it is expected that using this technique we will be 
able to gather results that are more precise in a smaller time frame. 
Nowadays there are several different types of hybrid methods, but overall they can 
be divided in two categories: addictive and subtractive. This distinction is made by taking 
into account the way the final energy is calculated. In the case of addictive methods, the 
final value for the energy is calculated by adding all the individual values obtain for each 
layer plus a coupling term, which describes how the single layers interact with each other. 
For subtractive methods, the final energy calculation can be a bit more complex. We 
shall explore subtractive methods further in the next section by illustrating how the 
ONIOM method works. 
 
2.5. ONIOM  
As referred previously, ONIOM (Our own N-layered Integrated Orbital and 
Molecular mechanics) 64-67 is a hybrid subtractive method in which the system we want 
to study is divided in different layers, each of which treated with different levels of theory. 
With the ONIOM method, systems are usually decomposed in two layers: the high 
layer, which is treated with a more precise mehtod (quantum mechanics) and the low 
layer, which is treated with a faster and less accurate methods, frequently molecular 
mechanics. The total energy of the model is calculated using the energies of each part 
calculated individually and according to the following expression: 
𝐸𝑂𝑁𝐼𝑂𝑀 =  𝐸𝐻+𝐿
𝑀𝑀 −  𝐸𝐻
𝑀𝑀 +  𝐸𝐻
𝑄𝑀 
(28) 
𝐸𝐻+𝐿
𝑀𝑀  and 𝐸𝐻
𝑀𝑀 refer to the energies of the whole system and the high layer, 
respectively, calculated using a low level method, and 𝐸𝐻
𝑄𝑀
 is the energy of the same 
high layer but this time calculated with a high level method. 
One of the main problems with ONIOM (as well as other hybrid methods) when 
used for systems composed of a single macromolecule, which is then divided in different 
regions, relates to how the interface between the two regions should be handled. We 
must bear in mind that when separating both QM and MM subsystems we are breaking 
covalent bonds between the atoms, and therefore creating unpaired electrons in the high 
layer. An easy and elegant way of dealing with this is by introducing link atoms. In this 
metodology, the layers are separated from one another and at the broken covalent bonds 
link atoms are added, usually hydrogen atoms, which allow the calculation of a 
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meaningful electronic structure and therefore a reasonable energy value for the model 
system 
Another problem as to do with how the electrostatic interaction between both layers 
should be calculated. This can be done using two different methods: electrostatic 
embedding or mechanical embedding. Electrostatic embedding includes the polarization 
of the QM region by the MM charge distribution in the QM calculation, which means that 
the electronic density/wavefunction of the high layer is modified and optimized according 
to the atoms on the low layer. Mechanical embedding, in the other hand, the electronic 
structure of the high layer is calculate in vacuum, without any influence from the low 
layer, and atomic partial charges are assigned to QM atoms based on the calculated 
electronic structure. Both approaches have their advantages and disavantages: 
electronic embedding yelds more accurate results, but is also more costly in 
computationally, so when choosing between one or the other one should bear this 
differences in mind.
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CHAPTER 3 
RECEPTOR-BASED VIRTUAL SCREENING PROTOCOL 
FOR DRUG DISCOVERY 
In the pharmaceutical arena, virtual screening is normally regarded as the top 
CADD tool to screen large libraries of chemical structures and reduce them to a key set 
of likely drug candidates regarding a specific protein target. This chapter provides a 
comprehensive overview of the receptor-based virtual screening process and of its 
importance in the present drug discovery and development paradigm. Following a 
focused contextualization on the subject, the main stages of a virtual screening 
campaign, including its strengths and limitations, are the subject of particular attention in 
this review. In all of these stages special consideration will be given to practical issues 
that are normally the Achilles heel of the virtual screening process.  
 
Adapted from reference 68 
In this review, Diana Gesto wrote several parts of the original manuscript, with 
special focus on section 3.4 (and all its subsections), helped with its editing and revision. 
 
3.1. Introduction 
The process of drug discovery is very complex and requires an interdisciplinary 
effort to design effective and commercially feasible drugs. The objective of drug design 
is to find a drug that can interact with a specific drug target and modify its activity. The 
drug targets are generally proteins that perform most of the tasks needed to keep cells 
alive. Drugs are small molecules that bind to a specific region of a protein and can turn 
it on or off. Some very powerful drugs, such as antibiotics or anticancer drugs, are used 
to completely disable a critical protein in the cell. These drugs can kill bacteria or cancer 
cells. 
It is generally recognized that drug discovery and development are very time and 
resource-consuming processes and the whole process is often compared to searching 
for a needle in a haystack. It is estimated that a typical drug discovery cycle, from lead 
identification to clinical trials, can take 17 years with a cost of 800 million US dollars. In 
this process it is estimated that five out of 40,000 compounds tested in animals 
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eventually reach human testing and only one in five compounds that enter clinical studies 
is approved. This represents an enormous investment in terms of time, money and 
human resources. It includes chemical synthesis, purchase, and biological screening of 
hundreds of thousands of compounds to identify hits followed by their optimization to 
generate leads, which require further synthesis. In addition, predictability of animal 
studies in terms of both efficacy and toxicity is frequently suboptimal. Therefore, new 
approaches are needed to facilitate, expedite and streamline drug discovery and 
development, save time, money and resources. 
On October 5, 1981, Fortune magazine published a cover article entitled “Next 
Industrial Revolution: Designing Drugs by Computer at Merck”. Some have credited this 
as being the start of intense interest in computer-aided drug design (CADD)69. 
CADD is defined by the IUPAC as all computer assisted techniques used to 
discover, design and optimize compounds with desired structure and properties. CADD 
has emerged from recent advances in computational chemistry and computer 
technology, and promises to revolutionize the design of functional molecules. The 
ultimate goal of CADD is to virtually screen a large database of compounds to generate 
a set of hit compounds (active drug candidates), lead compounds (most likely candidates 
for further evaluation), or optimize known lead compounds, i.e. transform biologically 
active compounds into suitable drugs by improving their physicochemical, 
pharmaceutical and ADMET/PK (pharmacokinetic) properties70. 
The fast expansion and popularity of this field of research has been made possible 
partially by the advances in software and hardware, computational power and 
sophistication. On the other hand, the knowledge of the 3D shapes of proteins, nucleic 
acids, and complex assemblies are fundamental to understand all aspects of potential 
drug targets. It is remarkable that, from 1970 to 2004, 50,000 structures have been 
deposited on the protein databank, in 2014 this number has tripled to 150,000 and in 
2018 it is expected that this latter number doubles. In addition, the increasing digital 
repositories containing detailed information on potential drugs and other useful 
compounds provide goldmines for the design of new drugs. 
CADD is widely used in the pharmaceutical industry to improve the efficiency of 
the drug discovery and development pipeline.  One method that was quickly adopted 
was the virtual screening of large compound databases against drug targets. The goal 
is to select a set of molecules with desirable properties (active, drug-like, lead-like) 
targeting a specific protein and eliminate compounds with undesirable properties 
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(inactive, reactive, toxic, poor ADMET/PK). The computational methodologies used for 
this purpose are known as virtual screening methodologies.  
The generic definition of virtual screening encompasses many different 
methodologies, which are generally divided in two main classes: the ligand-based virtual 
screening methods and the receptor-based virtual screening methods.  
Ligand-based virtual screening methods aim to identify molecules sharing common 
features, both at the chemical and physical levels grounded in the assumption that similar 
compounds can have similar effects on a drug target71. These methods normally discard 
all information related to the drug target and focus exclusively on the ligand. Within the 
lock-and-key paradigm, these approaches compare different keys, and neglect the lock. 
Thus, the model of the receptor is only implicitly built based on what binds to it72. The 
main downside of these methods is that substantial activity data regarding the 
compounds that are studied are required to get reasonable results.  
Receptor-based virtual screening methods, also called structure-based methods, 
require the existence of a 3D structure of the target. These methods involve explicit 
molecular docking of each ligand into the binding site of the target, producing a predicted 
binding mode for each database compound, together with a measure of the quality of 
the fit of the compound in the target-binding site. This information is then used to sort out 
ligands that bind strongly to the target protein from ligands that do not. Receptor-based 
approaches are gaining considerable importance over ligand-based techniques, 
particularly as more and more 3D structures of target proteins are determined and 
become available, and also because the results tend to be more reliable and accurate. 
The current state-of-the-art of receptor-based virtual screening is reviewed in this 
chapter, and general approaches, successes and pitfalls associated with the technology 
are highlighted. 
 
3.2. The Screening Process 
Receptor-based virtual screening encompasses a variety of sequential 
computational stages, including target and database preparation, docking and post-
docking analysis, and prioritization of compounds for experimental testing. A typical 
workflow of a receptor-based virtual screening is presented in Figure 17. All stages of 
this workflow depend on sound implementation of a wide range of computational 
techniques that will be discussed in detail in the following sections. In each section 
special attention will be given to practical issues that are normally the Achilles heel of 
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the virtual screening process. Since in this book chapter only the receptor-based virtual 
screening will be reviewed, we are going to adopt the general term, virtual screening 
(VS), to describe this type of screening methodologies. 
 
 
Figure 17 - General workflow of a receptor-based virtual screening. The typical workflow consists of a preparation 
phase for the database and the target, followed by a molecular docking phase, and concludes with the post-
processing and compound selection phases. 
 
3.3. Target Selection 
Target selection is among the first stages of a virtual screening campaign and it is 
pivotal for a successful drug development process. Among the four types of 
macromolecules that can be targeted (proteins, polysaccharides, lipids and nucleic 
acids) with small-molecule compounds, proteins, and within those enzymes, are 
generally the first choice, since their binding pocket properties allow for high specificity, 
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potency and low toxicity. When considering a potential protein target to modify a disease 
it should be pondered if it is advantageous to select an upstream, widely implicated target 
or, instead, a downstream target, very specific to the pathway that we want to tackle. 
Once a protein target with the potential to modify the disease has been identified, 
it is time to get its 3D structure. The Protein Data Bank is the leading repository for 
experimentally determined 3D structures of large biological molecules. This database is 
therefore the first approach to retrieve a protein 3D structure for a VS campaign. In the 
case that the experimental 3D structure of the protein does not exist, then homology-
modeling methods can be used to build it. There are several examples in the literature 
showing that these homology models can be used with success in VS campaigns73-75. 
 
3.3.1. Binding Site Detection 
Once the 3D structure of a protein has been obtained then it is possible to evaluate 
its druggability score. The Druggability can be understood as the capability that a 
receptor has to bind molecules with drug like properties. This depends of course on the 
ability of the molecule to favorably interact with a particular pocket or cleft in that protein.  
The location of these binding sites is easy when a ligand has been co-crystallized 
explicitly with the target protein. However, when this sort of information is not available, 
the location of the binding site can be cumbersome. In these cases computational tools 
can be used to identify and characterize potential binding sites. Among the available 
computational tools, some algorithms rely mostly on geometric characteristics to search 
for binding pockets, such as POCKET76, LIGSITE77, SURFNET78, SPHGEN79, 
FPOCKET80, etc., while others, such as Q-SITEFINDER81, GRID82-83, 
POCKETPICKER84, FLAPSITE85 , CS-MAP algorithm86, in order to calculate the energy 
of probes interacting with potential binding sites to identify and rank them. Geometry-
based algorithms are usually prized because they are fast and robust in dealing with 
structural variations or missing atoms/residues in the input structure87. Energy-based 
algorithms, on the other hand, are often more sensitive and specific88. Despite the 
distinctive approaches, the performance is very similar and both methods can correctly 
predict 95% of the known binding sites89. 
 
3.3.2. Target Preparation 
After the target has been defined and the most druggable binding site chosen, it is 
necessary to prepare the target for docking. The general steps in target preparation 
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require removing solvent and ligand molecules, adding hydrogen atoms, setting up bond 
orders and formal charges, capping chain termini and defining amino acid protonation 
states (atom types). It might also be necessary to refine the crystallographic structure 
and define the binding site portions that will be left flexible. Target preparation is usually 
overlooked but the effect on virtual screening enrichment might be considerable. 
 
3.3.2.1. Structure Refinement 
Crystallographic structures are pledged with uncertainty. A common example is 
the identification of the atoms in amide groups and in imidazole rings that are difficult to 
distinguish. For example, 180° flips of the terminal chi angle still fit in the electron density. 
These flips, in addition to the protonation state of aspartate, glutamate, lysine and 
histidine residues, the two tautomers of histidine residues or hydrogen orientation in 
hydroxyl and thiol groups can alter significantly the hydrogen bond network of the binding 
site. Sastry G. et al.90 have shown that careful attention to these details could improve 
virtual screening performance on 20 out of 36 targets. 
Another type of structure refinement that has a positive impact in the performance 
of the VS campaign is structure relaxation. A simple structure minimization removes 
clashes and tensions and improves the hydrogen bond network, two conditions that can 
be important to improve ligand fitting in the binding pocket of the target protein.90 
 
3.3.2.2. Water Molecules 
The 3D structure of proteins are often populated with a series of water molecules 
located inside the binding pocket. Some of these water molecules establish important 
interactions between the protein and the ligand and are thus important to take into 
account when studying protein-ligand interactions91. However, in many cases the water 
molecules are not important and may affect negatively the VS campaign, since they can 
occupy some region on the binding pocket that is required for the binding process.  There 
is no perfect strategy to determine which active-site waters are important for ligand 
binding and which are not92. Therefore it is always good practice to analyze with caution 
the role of the water molecules inside the active site. To this end, several models of the 
protein with a different number of water molecules inside the active site should be tested 
and the results should be confronted with experimental data whenever it is available. 
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3.3.2.3. Metals 
The preparation of metal sites in the receptor should be performed in accordance 
with the requirements of molecular docking programs. Scoring functions use various 
terms and formalisms to describe the interaction between docked ligands and the metal 
atom. In the simplest cases, scoring functions reward the proximity of potentially 
coordinating atoms, such as oxygen and nitrogen, to metals in receptor molecules. Other 
simplistic approaches treat metal atoms as regular hydrogen bond donors, including 
metal coordination in the hydrogen-bonds energy. In these situations, special attention 
is not required in the receptor model, but the protonation state of docked ligands might 
be important. 
Some specialized approaches attempt to improve the docking accuracy and 
binding affinity prediction by re-parametrization of the metal ion force field, which often 
results in significant improvements93-94. For instance, the metal-ligand interaction is still 
modeled by traditional electrostatic formalisms, but fine tuning of the electrostatic 
interactions by polarizing ligand charges using the metal ion and its protein ligands in a 
QM/MM calculation should be used instead. 
 
3.4. Ligand Selection 
With virtual screening we have the possibility to quickly test a great number of 
compounds without much effort. However, it is obviously impossible to screen the entire 
chemical space for a single target in a timely manner, which means that we must 
somehow restrict the number of compounds to be tested. In order to achieve a 
manageable library we need to filter out some molecules in advance, which can be 
achieved with the help of different methods. Still, it is important to bear in mind that for a 
successful virtual screening campaign, it is desirable to have a database with as much 
variety as possible. 
 
3.4.1. Databases 
Before starting a new virtual screening campaign, it is necessary to collect all the 
structures that we want to test. If the search space is very limited, and we know which 
kind of molecules is likely to bind our target, we can draw our own structures and readily 
start the docking process. However, for most campaigns this is not the case. Usually, 
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before docking, it is necessary to build a library of potential ligands, which can have 
thousands of structures that will eventually be tested. 
In recent years several databases of chemical structures have been developed, 
which can be easily accessed by most people who wish to build a compound library. 
These databases not only store the structure of these molecules, but also many chemical 
and biologically relevant information95. 
One of the most commonly used compound database is ZINC96. ZINC is a free 
database with over 35 million purchasable structures, including more than 4.5 million 
clean leads. The structures can be obtained in different formats, and several 
structural/functional filters are available to further limit the search space. Other 
databases include ChemSpider (32 million+ compounds), ChemDB97 (5 million 
compounds) and PubChem98 (63 million unique structures). Furthermore, all major 
pharmaceutical companies also have in-house corporate libraries, comprising several 
million compounds. 
 
3.4.2. Reducing the Search Space 
In theory, any molecule can be a ligand to some target. Nevertheless, for a 
compound to be considered a drug it needs other characteristics that make it suitable to 
be administered to the patient. For instance, if a ligand is known to have toxic, mutagenic 
or teratogenic properties, it can be automatically excluded as well as inorganic, insoluble, 
reactive and aggregating molecules. Also, since the ultimate goal of virtual screening is 
the creation of a new drug, we can easily reduce our search space if we focus solely on 
compounds that can be synthesized. There is no point in testing molecules that cannot 
exist outside the virtual world. 
In order to evaluate if a new substance is a good candidate to become a drug or 
not, scientists have come up with the concept of druglikeness. This means that in order 
to be considered drug-like, a new molecule must have some of the characteristics shared 
by the majority of drugs known so far, which are related to the bioavailability of the 
compound after administration. 
Currently, there are several methods that can be used to evaluate how drug-like a 
certain substance is, which allow us to reduce our database. Among them we have 
simple counting methods and functional group filters. 
It is important to point out that this exclusion method is not infallible, as there can 
be good drug candidates that do not abide by these rules. It is also worth mentioning that 
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even if a compound follows all these rules, it is not guaranteed that it will pass all stages 
of the clinical trials and, in fact, it can be excluded in the earlier stages. 
 
3.4.2.1. Counting Methods 
Counting methods allow us to easily limit the search space by selecting only 
molecules that have certain properties, which are associated with other drug-molecules. 
Counting methods take into account characteristics like the partition coefficient (log P), 
molecular weight, and hydrogen bonding groups, all of which are related to 
bioavailability. It is expectable that if we include only compounds that present favorable 
characteristics our chances of finding a new drug that successfully passes the clinical 
trials will increase immensely. 
One of the most famous counting methods is known as the Rule of Five and was 
developed by Christopher A. Lipinski99. It presents a rule of thumb that can be used to 
evaluate the drug likeliness of a compound, and dictates the following: 
• The number of hydrogen bond donors must be 5 or less; 
• The number of hydrogen bond acceptors must be 10 or less; 
• Less than 500 Da of molecular weight; 
• Log P smaller than 5. 
The name Rule of Five originates in the fact that all numbers are multiple of 5. 
Although there seems to be quite a few cases to which these rules do not appear to 
apply, most of them are antibiotics, vitamins, antifungals, and cardiac glycosides. 
Further work done by Ghose et al. allowed for the improvement of the Rule of Five. 
After analyzing the physicochemical property profiles of more than 6000 drugs (included 
in the Comprehensive Medical Chemistry Database), they established that 80% of these 
had the following properties100: 
• Log P between -0.4 and 5.6; 
• Molecular refractivity between 40 and 130; 
• Molecular weight between 160 and 480; 
• Number of atoms between 20 and 70; 
• Polar surface area smaller than 140 Å2. 
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Veber et al. proposed further that the number of rotatable bonds should be smaller 
than 7, in order to enhance oral bioavailability101. 
 
3.4.2.2. Functional Group Filters 
Functional group filters are based on the fact that certain functional groups are not 
suitable in a drug, either because they are highly reactive or toxic for the organism. 
Functional groups known to cause damage to the organism, such as potentially 
mutagenic or teratogenic groups are often discarded, since the compounds they form 
are usually also harmful. On the other hand, reactive groups (alkyl-bromides, metals, 
etc.) can often originate hits, which are subsequently not pursued because most of the 
times they give rise to false positives. Moreover, specific reactive groups such as alkyl-
bromides, metals, etc., often give rise to false positives. This allows us to save time by 
focusing solely on compounds that are more likely to be good leads. 
 
3.4.3. How to use Filters 
Usually we do not want to use only one type of filter. While filtering out compounds 
based solely on one aspect will definitely reduce our library, it will still be rather large and 
contain molecules that, had we used a different filter, would not be there. Since our 
ultimate goal is to find the most leads in the least amount of time it is good practice to 
use more than one type of filter in order to enrich our library with the molecules that have 
the best odds of being a hit. 
Another method for further reducing the search space is to cluster molecules based 
on their similarity. Similarity between compounds can be calculated with different 
methods, the most often used being the Tanimoto coefficient (section 3.4.3.2.). 
 
3.4.3.1. Similarity Searching 
When doing virtual screening, one of the most important parts is to find as much 
information on the target as possible: to know which the most favorable region to bind 
an inhibitor is, where the active site is, what kind of molecules is more likely to become 
hit compounds. However, we sometimes have little more knowledge about the target 
than its 3D structure and have to try and make the best out of it. In cases where 
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information is scarce, in order to maximize our chances of finding an active hit, it is best 
to use libraries with as much diversity as possible. 
The problem with libraries built on diversity is that they can have a very larger 
number of compounds, which might make them impossible to screen in a reasonable 
time frame. We can nonetheless restrict the search space if we assume that similar 
molecules usually display similar biological activities. What this means is that if we group 
molecules in sets based on their identity and use only one representative from each set 
we can have a highly diverse library with fewer elements, thus eliminating chemical 
redundancy. Although this assumption is widely accepted, one can easily find several 
arguments that contradict it as, sometimes, subtle changes in a molecule can cause its 
activity to change sharply, or the reverse, in which a structure is altered significantly and 
yet its activity remains identical. Still, this method of restricting the search space has 
been shown to work and it has been proved that a set of compounds related to an active 
hit have more biologically active molecules than a randomly generated set. However, if 
the chemical space is overly restricted, there is a reduced probability of finding hits, 
because even similar molecules can have different activities. We must therefore select 
a similarity cutoff big enough to broadly restrict the library size, and yet small enough so 
that all the molecules in a given set can be well represented by a single compound. 
Similarity search is not used only in cases where we have little to no information 
about the target. It can also be used when we already know some of the characteristics 
that an active compound must have (for example if we have information on a hit) and 
wish to find other molecules with higher affinity. In this case, we build our dataset by 
gathering molecules that exhibit a certain degree of similarity to our substructure. 
 
3.4.3.2. Tanimoto Coefficient 
Similarity can be defined in several different ways. In chemistry (and especially in 
virtual screening) one of the most important indexes used to represent similarity is the 
Tanimoto coefficient (or Jaccard coefficient). The Tanimoto coefficient is a measure to 
determine how similar (or how distant) two objects are. 
The Tanimoto coefficient is calculated by enumerating a list of attributes, which 
may or may not be present in a given object. To calculate how similar two different 
objects are, one simply needs to consider if these attributes are present in both objects 
or only in one of them. The coefficient that one gets by dividing the number of common 
attributes by the total number of attributes is the Tanimoto coefficient. In mathematical 
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terms, if we have two objects A and B, their Tanimoto coefficient will be given by the 
following expression: 
𝑇𝑐(𝐴, 𝐵) =
|𝐴 ∩ 𝐵|
|𝐴 ∪ 𝐵|
 
(29) 
Another way to express this coefficient is if we consider the following table, which 
represents the presence (1) or absence (0) of features in two objects: 
 
 
Object B 
0 1 
Object A 
1 a c 
0 d b 
 
a – number of features present in object A and not in object B 
b – number of features present in object B and not in object A 
c – number of features present in both objects 
d – number of features absent in both objects 
 
𝑇𝑐(𝐴, 𝐵) =
𝑐
𝑎 + 𝑏 + 𝑐
 
(30) 
Based on this equation, it is easy to see that the Tanimoto coefficient can vary from 
0 to 1, 1 meaning that both objects are identical (at least based on the characteristics we 
chose) and 0 meaning that they are completely different. To exemplify, let us consider 
ten different attributes for objects A and B, which are either present or not in the following 
manner: 
 
A 0 1 1 0 0 1 0 1 0 0 
B 1 0 0 0 1 1 1 1 1 0 
 
 
If we create a table identical to the one above, we get the following: 
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Object B 
0 1 
Object A 
1 2 2 
0 2 4 
 
To calculate the Tanimoto coefficient we must divide 2 (number of attributes 
present in both objects) by 8 (number of attributes present in either both or only one 
object), which gives us a similarity of 0.25. It is important to note that the Tanimoto 
coefficient does not take into account features that are absent from both objects, even 
when we are comparing more than two, while other methods, like the Euclidian 
coefficient, do. This indicates that different methods may give different results, depending 
on the number of features we consider. 
The Tanimoto similarity is used in Chemistry to compare different molecules and 
substructures and to find out how identical they are in relation to one another. Similarity 
is calculated by selecting different attributes and checking whether they are present or 
absent in each compound. 
 
3.5. Molecular Docking 
Once the target protein and a database of compounds have been selected, 
molecular docking is ready to run. This is the stage that requires more computational 
cost and time in the VS and for this reason it is regarded as the heart of any virtual 
screening campaign. 
Molecular Docking is a computational method that allows predicting the preferred 
pose and conformation of one molecule (ligand) in relation to a second one (often larger 
and called receptor), when the binding between the two forms a stable complex. The 
preferred orientation of the molecule in relation to the receptor can then be used to 
predict the strength of association or the binding affinity between both receptor and 
ligand. In a virtual screening campaign, the molecular docking stage is repeated, as 
many times as the number of compounds that exists in the compound library. 
Currently, there is a relatively large and ever increasing number of molecular 
docking programs that can be used in virtual screening campaigns. Generally speaking, 
these programs have similar implementations. All of them involve the search for the 
preferred poses/conformations of the ligand in relation to the receptor. These 
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poses/conformations can be accomplished using two types of algorithms: the search 
algorithm and the scoring function. The search algorithm generates the various possible 
poses (conformations and orientations) to fit the ligand into the binding pocket of the 
receptor. The scoring function ranks the different poses and locations of the ligand that 
are generated by the search algorithm, and orders them by a score. This value should 
ideally represent the thermodynamics of interaction of the protein–ligand system in order 
to distinguish the true binding modes from all the others that are explored. 
In the end of this process, the best-scored solution should correspond to a true 
binding conformation and should be close to the one that is observed experimentally, if 
such information exists. 
The majority of molecular docking programs are developed to be fast since they 
are supposed to be applied to large databases of compounds. To this end, several 
assumptions and simplifications are included in the search algorithms and scoring 
functions that will be described briefly in the next sections.  
 
3.5.1. Search Algorithms 
The goal of a search algorithm is to provide enough degrees of freedom to the 
system, so that it will more accurately predict and/or reproduce experimental data 
(structures obtained from X-ray crystallography or NMR). 
A real biological binary protein-ligand system requires searching over a space of 
(N*M + 6) dimensions (N and M parameters describe the protein and ligand 3D 
structures, respectively, and 6 are the rotation and translation components of the spatial 
arrangement of one unit onto the other). This high dimensional space is computationally 
untreatable, and to overcome this issue, the docking algorithms integrate different 
approximations to efficiently sample the search space. The number of available search 
algorithms is continuously increasing to optimize the speed, reliability and accuracy in 
sampling the relevant conformational space. The speed is particularly crucial for virtual 
screening campaigns, in which millions of different ligands are evaluated. Currently, the 
docking algorithms can be categorized into three main classes: rigid-body, flexible-ligand 
and flexible target methods.  
Rigid-body Search Algorithms are the most basic and fastest algorithms to sample 
the conformational space in molecular docking. They do not take into account the 
flexibility of neither ligand nor receptor and therefore the final results are just based on 
the geometrical complementarity between both molecules. This simplest approach was 
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widely applied in the earlier protein-ligand docking studies and, currently, in protein–
protein docking protocols or in the initial stages of virtual screening studies102 103-104. 
Popular implementations of this algorithm are found in ZDOCK105, FTDOCK106, 
SYSDOC107, EUDOC108, DOCK102, 109, MSDOCK110, LigandFit111 and Glide112. 
Flexible-Ligand Search Algorithms consider the conformational space of the ligand 
while the receptor is kept rigid. Nowadays, these algorithms are the most popular ones 
and used in a wide range of molecular docking packages113-115. Taking into account the 
type of algorithm that is used to flexibilize the ligand they are divided in two main classes: 
systematic algorithms and random or stochastic algorithms. 
Systematic search algorithms try to explore all the degrees of freedom of the ligand 
through conformational searches, fragmentation base methods or resorting to databases 
where this sort of information can be found. The systematic conformational approach is 
implemented in DOCK109,  the fragmentation base methods in LUDI116, FlexX117, 
DOCK109, ADAM118, Hammerhead119, Surflex120-121, eHiTS122, FLOG123 and the 
databases approaches in FLOG123. 
The random search algorithms sample the ligands’ (or a population of ligands) 
conformational space by doing stochastic modifications in its conformation, which could 
be accepted or rejected based on a predefined probability function. This is generally 
implemented using Monte Carlo methods, Genetic Algorithms or Tabu Search methods. 
Monte Carlo (MC) methods take into account a Boltzmann probability function as the 
acceptance criterion for a newly generated ligand pose. MC algorithms dock the ligand 
inside the protein binding site through many random translations, rotations and 
conformations, decreasing the probability of becoming trapped in local minima. 
Prodock124, ICM125, MCDOCK126, DockVision127 and QXP128 are some examples of 
docking programs that have an MC-based algorithm. 
Genetic algorithms (GA) are a global searching strategy that belongs to the 
evolutionary programming methods with the purpose of finding solutions for search 
problems and, in the molecular docking case, of trying to find the pose closest to the 
global energy minimum for a given protein conformation. GA methods are heuristic 
algorithms that emerged from genetics and the theory of biological evolution. GOLD129-
130, AutoDock131, DIVALI132, and DARWIN133 are some examples of docking programs 
that implement genetic algorithms in their search engines. 
Tabu Search methods are meta-heuristic methods characterized by an iterative 
procedure that moves the ligand from one pose to another and imposes several 
restrictions to prevent revisiting previously considered poses. Earlier visited poses are 
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stored in a tabu list and the root-mean-square deviation (RMSd) of a new conformation, 
in relation to the previous ones, is calculated and used as criterion to accept or reject the 
new conformation relatively to the previous ones. PRO_LEADS134-135 is the most popular 
docking program that uses a tabu-search algorithm. 
Several protein-ligand docking studies have shown that the application of the 
flexible-ligand docking algorithms only give successful results when the protein is rather 
rigid and its 3D structure is representative of the target conformation in the docked 
complex. However, many proteins display significant structural changes upon ligand 
binding, such as the local rearrangement of side chains near the binding site. This is 
particularly evident for enzymes because they can possess different conformations to 
recognize their substrates and also for the transition state’s stabilization along catalysis. 
This means that these small movements can have a high impact on the molecular 
docking results and the generation of false positive binding solutions136. 
To solve this challenging docking problem, some specialized search algorithms 
and computational strategies were developed to accurately account for the partial protein 
flexibility, in addition to the ligand flexibility, i.e. Flexible-Ligand and Receptor Search 
Algorithms. Nowadays, several docking programs offer this treatment. Approaches 
addressing the target flexibility can be classified as Molecular Dynamics (MD) and Monte 
Carlo (MC) methods, rotamer libraries, protein ensemble grids and soft-receptor 
modeling. 
MD simulations and MC methods generate different configurations for the system, 
and their main advantage is that they are very accurate and can model explicitly all the 
degrees of freedom of the protein-ligand system and may also include the solvent if 
necessary. However, the high-dimensionality of the search space involved in these 
simulations tools, makes an ergodic exploration of the protein conformations unfeasible, 
due to the higher computational time required137. Rotamer library based methods are 
currently the most popular methods as they can represent the protein conformational 
space as a set of experimentally observed and preferred rotameric states for each 
residue side chain (Figure 18)124, 138-140. An ensemble of protein conformations, obtained 
from X-ray crystallography, NMR or MD/MC simulations, can be used as another strategy 
to include protein flexibility141-142. However, these search methods have two 
disadvantages: how the initial protein conformations are generated and how they are 
combined among themselves. A popular ensemble docking method is FlexE143, an 
extension of the docking tool FlexX. The soft-receptor modeling method combines the 
information derived from several different experimental and computational protein 
conformations to generate one energy weighted average grid, which is subsequently 
FCUP 79 
New Therapeutic Strategies to Lower Blood Stream Cholesterol Levels through the Inhibition of HMG-CoA Reductase  
 
used to dock the ligands141, 144. This protein flexibility docking technique is the less 
computationally demanding approach, however, it cannot manage large-scale motions. 
 
 
Figure 18 - Prediction of the binding pose of a carbohydrate into a carbohydrate binding module (Cbm) using two 
different molecular docking approaches.  A: Flexible-ligand molecular docking protocol (Autodock145). B: Flexible 
ligand and flexible receptor molecular docking protocol (MADAMM136). The results have shown that in this case, 
it was very important to introduce some degree of flexibility into the binding site of the Cbm during the molecular 
docking stage. This created a suitable cleft into the Cbm structure that allowed an unbiased binding of the 
carbohydrate in it. The complexes generate by this process are in agreement with the available experimental 
data146 and allowed to gather a better understanding of these proteins that are attached to enzymes that can 
decompose cellulose into glucose units147. 
 
As in a virtual screening campaign, hundreds or thousands of ligands are 
evaluated, the Flexible-Ligand and Receptor Search Algorithms are often discarded due 
to the time and computational cost that they require. Currently, the Flexible-Ligand 
Search Algorithms are used instead since they provide very good results.  
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3.5.2. Scoring Functions 
The main goal of a scoring function is to calculate computationally an energy value 
that estimates the binding affinity between the protein and the ligand. There are a wide 
variety of different algorithms for predicting the binding free energy of a protein-ligand 
complex. These techniques differ significantly in accuracy and speed. If one wants to 
predict the binding free energy of only one ligand, very accurate but time-consuming 
techniques such as Free Energy Perturbation (FEP) or Thermodynamic Integration (TI) 
can be used.  If the aim is, however, to compare binding free energies of hundreds or 
thousands of protein-ligand complexes as generated by virtual screening, then “scoring 
functions” are used instead.  
A “scoring function” is a method that relies on several assumptions and 
simplifications. These methods are very fast since the complexity and computational cost 
required for the calculation of protein-ligand binding is dramatically reduced. However, 
the accuracy of the final results can be compromised, as a number of physical 
phenomena that determine molecular recognition are not included in the calculation or 
are modeled by predefined parameters that are obtained from experimental observations 
or quantum chemical calculations. The development of scoring functions is thus not an 
easy task, as it can have a major impact on the quality of molecular docking results. 
Generally speaking, the accuracy of a scoring function can be evaluated taking into 
account its capability to follow the following criteria: i) it must be capable of estimating 
the interaction between the receptor and the ligand and this value should be close to the 
free energy of binding. ii) different binding poses must be ranked correctly, i.e. those that 
resemble most closely the experimental structures should be the best scored. iii) if 
multiple ligands are docked, their binding free energies need to be ranked accurately 
and it must be possible to discriminate between molecules that bind the target and 
molecules that do not. iv) a scoring function must be sufficiently fast to be applied in a 
docking algorithm148. 
Currently, the number of scoring functions available to assess and rationalize 
ligand protein interactions is large and increasing. Many algorithms share common 
methodologies with novel extensions, and the diversity in both their complexity and 
computational speed provides a plethora of techniques to tackle modern structure-based 
drug design problems. Roughly speaking, the scoring functions can be grouped into 
three main categories:  force field scoring functions, empirical scoring functions and 
knowledge-based potentials. 
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Force-field-based scoring functions have been used for more than 2 decades and 
apply classical molecular mechanics energy functions to compute the binding energy 
between the receptor and the ligand and, in some cases, the internal energy of the ligand. 
Popular implementations of these scoring functions are D-Score that is based on the 
Tripos force field149, and DOCK150 and AutoDock145, 151, both based on the Amber force 
field152.  
The functional form of the empirical scoring functions is often simpler than the 
force-field based scoring functions, although many of the individual contributing terms 
have counterparts in the force-field molecular mechanics terms. Currently, several 
empirical scoring functions are available in diverse molecular docking software, such as 
FlexX117, F-Score153, the Piecewise Linear Potential (PLP)154, Chemscore155-156, Glide 
SP/XP157, SCORE158, Fresno159 and X-SCORE160. 
Knowledge-based scoring functions are pure statistical methods that are designed 
to reproduce experimental structures rather than reproduce binding affinities (such as 
the force field and empirical based scoring functions).  These scoring functions use 
simple statistical potentials that estimate the frequency of occurrence or non-occurrence 
(i.e. negative data) of different atom–atom pair contacts and other typical interactions 
that are obtained from the structural information embedded in experimentally determined 
atomic structures. In this process, it is assumed that if an interatomic distance occurs 
more often than some average value, it should represent a favourable contact and vice-
versa. In addition, the observed distribution of distances between pairs of different atom 
types must reflect their interaction energies. Muegges's Potential of Mean Force 
(PMF)161-163, DrugScore164-165 and SMall Molecule Growth (SMoG)166 are the most 
popular examples of knowledge-based scoring functions. 
 
3.6. Validation of the VS 
Since many stages of the VS, as well as each of those stages, rely on many 
parameters, it is important to design a protocol to validate it. This will allow to have 
confidence on the computational results but also to decrease the number of false 
positives in the final results. Generally, the procedures employed to validate the VS 
campaign and in particular the molecular docking stage are classified in three groups: 
(1) quality of docked poses, (2) accuracy of scores or affinity estimates and (3) power to 
discriminate between active and non-active compounds.  
 
FCUP 82 
New Therapeutic Strategies to Lower Blood Stream Cholesterol Levels through the Inhibition of HMG-CoA Reductase  
 
3.6.1. Quality of the Docked Poses 
The quality of the docked poses obtained from a molecular docking protocol is 
assessed by re-docking experiments. The term re-docking is used because the test 
consists in docking ligands for which the experimental binding modes have already been 
established, almost always by x-ray crystallography. The standard way to compare a 
docked pose with a known structure is to calculate the Root Mean Square deviation 
(RMSd) between the docked and experimental conformations of the ligand. It is common 
to exclude hydrogen atoms because they are rarely found in crystallographic structures. 
Cutoff values used to classify poses as correct or incorrect are usually around 2.0 Å.  
RMSd values can be calculated in an adapted way, with the aim of compensating 
for symmetric conformations in the docked molecule151, 167. For example, a 180º rotation 
of a phenyl ring results in an equivalent conformation, but a standard RMSd calculation 
produces an artificially high value. Adapted methods search for the lowest RMSd within 
groups of exchangeable atoms, which are defined based on atom type or element. 
An alternative metric to the traditional RMSd is to quantify how well the docked 
poses fit the experimental electron density of the crystallographic structure. It removes 
any bias of crystallographic models that may have been imposed when fitting the 
crystallographic model to the electron density, and it does not have any issue with 
symmetric conformations. 
The re-docking test outcome is primarily related to the power of the docking engine 
and quality of the receptor model. However, it is worth to note that every docking engine 
must use a scoring function during the search to select among good and bad poses and 
finally lead to the correct binding mode. For this reason, re-docking tests are also related 
to the quality of the scoring function used in conjunction with the search algorithm.  
When performing re-docking evaluations, it is advisable to perform visual 
inspection to double check low RMSd poses. Sometimes, the human eye can uncover 
issues not seen in the RMSd value. 
 
3.6.2. Accuracy of the Scores 
The process of scoring molecules takes place upon the prediction of binding poses. 
Correct poses influence the scoring outcome positively but sometimes inaccurate scores 
are generated for good quality poses. A direct assessment of the scoring function is 
important for the development and validation of a virtual screening protocol168. 
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Experimental dissociation constants (Kd) or inhibition constants (Ki) constitute the 
most valuable information to support this validation procedure. These constants are 
directly associated with the free energy of binding, and are within the scope of physical 
properties modeled by a molecular docking program. On the other hand, IC50 values 
depend on experimental conditions, such as substrate concentration, rendering different 
experiments incomparable. Also, this kind of data can derive from experiments at the 
cellular level, where several additional factors influence binding in one way or another, 
making it difficult for molecular docking to reproduce the observed properties. Thus, IC50 
values can only be useful if all data originates from the same experiment169. 
The scores produced for docked molecules should be indicative of the binding 
affinities in order to enable identification of active molecules in large and diverse 
compound datasets. These scores can be expressed in units of free energy or a number 
without physical meaning. Independently of the scoring units, better accuracy means an 
increased correlation with the binding affinity of the molecules. In this line of thought, a 
linear fit between scores and the experimental values allows one to predict the quality of 
the virtual screening, since a good fit means the relative affinity of a series of ligands is 
well reproduced. Typically, the ordinary least squares method is used, yielding a linear 
regression model where the r-free value is indicative of the quality of the fit. This 
statistical variable can be used to compare and choose among different scoring 
functions, and also to evaluate other parameters in the virtual screening setup170. 
 
3.6.3. Actives and Decoys 
The most straightforward way to evaluate the performance of a VS campaign is to 
quantify its power to discriminate between active and inactive molecules. For this 
purpose, each molecule needs to be classified as active or decoy. It is rare to find explicit 
information on inactive molecules reported in scientific literature, even though some 
information is available in the Chembl and PubChem databases. Alternatively, random 
molecules are used as decoys, based on the assumption that they are not active for the 
target of interest. This has been most effectively introduced by the Directory of Useful 
Decoys approach171-172. 
In a perfect scenario, active molecules are scored significantly better than inactive 
ones, and the worst score for an active is better than the best score for an inactive. In 
reality, there is significant overlap of the distribution of scores for active and inactive 
molecules. 
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The statistical tools to quantify the performance of scoring methods given a ranked 
list of positive (active molecules) and negative (decoys) observations are well 
established. Most performance metrics are based on a cutoff or threshold value to 
classify molecules in active or inactive. Active molecules scored above the cutoff are 
called true positives, while decoys incorrectly classified as actives, are false positives173. 
Similarly, decoys under the cutoff score are true negatives and actives misclassified as 
inactive are false negatives174. 
Accuracy, precision and recall are typical metrics used to measure the 
performance of binary classification systems. In the realm of VS, enrichment factor (EF) 
is used instead, but it is conceptually similar to recall. Accuracy is the ratio between 
correctly classified molecules and the total number of molecules. Precision is the 
proportion of real actives (true positives) within all positives (true positives + false 
positives). Recall is the ratio between recovered actives (true positives) and the total 
number of actives (true positives + false negatives). Enrichment factor is defined as the 
ratio between recovered actives and the expected number of recovered actives using 
random scores. Note that all these measures are calculated upon discretization of the 
scores by a threshold. 
The relative importance of precision and recall depends on the subsequent actions 
to be performed after the VS campaign. For example, if a small number of molecules is 
to be tested experimentally, high precision is critical to increase the odds of finding hits. 
On the other hand, in situations where a large number of compounds are selected from 
VS, lower precision can be afforded in order to allow for a greater recall, increasing the 
number of hits at the expense of a lower ratio of hits per inactive molecule. In order to 
account for a more complete picture of the performance, enrichment factors are usually 
reported for more than one threshold, which is represented as the score cutoff for which 
a determined portion of the chemical library or compound dataset. Typical enrichment 
factors are reported at around 1% of datasets, but up to 20% is not uncommon175. 
The choice of a threshold, even if tailored for a specific need, hinders a general 
view of the performance. The Receiver Operator Characteristic (ROC) curve was 
developed to graphically represent the overall performance of a ranking method, 
independently of a particular threshold. It consists in a plot of the true positive rate (TPR) 
in the y-axis and the false positive rate (FPR) in the x-axis. The TPR and FPR are the 
numbers of true positives and false positives expressed as a percent value of total 
number of actives and decoys, respectively. The area under the ROC curve (AU-ROC) 
is the probability of ranking actives better than inactives. A random ranking method 
corresponds to the equality line TPR = FPR, and has an AU-ROC of 0.5 (or 50%).  
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Figure 19 - Example of consensus scoring. A) the plot of score X versus score Y reveals that active compounds 
(green circles) are ranked with higher scores in both ranking methods. A linear combination of scores X and Y 
provides a better separation from decoy molecules (red dots), as it is illustrated by the black dashed line. The 
normalized distributions of scores X, Y and 2X + Y are provided by green and red bars for active and decoy 
molecules, respectively. B) The ROC curves associated with scores X, Y and the linear model 2X + Y show that 
score Y is the weakest of all scores. The consensus score has slightly better performance than score X. 
 
In general, the number of compounds selected for further development in VS is 
significantly lower than the molecules in chemical libraries. Thus, it is more important to 
use these metrics for the top ranks of the dataset or, in other words, to evaluate the early 
recognition. Several tests have been developed for this purpose, generally as 
adaptations of the AU-ROC metric. An example of a simple adaptation is to calculate the 
area under a logarithmic plot of the ROC curve, which gives more emphasis to the 
performance in the early ranks. Another alternative is BEDROC, as it gives the possibility 
to control the earliness of the recognition. The performance of this kind of metrics is 
sensitive to the ratio between actives and decoys and its statistical power, or reliability, 
decreases if excessive earliness is requested176. As a rule of thumb, it is recommended 
to use AU-ROC for its good statistical power, together with one of the early recognition 
metrics (BEDROC) as well as enrichment factors at the relevant early ranks of the 
dataset. 
Finally, an important aspect that is easily forgotten in this type of analysis is the 
scaffold variety. While using DUD (Directory of Useful Decoys)172, it was observed that 
a single scaffold could be responsible for high enrichment. If such a situation occurs 
while validating a Virtual Screening protocol, the probability of finding new and different 
active molecules is severely limited. 
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3.7. Post-Processing Stage 
Once all of the compounds from the library database have been docked into the 
binding pocket of the drug target, it is time to select which ones should carry on to the 
experimental testing. The easiest way of doing it, is to simply use the scores of the 
scoring function directly implemented in the docking algorithm, rank the compounds 
according to these values and take the top scorers for experimental testing.  However 
this is not a straightforward process. At the end there are still too many compounds to 
test, or the compounds in the hit list resemble one another to such an extent that there 
is no point in testing all of them. Additionally, there are normally many undesirable false 
positives among the top scored list that need to be eliminated. To overcome these issues 
a selection of post-filters and /or consensus scoring methods are normally applied to limit 
the number of hits to be considered in subsequent drug development efforts. 
 
3.7.1. Post-Filters 
3.7.1.1. Visual Inspection 
Visual inspection is naturally the number one option for post-filters. Such analysis 
helps to detect artifacts, such as incorrect metal coordination poses or badly oriented 
hydrogen bonds177. However this sort of analysis is not suitable for large-scale 
applications, when too many hits have been identified. It is normally advisable at this 
stage to apply automatic filters. A common strategy is to re-apply some of the filters 
initially used to reduce the number of species in the compound library, but now following 
more rigorous criteria.  
 
3.7.1.2. Clustering Molecules 
In many cases, at the end of a VS campaign, there are many compounds in the hit 
list that resemble one another to such an extent that there is no point in testing all of 
them. In these cases it is advisable to cluster the hit list into groups of similar compounds 
and select only a representative compound from each cluster to retrieve new and varied 
molecular scaffolds for further enhancement.  
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3.7.1.3. Consensus Scoring  
It has been shown that the main reason for the misranking of compounds in VS 
lies in the scoring functions of the molecular docking stage that very often do not rank 
the correct conformational solution first, and more importantly, that often fail in the 
comparison of the binding affinity of different ligands. As a result, they fail to distinguish 
inactive from active compounds, therefore causing many false positives to be among the 
top scorers of a single ranking list. 
Several groups suggested approaches to improve the selection of the correct 
bioactive conformation out of the set of generated conformations. One possible approach 
is the so-called “consensus scoring” in which docked poses are rescored with several 
different scoring functions. This method was introduced by Charifson et al178. In their 
study, they docked the ligands with their in-house docking tool Gambler, rescored the 
generated docked ligand conformations with 2-3 scoring functions and took then the 
intersection of the top N% of each of the sorted ranking lists (consensus list). They 
considered altogether thirteen different scoring functions in their study and have shown 
that the consensus lists contain significantly less false positives than obtained with a 
single scoring function, and conclude that a combination of scoring functions significantly 
enhances hit rates (40). This shows that the false positives of one scoring function are 
not the same as the false positives of another, resulting in a significant elimination of 
false positives when generating the consensus. A second study was published by Stahl 
et al, who carried out a detailed analysis using FlexX as the docking engine and four 
scoring functions (FlexX, PLP, PMF, Drugscore) for rescoring179. They mainly confirmed 
the result of Charifson et al, stating that consensus scoring is generally successful when 
two scoring functions are combined that perform well individually.  
 
3.8. Future Developments and Perspectives 
It is generally recognized that drug discovery and development are time and 
resources consuming processes. There is an ever-growing effort to apply computational 
power to the combined chemical and biological space in order to streamline drug 
discovery, design, development and optimization. In the pharmaceutical industry, CADD 
is being utilized to expedite and facilitate hit identification, hit-to-lead selection, optimize 
the absorption, distribution, metabolism, excretion and toxicity profile and avoid safety 
issues. 
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The contribution of computational methods, such as VS, to drug discovery is no 
longer a matter of dispute. All the world’s major pharmaceutical and biotechnology 
companies use computational design tools. Nowadays, it is estimated that CADD 
accounts for 10% of pharmaceutical R&D expenditure and that they will rise to 20% by 
2016180. 
There is a good number of successful studies where CADD, and in particular VS, 
aided in the development of new drugs. However, and in spite of the very positive picture 
that is often drawn with these methodologies, the effectiveness and impact of VS are 
currently limited by major scientific problems that are far from being solved. Firstly, the 
problems include imprecise pose scoring and binding energy predictions as well as 
incorrect similarity-based compound rankings all of which require a time consuming 
follow-up analysis to select candidate leads on the basis of knowledge or intuition. In 
addition, although ligands are commonly handled with full flexibility, the protein flexibility 
is still, at best, only partially considered. Further studies are still necessary to tackle this 
issue and address the induced-fit problem. Moreover, the dynamic inclusion of water 
molecules during the docking process, to take account of eventually important water-
mediated hydrogen bond bridges between the ligand and the protein, could increase the 
efficiency of the approach. 
In order to turn VS the key step in drug development, it is still necessary to prove 
that the aspects on which it depends on are correct and reproducible. This can be 
achieved either by scrupulous experimental validation, or by the development of new 
virtual screening methodologies. The interplay between computational modeling and 
experimental research is therefore a decisive stage where the inputs from each of these 
disciplines are essential for their mutual growth. 
Despite these limitations, VS is still the best option available nowadays to explore 
a large chemical space in terms of cost effectiveness and commitment in time and 
material, as it allows access to a large number of possible ligands, most of them easily 
available for purchase and subsequent test. With the increasing number of targets 
identified by genomics and proteomics, and improved methodologies capable of 
predicting better hit rates and better predictions of geometries, VS methodologies will 
gather an even more preponderant role in drug design in the near future. 
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CHAPTER 4 
CHOLESTEROL BIOSYNTHESIS: A MECHANISTIC 
OVERVIEW 
Cholesterol is an essential component of cell membranes and the precursor for the 
synthesis of steroid hormones and bile acids. The synthesis of this molecule occurs 
partially in a membranous world (especially the last steps), where the enzymes, 
substrates and products involved tend to be extremely hydrophobic. The importance of 
cholesterol increased in the last half century due to its association with cardiovascular 
diseases, which are considered one of the top leading causes of death worldwide. Facing 
the current need for new drugs capable of controlling the levels of cholesterol in the 
bloodstream, it is important to understand how cholesterol is synthesized in the organism 
and identify the main enzymes involved in this process. Taking this into account, this 
review presents a detailed description of several enzymes involved in the biosynthesis 
of cholesterol. In this regard, the structure and the catalytic mechanism of the enzymes 
involved in the cholesterol biosynthesis, from the initial 2-carbon acetyl-CoA building 
block, will be reviewed and their current pharmacological importance discussed. We 
believe that this manuscript may contribute to a finer level of understanding of cholesterol 
metabolism and that it will serve as a useful resource for future studies of the cholesterol 
biosynthesis pathway. 
 
Adapted from reference 181 
In this review, Diana Gesto wrote several parts including sections 4.2.3 and 4.2.10, 
reviewed the whole manuscript and did some of the figures. 
 
4.1. Introduction 
Cholesterol is the major sterol present in animal tissues. This molecule is almost 
planar and rigid and contains a steroid nucleus of four fused rings, three of which with 
six carbons and a forth with five. The molecule is amphiphilic, having a hydrophobic 
hydrocarbon body and a hydrophilic hydroxyl head group. 
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In mammals, cholesterol plays a vital role in life, being an essential component for 
the normal functioning of cells. Its roles range from component in cell membranes to 
precursor of several steroid hormones. 
Cell membranes are very complex systems, which separate the cells cytosol from 
the external medium or from the medium inside cell compartments (like lysosome or 
peroxisomes), while still allowing for the transfer of compounds from the inside to the 
outside and vice-versa, as well as carrying other important functions. Still, in a simplistic 
manner, they can be seen essentially as a double layer of phospholipids. Cholesterol is 
normally present in membranes and its importance can be easily understood just by 
comparing the difference in fluidity of membranes with different cholesterol 
concentrations. The polar head group of cholesterol interacts with the similar head group 
of phospholipids, while the nonpolar group interacts with their hydrophobic tails. Since 
cholesterol is somewhat rigid (more rigid than phospholipids), membranes with larger 
cholesterol content will tend to be more rigid and packed, while those with less 
cholesterol will be more fluid. Cholesterol is also important in other membrane 
processes, such as endocytosis. 
In addition to being a structural component of membranes, cholesterol also serves 
as a precursor for the biosynthesis of several compounds like bile acids, vitamin D and 
several steroid hormones that are produced by the adrenal gland and by the male and 
female sex glands. 
Over the years cholesterol has gained a bad reputation in the world of health and 
nutrition, especially because of its association with cardiovascular diseases. According 
to the World Health Organization (WHO), from the top 10 leading causes of death 
worldwide in 2008, ischemic heart diseases was number one, accounting for 12.8% of 
deaths, followed by stroke and other cerebrovascular disease as number two (10.8%). 
Since both of these diseases are associated with high levels of cholesterol in the blood 
(hypercholesterolemia), it is easy to understand why this molecule has acquired such a 
bad name. 
Despite its association with several heart conditions, cholesterol should not be 
perceived as a bad compound that needs to be avoided at all costs. In fact, life as we 
know it would not be possible without cholesterol. 
In terms of composition, it is possible to distinguish between good and bad 
cholesterol. Since it is a lipid, cholesterol cannot be dissolved in the bloodstream, which 
is water-based. To get around this problem, the body packages cholesterol and other 
fats into protein-covered molecular assemblies called lipoproteins that do mix easily with 
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blood. The proteins that are used in this assembly are known as apolipoproteins. When 
the proportion of protein to lipids (cholesterol and others) in the lipoprotein is high, they 
are known as high-density lipoprotein (HDL), or good cholesterol. On the other hand, 
when this proportion is small, meaning that there is a larger lipidic content, they are called 
low-density lipoprotein (LDL), or bad cholesterol.  
The high levels of cholesterol are especially dangerous when the concentration of 
LDL in the blood is high and that of HDL is low. High levels of LDL may lead to 
atherosclerosis, which is one of the main causes for both ischemic heart disease and 
cerebrovascular diseases182-183. Atherosclerosis is nothing more than the accumulation 
of fatty materials, such as cholesterol, in the blood vessels. It is a complex process, which 
involves a chronic inflammatory response to oxidized LDL on the walls of arteries. LDL 
is very rich in cholesterol and cholesteryl esters, which, when oxidized, are toxic to the 
cells on the walls of arteries, triggering an inflammatory response. This leads to a 
pathogenic accumulation of cholesterol in blood vessels and the formation of 
atherosclerotic plaques, resulting in the constriction of blood vessels. Atherosclerosis 
occurs when the amount of cholesterol in the blood, due to either unregulated synthesis 
or considerable ingestion of cholesterol rich foods, exceed the amount needed for the 
production of steroids, bile acids and membranes8. 
Hypercholesterolemia is currently treated with a combination of dietary and 
pharmaceutical therapies184-185. Often, more than a single pharmaceutical agent and a 
dietary regimen are necessary to decrease total cholesterol and LDL levels to the desired 
level. Drugs such as bile acid sequestrates, niacin and statins are commonly used to 
treat hypercholesterolemia and atherosclerosis. The application of several of these 
compounds is, however, limited by the numerous side effects that can be experienced 
by patients. Thus, the need for therapeutic agents that would decrease cholesterol levels 
still exists nowadays. 
Facing the current need for new drugs capable of controlling the levels of 
cholesterol in the bloodstream, it is important to understand how the organism 
synthesizes this molecule and identify the main enzymes involved in this process. Taking 
this into account, the most important enzymes participating in the cholesterol 
biosynthesis will be described in this review and special attention will be given to those 
that are current drug targets. 
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4.2. Enzymes involved in the Cholesterol Pathway 
All cholesterol present in our bodies arises from two different sources: it can be 
either synthesized de novo within our cells, or obtained through ingestion of certain 
foods. Although many people regularly include these foods in their diet, there is no need 
to ingest them for the sole purpose of obtaining cholesterol, since our own cells are 
capable of producing enough quantities of this molecule for our bodily requirements186. 
Nonetheless, whether or not there is dietary intake of cholesterol, its levels are 
maintained through regulation of the synthesis and absorption, which means that when 
low quantities of cholesterol are ingested, absorption and synthesis will be upregulated. 
Likewise, if the dietary intake is high, its excretion will be increased and its rate of 
synthesis will be decreased. 
The biosynthesis of cholesterol is a complex process, heavily regulated at several 
points throughout its progression. Some of the intermediaries can be diverted and used 
as precursors in the biosynthesis of other compounds or perform themselves certain 
functions on the body. This process requires numerous enzymes, some of which are 
accounted amongst the most regulated enzymes currently known. 
The first step in the synthesis of cholesterol is the formation of mevalonate from 
acetate. It begins with the condensation of two acetyl coenzyme A (acetyl-CoA) 
molecules to form acetoacetyl-CoA, a process catalysed by the enzyme thiolase. Next, 
HMG-CoA synthase catalyses the reaction between acetoacetyl-CoA and another 
molecule of acetyl-CoA in order to form HMG-CoA. The final step in the synthesis of 
mevalonate is accomplished by HMG-CoA reductase. This step is not only the committed 
step of the whole process, but also the rate-limiting one.  
The subsequent step in the biosynthesis of cholesterol comprises the conversion 
of mevalonate into two activated isoprenes (isopentanyl-5-pyrophosphate and 
dymethylallyl pyrophosphate). Following a series of successive condensations of 
activated isoprenes, a 30 carbon molecule, squalene, is formed. Squalene is the 
biochemical precursor of all steroids, and despite being a linear compound, its structure 
can still be linked to that of cyclic steroids. In order to form cholesterol, squalene has to 
endure a succession of changes, being initially converted to lanosterol, a four-ring 
compound, which is finally transformed into cholesterol after several sequential 
reactions.  
Figure 20 describes the overall process by which cholesterol is synthesized, from 
acetyl-CoA to lanosterol. Each of these reactions will be described in more detail in the 
next sections. 
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Figure 20 - Diagram describing most of the enzymes involved in the cholesterol biosynthesis. Each enzyme is 
identified with a different letter that corresponds to the header of the following sections, where each enzyme is 
describe in more detail. When this letter is followed by an “s” it means that multi enzymes are involved in that 
step. 
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4.2.1. Thiolase 
Thiolases, also known as acetyl-coenzyme A acetyltransferases (ACAT), are the 
enzymes responsible for the conversion of two units of acetyl-CoA in acetoacetyl-CoA. 
The acetyl-CoA is either obtained from an oxidation reaction (e.g., fatty acids or pyruvate) 
in the mitochondria or synthesized from the cytosolic acetate derived from cytoplasmic 
oxidation of ethanol, which is initiated by cytoplasmic alcohol dehydrogenase. 
Thiolases are ubiquitous enzymes that have key roles in many vital biochemical 
pathways187. The members of this family of enzymes can be divided into two broad 
categories: degradative thiolases (3-ketoacyl-CoA thiolase, (EC 2.3.1.16)) and 
biosynthetic thiolases (acetoacetyl-CoA thiolase, (EC 2.3.1.9)). 3-ketoacyl-CoA thiolases 
have broad chain-length specificity for its substrates and are involved in degradative 
pathways such as fatty acid beta-oxidation188. Acetoacetyl-CoA thiolases are specific for 
the thiolysis of acetoacetyl-CoA and are involved in the first step of many biosynthetic 
pathways, including those that generate cholesterol, steroid hormones and ketone body 
energy storage molecules189. There are two types of acetoacetyl-CoA thiolases, the 
mitochondrial ACAT1 and the cytosolic ACAT2. Kovacs et al. suggest a possible 
distribution of ACAT1 between peroxisomes and mitochondria, as experimental 
evidence supports the formation of acetoacetyl-CoA in peroxisomes190. 
The physiological importance of thiolases can be illustrated by the severe, and 
usually lethal, phenotypes of patients with deficient thiolases191-192, particularly in the 
case of defective biosynthetic thiolases193-194. Currently, inhibitors against ACATs have 
been used to develop new drugs against African sleeping sickness and other diseases195-
196. 
Most enzymes of the thiolase family are dimers. The active site of the biosynthetic 
thiolases is located in a shallow cleft at the protein surface. Enzyme kinetics, active-site 
labeling and site-directed mutagenesis experiments allowed the identification of three 
important residues, Cys89, His348 and Cys378 , which have been found to be important 
for the catalytic activity of the enzyme (Figure 21-A). These residues are part of an 
extensive hydrogen bond network, which stretches from the active site to the enzyme 
backside, suggesting that this hydrogen bond network is important for the stabilization of 
different protonation states of the catalytic residues188. 
On the basis of these studies, a ‘ping-pong’ reaction mechanism consisting of two 
steps has been proposed197 (Figure 21-B). The first step of the mechanism involves the 
deprotonation of Cys89 by His348 (Figure 21-B step 2)198. Simultaneously, the 
nucleophilic Cys89 attacks the acyl-CoA substrate, leading to the formation of a covalent 
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acyl-CoA tetrahedral intermediate (Figure 21-B step 2). It has then been proposed that 
afterwards Cys378 becomes negatively charged, following the donation of its proton to 
the leaving group of the acetylation reaction, CoA (Figure 21-B step 3). Subsequently, in 
the second half of the synthesis reaction, Cys378 acts as a catalytic base which 
deprotonates carbon C2 of a new acetyl-CoA molecule, resulting in the formation of an 
enolate intermediate (Figure 21-B, step 4). The following steps of the catalytic 
mechanisms are the reverse of step 2 and 3 and involve the formation of a second 
covalent tetrahedral intermediate (Figure 21-B step 5), the transference of a proton from 
His348 to Cys89 and the subsequent release of the product of the reaction (Figure 21-B 
step 6 and 7). During the catalytic process, the formation of the negatively charged 
tetrahedral intermediates are stabilized the oxyanion hole, which is composed by the 
Asn316-Wat82 dyad and His348. 
 
4.2.2. HMG-CoA Synthase 
HMG-CoA synthase (HMG-CoA-S, E.C. 2.3.3.10) is a 42 kDa homodimeric protein 
that catalyses the irreversible condensation of acetyl-CoA and acetoacetyl-CoA to form 
3-hydroxy-3-methylglutaryl–CoA (HMG-CoA) and CoA.  
HMG-CoA-S is found in eukaryotes, archaea and certain bacteria199. Cells of 
higher eukaryotes have three forms of HMG-CoA synthase: the cytosolic, the 
mitochondrial and the peroxisomal200-202. Cytosolic and peroxisomal HMG-CoA-S 
(cHMG-CoA-S and pHMG-CoA-S) catalyse the second step in the synthesis of 
cholesterol. This starts the isoprenoid pathway, from which results cholesterol and other 
important products, such as ubiquinone, dolichol, isopentenyl adenosine and farnesyl 
groups. Mitochondrial HMG-CoA-S (mHMG-CoA-S) participates mainly in the 
ketogenesis pathway for acetoacetate biosynthesis. Acetoacetate is then transformed 
into hydroxybutyrate and acetone, often known as ketone bodies. In bacteria, isoprenoid 
precursors are generally synthesized via an alternative non-mevalonate pathway. 
However, a number of Gram-positive pathogens use a mevalonate pathway involving a 
bacterial HMG-CoA-S isoform that is parallel to that found in eukaryotes203. 
The main structure of HMG-CoA-S can be divided in two main regions: the larger 
upper region that contains a conserved αβαβα structure from the thiolase fold, and the 
smaller lower region, which is unique among HMG-CoA-S enzymes and consists of 
several α-helices and β-strands204. The interface between the upper and lower regions 
defines a 15 Å-deep narrow tunnel that forms the active site in each monomer (Figure 
22-A). 
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Figure 21 - A: Structure of Thiolase II from Zoogloea ramigera (pdb code 1DM3188) and the active site with a 
reaction intermediate (the enzyme is acetylated at Cys89 and a molecule of acetyl-CoA is found in the active site 
pocket). B: Proposed catalytic mechanism197. 
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Both substrates, acetyl-CoA and acetoacetyl-CoA, fit in the active site tunnel with 
the nucleotide part pointing toward the protein surface. The pantetheine part of the 
substrate is located in the centre of the tunnel that is enclosed by a hydrophobic sleeve, 
and the CoA thiol group is buried in the bottom of the active site tunnel, where the 
catalytic triad, formed by Glu95, Cys129 and His264, is located204(Figure 22-A). Cys129 
is placed in the deepest portion of the active site and is responsible for the nucleophilic 
attack on the substrate. The main function of His264 and Glu95 is to remove the proton 
from the Cys129 and turn it into a stronger nucleophile. Mutations on any of these 
residues inactivate the enzyme205-207.  
From a mechanistic point of view, the condensation reaction catalyzed by HMG-
CoA-S is similar to that of thiolase. However, the mechanism diverges on the second 
(condensation) step of the reaction, where the methyl group of the acetylated enzyme is 
activated and attacks the incoming β-keto thioester, whereas the members of the thiolase 
family activate a carbon of the second substrate to attack the enzyme-bound thioester208. 
Based on these mutagenic studies, other kinetic studies207, 209 and co-crystallized X-ray 
structures with bound intermediates204, 208, 210, one can propose the mechanism of HMG-
CoA synthase which is summarized in Figure 22-B. 
The first step of the catalytic process involves the activation of Cys129, through 
the action of His264, which abstracts a proton from that residue (Figure 22-B, step 2). 
The negatively charged cysteine promptly attacks the acetyl-CoA and forms a thioester 
acyl−enzyme intermediate at the same time that a reduced CoA is generated. The next 
step involves a Claisen-like condensation of the second substrate of the reaction, 
acetoacetyl-CoA, with the thioester acyl−enzyme intermediate to form HMG-CoA, while 
it still retains the thioester bond to the enzyme (Figure 22-B, step 3). This reaction is 
favored by the close presence of Glu95, which abstracts a proton from the methyl group 
of the thioester acyl−enzyme intermediate, turning it into a better nucleophile, and by 
His264, which gives a proton to one of the carbonyl groups of acetoacetyl-CoA, turning 
it into a better electrophile 204, 211. The last two steps of the catalytic process involve the 
hydrolysis of the acetylcysteine bond (Figure 22-B step 4 and 5), from which results the 
free HMG-CoA. In the end of this step Cys129 becomes reduced and it is suggested that 
Glu95 loses a proton to the solvent, thus making the active site ready for a new catalytic 
cycle211. 
 
 
 
FCUP 98 
New Therapeutic Strategies to Lower Blood Stream Cholesterol Levels through the Inhibition of HMG-CoA Reductase  
 
 
Figure 22 - A: Structure of cHMG-CoA synthase (PDB code 2P8U204) and the active site with the product of the 
reaction and Cys117 acetylated. B: Proposed catalytic mechanism of the enzyme204 205-207. 
 
HMG-CoA-S is currently a potential drug target. Inhibitors addressed to this 
enzyme can be used to regulate the serum cholesterol level or even in the development 
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of novel antibiotics against certain pathogens. This last area of research goes in line with 
the discovery that many human pathogenic gram-positive bacteria can only produce 
isopentoyl disphosphate (IPP) through the mevalonate pathway, which is a necessary 
pathway for bacteria to live. Taking into account the differences between the prokaryotic 
and eukaryotic HMG-CoA-S, this suggests that the inhibition of the mevalonate pathway 
in bacteria may not affect the HMG-CoA-S enzymes of the host body. This could thus 
lead to a new generation of antibacterial drugs that have a significant therapeutic 
advantage over the commonly used broad-spectrum antibiotics212-213. 
mHMG-CoA-S has also an important role in diabetes. The reaction catalyzed by 
this enzyme is over-activated in patients with diabetes mellitus type I and if left untreated, 
due to prolonged insulin deficiency and the exhaustion of substrates for 
gluconeogenesis, results in the shunting of excess acetyl-CoA into the ketone synthesis 
pathway and the development of diabetic ketoacidosis. This means that under such 
prognostic, inhibitors of this enzyme could help in the reversion of the process and 
decrease in the levels of ketonic compounds in blood serum. 
 
4.2.3. HMG-CoA Reductase 
3-hydroxy-3-methyl-glutaryl-CoA reductase or HMG-CoA reductase (HMG-CoA-R) 
catalyses the NADP-dependent (in mammals) or NAD-dependent (in prokaryotes) 
synthesis of mevalonate from HMG-CoA190, 214. For this reason the enzyme commission 
designated this enzyme as EC 1.1.1.34 for the NADPH-dependent enzyme, whereas 
1.1.1.88 links to the NADH-dependent enzyme. 
From sequence analysis it was possible to divide different HMG-CoA-R in two main 
classes. Class I enzymes comprise those found in eukaryotes and the majority of 
archaea, while class II enzymes are found in prokaryotes and some archaea. 
Class I HMG-CoA-R contains a transmembrane domain (lacking in archaeal 
enzymes), and a C-terminal catalytic region215. The catalytic region of these enzymes is 
well conserved, with sequence identities of ~60%, and can be subdivided into three 
domains: an N-domain (N-terminal), a large L-domain, and a small S-domain (inserted 
within the L-domain). The L-domain binds the substrate, while the S-domain binds 
NADPH. The membrane region is diverse in sequence and length, and exhibits functional 
differences. For instance plants have two membrane domains, yeast seven and 
mammals eight216. Class II HMG-CoA-R lacks the membrane domain and so it is found 
dissolved in the cytosol. Their catalytic region is structurally related to the one found in 
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class I, but it consists of only two domains: a large L-domain and a small S-domain 
(inserted within the L-domain). As with class I enzymes, the L-domain binds the 
substrate, whereas the S-domain binds NADH (instead of NADPH in class I). 
HMG-CoA-R from both classes has a dimeric active site (Figure 23–A), with 
residues contributed by both monomer, and a nucleotide-binding motif that is found in 
many enzymes that use the dinucleotides NADH or NADPH for catalysis217. The core 
regions containing the catalytic domains of the two enzymes have similar folds. Despite 
the differences in amino-acid sequence and overall architecture, functionally similar 
residues participate in the binding of coenzyme A, and the position and orientation of 
four key catalytic residues (glutamate, lysine, aspartate and histidine) is conserved in 
both classes of HMG-CoA-R.  
Both classes of HMG-CoA-R are catalytically competent and have similar reaction 
mechanisms and kinetic parameters216, 218-220. The currently available proposal for the 
catalytic mechanism of HMG-CoA-R is based on kinetic and labeling experiments, site-
directed mutagenesis, protein sequencing and in the mechanism of dehydrogenases, 
which catalyze a similar reaction221-225226. 
The overall reaction catalyzed by these enzymes can be divided into three main 
stages (Figure 23-B). Once the HMG-CoA and NADH (or NADPH) bind to the active site, 
the thioester of HMG-CoA-R is reduced and the generated intermediate is stabilized by 
the protonated Glu559 and Lys691 (Figure 23-B step 1 and 2). By the end of this reaction, 
a mevaldyl-CoA hemi-thioacetal intermediate is generated, and the NAD+ (or NADP+) 
cofactor dissociates from the active site. In the second stage of the mechanism, Glu559 
assists the base-catalyzed decomposition of the hemithioacetal to produce mevaldehyde 
and the CoA thiolate anion, which is promptly protonated by the cationic His752 (Figure 
4-B step 3). In the third stage of the catalytic mechanism, the mevaldehyde is reduced 
by a second NADH (or NADPH) molecule and the intermediate is again stabilized by the 
protonated Glu559 and Lys691 (Figure 23-B Step 3). Subsequently, the product 
mevalonate, CoASH, and the oxidized cofactor (NAD+ or NADP+) are released and the 
enzyme is ready for a new turnover (Figure 23-B Step 5). During the full catalytic process, 
Asp690 established an important hydrogen bond with Lys691 that has been shown to be 
important for the catalytic process227. 
The reaction catalyzed by HMG-CoA-R is the point of feedback control for the 
mevalonate pathway, which is responsible for the biosynthesis of many important 
isoprenoid compounds in humans. This enzyme is also one of the most regulated 
enzymes in our body10. Dietary cholesterol exerts feedback control mostly at a 
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translational level228-230, but regulation mechanisms at the transcription level20-21, enzyme 
degradation23, 231 and modulation of enzyme activity24 are also known. 
Because of its importance, this enzyme is also a main target for medical 
intervention. Currently, this enzyme is the target of a class of drugs called statins, which 
are used to treat hypercholesterolemia and reduce the risk of cardiovascular disease. 
Additionally, this enzyme has been a target for the development of new antimicrobial 
agents, which take advantage of the evolutionarily divergence between the HMG-CoA-
R of pathogenic bacteria (from Class II) and that of eukaryotes (Class I). 
 
 
Figure 23 - A: Structure and active site of HMG-CoA-R (pdb code 1DQ9216). B: Currently accepted catalytic 
mechanism of HMG-CoA-R221-225, 232. 
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Statins are potent competitive inhibitors of HMG-CoA-R37 and can be divided in 
two different types based on their structure38. Type I statins (lovastatin, pravastatin and 
simvastatin) are natural fungal products, whereas type II statin are fully synthetic, 
characterized by the presence of larger hydrophobic regions and attached fluoro-phenyl 
groups40. The ability of statins to inhibit HMG-CoA-R arises from their HMG-like moiety, 
which competes with HMG-CoA to bind to the HMG binding site of the enzyme (see pdb 
codes 1HW838 and 1HMK38 where HMG-Coa-R is bounded to mevastatin and 
atorvastatin, respectively). Although the hydrophobic part of statins is normally very 
different from that of the coenzyme A portion of the substrate, these non-polar groups 
also contribute to block the access of HMG-CoA to the active site. The affinity of the 
enzyme for statins is slightly higher than its affinity for the substrate41. 
HMG-CoA-R can also be inhibited at a translational level. The oxylanosterol 15-
oxa-32-vinyl lanost-8-ene-3b,32 diol is one of the inhibitors that work at this level and it 
is a potent hypocholesterolemic agent233.  
New antimicrobial agents that target HMG-CoA-R of pathogenic bacteria (class II) 
are also a hot topic of research in this field, in part due to the increasingly problematic 
broad antimicrobial resistance among gram-negative bacteria to the current available 
drugs234. Very few novel pharmacologic agents are in the research and development 
pipeline and several recent studies have shown that some statins exhibit antibacterial 
action235-236.  
 
4.2.4. ATP-dependent Enzymes involved in the 
Cholesterol Pathway. 
In animal cells, the cholesterol biosynthetic pathway contains a unique series of 
three sequential ATP-dependent enzymes that convert mevalonate to isopentenyl 
diphosphate: mevalonate kinase (MK), phosphomevalonate kinase (PMK), and 
mevalonate 5-diphosphate decarboxylase (MDD). According to Hogenboom and co-
authors, the enzymes MK, PMK and MDD are cytosolic enzymes237-239, but this 
contradicts recent studies of Kovacs and co-authors, which confirm their previous 
findings of peroxisomal localization of the three enzymes using stable isotopic 
techniques and human cells190, 240-241. 
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4.2.4.1. Mevalonate Kinase 
Mevalonate kinases (EC 2.7.1.36) catalyze the transfer of the γ-phosphoryl group 
of ATP to the C5 hydroxyl oxygen of mevalonic acid to form mevalonate 5-phosphate, a 
key intermediate in the biosynthetic pathway for isoprenoids and sterols from acetate242-
243. 
The enzyme MK was discovered in the late 1950s in yeast244, but it suffered from 
more than three decades of neglect, as research on the isoprenoid pathway was mainly 
focused on HMG-CoA-R. The interest in MK has been revived, however, because this 
enzyme was found to be involved in the synthesis of diverse non-sterol isoprenoid 
metabolites that participate in numerous cellular functions, e.g., protein prenylation, 
protein glycosylation, and cell cycle regulation. This enzyme is also currently being 
studied as a promising anticancer target since certain types of cancer are particularly 
sensitive to mevalonate pathway inhibition245. In addition, the significance of MK has 
been further highlighted by the implication of the enzyme in human inherited diseases, 
such as mevalonic aciduria and hyperimmunoglobulinemia D/periodic fever syndrome. 
MK can be found in eukaryotes, archaebacteria, and some eubacteria. The 
mammalian enzyme is reported to be a homodimer with a subunit molecular mass of 42 
kDa246. 
Kinetic studies suggest that the enzyme catalyzes an ordered sequential reaction, 
with mevalonic acid binding prior to the enzyme in relation to ATP and the 
phosphomevalonate being the first product of the reaction247. Site-specific mutagenesis 
studies have been employed to identify catalytic residues and to investigate the 
mechanism of the enzyme. Asp204 has been suggested as the catalytic base that 
abstracts the proton from the C5-OH group of mevalonic acid246. Ser146 and Asp204, 
located in a conserved glycine-rich region, have been implicated in the binding of Mg-
ATP248. Lys13 has been shown to be involved in the binding of ATP as well as facilitating 
catalysis249(Figure 24-A). 
The reaction mechanism has not yet been deeply studied. However, the reaction 
is likely to be initiated by the nucleophilic attack of the 5′-OH of mevalonate to the γ-
phosphorus of ATP. At the same time, one proton is transferred from mevalonate to 
Lys13 and another from Lys13 to the phosphate group (Figure 24-B-step 1). Based on 
mutation data available for human MK, it is likely that Lys13 or even Asp204 may function 
as a general base in this process, and abstract a proton from the 5′-OH of mevalonate, 
thereby facilitating the nucleophilic attack of mevalonate250. The Mg2+ is coordinated by 
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Glu193 and Asp204 (being this one stabilized by the close Ser146), which are suggested 
to be responsible for the activation of the γ-phosphate. 
 
 
Figure 24 - A: Structure and active site topology of mevalonate Kinase (pdb entr 1KVK242). B: Schematic proposal 
for the catalytic mechanism of mevalonate kinase250. 
 
Currently, most of the inhibitors targeting MK have in their structure phosphate 
groups. For example, farnesyl diphosphate and related compounds are potent and 
competitive inhibitors of MK. They bind in the active site similarly to what is observed 
with ATP, through the same type of interactions that were described above (see PDB 
code: 2R42243). 
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4.2.4.2. Phosphomevalonate Kinase 
Phosphomevalonate kinase (EC 2.7.4.2) catalyzes the transfer of a second γ-
phosphoryl group from ATP to mevalonate 5-phosphate (MVAPP), which results in the 
formation of ADP and mevalonate 5-diphosphate.  
 
 
Figure 25 - Structure of phosphomevalonate kinase (PMK) and some important active site residues that have 
been identified by experimental means (PDB code: 3CH4251). 
 
The crystal structure of the human phosphomevalonate kinase has 192 amino acid 
residues and a predicted molecular weight of 21.8 kDa. Despite its importance on the 
biosynthetic source of a diverse class of metabolites, the mechanism of PMK is not 
completely characterized. The only PDB structure of PMK that is currently available on 
the protein databank (Figure 25, PDB code: 3CH4251) reveals a positively charged cavity 
on the protein surface that is believed to be essential for the binding of the phosphate 
group and hydroxyl groups of the substrate. This cavity includes the residues Lys48, 
Arg73, Arg84, Arg110, Arg111 and Lys73252-253. Site-directed mutagenesis studies have 
also identified four additional amino acid residues, Lys17, Arg18, Lys19, and Lys22 that, 
if mutated, decrease the catalysis up to 10,000-fold and are believed to be part of the 
ATP binding motif254-256. This means that these residues are directly involved in the 
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catalysis and therefore in the binding and transfer of the γ-phosphoryl group of ATP to 
mevalonate 5-phosphate.  
Presently, no co-crystallized structure of PMK with the substrate, reaction 
intermediate or inhibitor is available. Thus, no absolute conclusions about the catalytic 
mechanism can be inferred. The current understanding of the mechanism considers that 
bringing two phosphate groups in proximity to react is especially challenging, given the 
high negative charge density on the four phosphate groups in the active site. Therefore, 
only a very specific and highly positively charged active site, like the one found in PMK, 
can catalyze this sort of reaction. Furthermore, the possible involvement of one or more 
magnesium ions should not be discarded, as they could help the binding of the 
phosphate groups as well as the catalysis, alike to what is observed in the previously 
described kinases. 
 
4.2.4.3. Diphosphomevalonate Decarboxylase 
Diphosphomevalonate decarboxylase, also known as mevalonate diphosphate 
decarboxylase (MDD, EC 4.1.1.33), catalyses the final step of the mevalonate pathway, 
i.e., the divalent cation-dependent decarboxylation of MVAPP to isopentenyl 
diphosphate (or isopentenyl pyrophosphate, IPP), with concurrent hydrolysis of ATP to 
form ADP and inorganic phosphate. This reaction is required for the production of 
polyisoprenoids and sterols from acetyl-CoA. 
Inhibition of this enzyme effectively diminishes biosynthesis of cholesterol257 60 
and low MDD activity correlates with decreased cholesterol levels in a hypertensive rat 
strain258. Genes encoding this enzyme have been detected in archaebacteria, some 
eubacteria, protozoa, plants, fungi and animals. 
The X-ray structure of human MDD shows that it consists of two domains (Figure 
26-A) and has many similarities to the structures of bacterial, protozoan and yeast259-260. 
This structure revealed the presence of tightly bound PO4- and SO4- anions, suggesting 
that they might be important for the catalytic process. Site-directed mutagenesis studies 
also revealed four conserved residues that are important for catalysis, Asp17, Ser127, 
Arg161 and Asp305259, 261-262. Asp17 and Arg161 are believed to be part of the 
phosphoryl acceptor-binding site. Asp305 and Ser127 are suggested to be actively 
involved in the base catalysis that takes place in the active site. The correct position of 
the magnesium ion in the active site is still not fully established. Based on these studies, 
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the catalytic mechanism of MDD has been proposed to be as it is illustrated on Figure 
26-B. 
 
 
Figure 26 - A: Structure and active site of MDD (PDB code: 3D4J259). B: Proposed catalytic mechanism of MDD259, 
261-262. 
 
Once the substrate, MVAPP, binds in the active site, it is suggested that it is 
positioned so that the terminal phosphate is located near the sulfate/phosphate anions 
that were detected in the X-ray structure (Figure 26-B step 1). The C3 hydroxyl group of 
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MVAPP stands in juxtaposition to the catalytic Asp305 and the ATP’s gamma phosphoryl 
group is oriented to facilitate the gamma phosphoryl transfer to MVAPP, with the help of 
Ser127. The proposed general base catalyst, Asp305, is believed to deprotonate 
MVAPP’s C3 hydroxyl in the first step of the catalytic process to facilitate the attack on 
the gamma phosphoryl of ATP (Figure 26-B step 2). From this reaction result the release 
of ADP and the formation of the 3-phosphoMVAPP intermediate259. The next step of the 
catalytic process involves the dissociation of phosphate, which generates a carbocation 
intermediate at carbon C3 (Figure 7-B step 3). The positively charged carbon at C3 
creates an electron sink that accelerates the decarboxylation process with the help of 
Arg161. At the end of the reaction, carbon dioxide is generated concomitant with the 
formation of IPP (Figure 26-B step 4). 
Inhibitors of MDD, in particular inhibitors of the bacterial enzyme form, are currently 
under development to be used as antimicrobial agents. Several substrate analogues, 
such as diphosphoglycolylproline (see PDB code: 4DU8263) and 6-fluoromevalonate 
diphosphate, were shown to be competitive inhibitors for the substrate in the bacterial 
enzyme.263 
 
4.2.5. Isopentenyl-diphosphate Delta Isomerase 
Isopentenyl-diphosphate delta isomerase (or isopentenyl pyrophosphate 
isomerase, IPP isomerase, EC 5.3.3.2) catalyzes the conversion of the relatively 
unreactive IPP to the more-reactive electrophile dimethylallyl pyrophosphate (DMAPP). 
Both reactants and products of this reaction are substrates for the successive reaction 
that results in the synthesis of farnesyl diphosphate (FPP) and, ultimately, cholesterol. 
This isomerization is therefore a key step in the biosynthesis of isoprenoids through the 
mevalonate pathway. 
Crystallographic studies have shown that the active form of IPP isomerase is a 
monomer with alternating α-helices and β-sheets264-265 (Figure 27-A). The active site of 
IPP isomerase is deeply buried within the enzyme and consists of a glutamic acid residue 
(Glu116) and a cysteine residue (Cys67) that interact with opposite sides of the IPP 
substrate, consistent with the antarafacial stereochemistry of isomerization. The enzyme 
also contains two metal sites: a first site occupied by Mn2+, which is coordinated with 
three histidine and two glutamate residues; and a second site containing Mg2+, which is 
coordinated with two pyrophosphate oxygens, the carbonyl group of the highly conserved 
residue Ala67, a carboxylate oxygen of Glu87 and two water molecules.  
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Figure 27 - A: Structure and active site of the enzyme isopentenyl pyrophosphate isomerase (pdb code: 1Q54266). 
B: Proposed catalytic mechanism for IPP isomerase266. 
 
The mechanism through which the enzyme undergoes the initial protonation step 
(Figure 27-B step 1) has not been conclusively established. Recent evidence suggests 
that Glu116 is involved in the protonating step of the C3-C4 double bond, forming a 
carbocation266. The thiolate of Cys67 then removes a proton from carbon C2, resulting 
in the isomerization of IPP into DMAPP (Figure 27-B step 2). During this process, the 
two metal centers have an active role in catalysis. The Mg2+ is required for the 
stabilization of the phosphate groups during the catalytic process, whereas the Mn2+ is 
actively involved in catalysis. It is also proposed that the reaction is facilitated by the 
conversion of the carboxyl group of Glu116 to a carboxylate, resulting in an electro-
neutral Mn2+ with a bis-carboxylate complex. The water molecules present in the active 
site are also proposed to be involved in the catalysis, but the mechanism how this 
happens remains unknown267-268. 
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4.2.6. Farnesyl Diphosphate Synthase 
Farnesyl diphosphate synthase also known as farnesyl pyrophosphate synthase 
(FDPS, EC 2.5.1.10) is an Mg2+-dependent homodimeric enzyme, localized in 
peroxisomes, which catalyzes a chain elongation reaction and controls the first branching 
point of the mevalonate pathway.  
Chain elongation enzymes can be divided into two genetically different families 
depending on whether the stereochemistry of the newly formed double bond during each 
cycle of chain elongation is E or Z. FDPS is a member of the E-double bond family and 
catalyzes the sequential addition of IPP and DMAPP to form geranyl diphosphate (GPP) 
and then FPP. 
FDPS is essential for the post-translational prenylation of all small GTPase 
proteins that play a crucial role in cell signaling, cell proliferation, and osteoclast-
mediated bone resorption. Inhibition of FPP production can decrease the activity of 
mutated H-Ras, K-Ras, and N-Ras proteins that function as major drivers of tumor 
growth in many cancers269-270. Thus, the clinical benefits of human FDPS inhibition 
include both decrease of prenylation of mutated Ras proteins, leading to a decrease in 
cellular growth and/or survival, as well as alleviation of tumor-associated bone 
destruction via inhibition of osteoclast activity271-272. Additionally, blocking the catalytic 
activity of human FDPS impacts both the downstream and upstream levels of 
isoprenoids in the mevalonate pathway, leading to numerous cellular changes, including 
the inhibition of cholesterol biosynthesis273-274. Currently, FPPS inhibitors are mainly 
used in the treatment of a number of bone disorders, such as Paget’s disease, 
hypercalcemia, metastatic osteolysis and osteoporosis275.  
The available X-ray structure for the human FDPS shows that the protein is a 
homo-dimer (Figure 28-A)276-277. Each subunit is folded in a single domain whose central 
feature is a core composed of 10 helices that surround a large deep cleft identified as 
the substrate-binding pocket. The active site is located in the bottom of the cleft and it 
comprises two conserved aspartate-rich motifs278. One includes the residues Asp117, 
Asp118, Ile119, Met120 and Asp121 and the other the residues Asp227, Asp258, 
Tyr259, Leu260 and Asp261. The aspartate-rich motifs are positioned so that the side 
chain carboxylate groups point into the cleft from opposite sides 279. The Asp residues in 
the two aspartate-rich motifs, except the last one in the second motif, are important for 
catalysis, while the remaining residues of the second motif are essential for substrate 
binding. These results are consistent with the co-crystal structure of avian FPP in 
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complex with GPP and IPP280. The active site also lodges three magnesium cations, 
whose chelation with the substrate is required for enzyme activity. 
Taking into account the crystallographic and kinetic evidence, two types of catalytic 
mechanisms have been proposed for FDPS: those in which condensation is initiated by 
heterolytic cleavage of the carbon−oxygen bond of the allylic pyrophosphate, yielding a 
cationic intermediate, and those where the formation of the C1-C4 bond between the two 
substrates and rupture of the C1 oxygen bond is simultaneous through a transition state 
(TS) with a carbocation character. 
 
 
Figure 28 - A: Monomeric structure and active site of FDPS (PDB code: 1RQJ281). B: Catalytic mechanism of FDPS. 
R= Me or , depending on whether FDPS catalyzes the first or second reaction278
,279. 
 
Both mechanisms suggest the involvement of a dissociative electrophilic alkylation 
(Figure 28-B). During the reaction, the bond between carbon C1 and its neighboring 
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oxygen in the diphosphate (in DMAPP or GPP) is cleaved to generate a resonance-
stabilized allylic cation, which then alkylates the double bond in IPP to produce a tertiary 
carbocation. Whether this occurs in two independent steps or in a concerted manner is 
still a matter of some controversy, but recent QM/MM studies suggest that the latter type 
of mechanism is more favorable282. It is also suggested that the main chain carbonyl 
oxygen of Lys202, and the side chain oxygens of Thr203 and Gln241 are important to 
stabilize the allylic cation transition state (Figure 9-A). 
The next step involves the elimination of a proton from carbon C2 of the IPP unit 
to give rise to a new E-double bond between carbons C2 and C3. Hosfield et al, suggest 
that the non-metal-ligated pyrophosphate oxygen is the catalytic base that deprotonates 
the condensed intermediate to generate the C5-extended isoprenoid reaction product, 
and that Arg116 and Lys258 might be important for such reaction281. The new allylic 
diphosphate is then generated and it is one isoprene unit longer than the initial substrate. 
The role of the magnesium cations present in the active site is believed to be the 
stabilization of the pyrophosphate groups and, at the same time, the enhancement of the 
rate of the reaction. 
 
4.2.7. Squalene Synthase  
Squalene synthase or farnesyl-diphosphate:farnesyl-diphosphate farnesyl 
transferase (SQS, EC 2.5.1.21) catalyzes an unusual head to head reductive 
dimerization of two molecules of FPP to form squalene. This enzyme is of particular 
importance as it is the first enzyme in the pathway responsible for the production of a 
metabolite that is solely committed to cholesterol synthesis.  
SQS is located in the membrane of the endoplasmic reticulum. It is anchored to it 
by a short C-terminal membrane-spanning domain, whereas the N-terminal catalytic 
domain of the enzyme protrudes into the cytosol. 
Mammalian forms of SQS are approximately 47 kDa and consist of approximately 
416 amino acids. The crystal structure of human SQS was determined in 2000283, and 
revealed that the protein was composed entirely by α-helices. The active site of this 
enzyme is located in a large channel that is found in the middle of the protein. One end 
of the channel is open to the cytosol, from where the substrates are obtained (soluble 
allylic compound containing 15 carbon atoms). The other end forms a hydrophobic 
pocket that allows the product of the catalytic process to reach the membrane 
environment (squalene - an insoluble compound with 30 carbon atoms) (Figure 10-A). 
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The detailed mechanism by which SQS operates has not been fully resolved yet. 
The uniqueness of the head-to-head coupling of two FPP molecules to form squalene 
via a stable cyclopropylcarbinyl diphosphate intermediate has elicited much mechanistic 
speculation over the years284-285. In order to shed some light on the catalytic mechanism 
of SQS, several site-directed mutagenesis experiments on diverse amino acid residues 
of the SQS active site were conducted. The results showed that mutations of Phe288 
prevent the enzyme from catalysing the second reaction, in which the cyclopropyl 
intermediate is rearranged to produce squalene286. On the other hand, mutations at 
Tyr171 hinder the enzyme inactive. This result suggests that Tyr171 is required for the 
first half reaction: the ciclopropanation. Because tyrosine is an aromatic residue and has 
a hydroxyl group, a proposal was created in which Tyr171 loses a proton to the leaving 
pyrophosphate group. This would turn Tyr171 more negative, which in turn would 
stabilize the carbocation intermediate that is generated during the reaction. In 2000 and 
with the release of the SQS structure283, this hypothesis gathered more consensus, as 
Tyr171 was found to be in the binding pocket. Also, likely to play a key role in catalysis 
are the conserved Tyr73 and Gln212. In addition, three magnesium ions are important 
for the catalysis and might have a major role in the stabilization and orientation of the 
two FPP molecules in the active site of SQS. 
In 2010, the crystal structure of a very similar enzyme, dehydrosqualene synthase 
(crtM), was crystallized with a substrate analogue, farnesyl thiopyrophosphate (PDB 
code 3W7F287) and the intermediate, PSDP (PDB code: 3NPR288). Superimposition of 
the substrate and intermediate in the SQS structure revealed that one of the substrate 
molecules remains in the same position during the first half reaction, and keeps the 
pyrophosphate moiety (Figure 29-A).  
Based on the available data, it is suggested that the reaction catalyzed by SQS 
proceeds in two distinct steps, both of which involve the formation of carbocationic 
reaction intermediates (Figure 29-B). In the first half-reaction, two identical molecules of 
FPP bind in distinct regions of the active site of SQS. The pyrophosphate group of one 
of the FPP (normally designated as donor FPP) is then cleaved and an allylic carbocation 
intermediate is generated concomitant with the release of pyrophosphate (Figure 29-B 
step 1). The carbocation promptly reacts with the C-2,3 double bond of the acceptor FPP 
in a 1',2,3 prenyl transferase reaction that is accompanied by the loss of a proton (Figure 
10-B step 2). The product of this condensation is presqualene pyrophosphate (PSPP), a 
stable cyclopropylcarbinyl pyrophosphate intermediate that remains associated with 
SQS for the second reaction (Figure 29-B step 3). 
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In the second half-reaction of SQS, PSPP loses the pyrophosphate group and the 
resulting cyclopropylcarbinyl carbocation undergoes a ring opening and reduction by 
NADPH (through a hydride transference) to the linear and final product, squalene (Figure 
10-B step 4,5 and 6). SQS, then releases squalene into the membrane of the 
endoplasmic reticulum (Figure 29-B step 7). 
 
 
Figure 29 - A: Structure and active site of squalene synthase (SQS). The image of the SQS active site was built 
through the superimposition of two X-ray structures: 3W7F (enzyme analogous to SQS, carotenoid 
dehydrosqualene synthase, which catalyses a similar reaction)287 and 1EZF283 (Human SQS). The amino acid 
residues represented on figure A are from the Human SQS. Only the FPP was retrieved from the PDB code 3W7F 
B: Proposed catalytic mechanism for SQS283, 287. 
 
From a metabolic perspective, SQS has a pivotal role as it takes FPP from the 
more general mevalonate pathway, to commit it into the cholesterol synthesis289. This 
raised interest in using SQS as a drug target for the treatment of hypercholesterolemia. 
Currently, strong inhibitors against SQS have been found, such as Zaragozic acid A290-
291, Lapaquistat (recently discontinued from clinical development)292 and DF-461293. 
Several authors suggest that the use of SQS in the treatment of hypercholesterolemia 
could have fewer side effects than the classical statin treatments, which inhibit the whole 
mevalonate pathway by targeting HMG-COA-R. At the moment this is still speculative, 
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since only one inhibitor of SQS, lapaquistat, went through clinical trials, but failed due to 
potential hepatic safety issues294. 
SQS was also pointed out as an interesting chemotherapeutic target against 
Trypanosoma cruzi and Leishmania parasites, which are responsible for large parasitic 
disease loads and socioeconomic losses, particularly in developing countries295. Specific 
chemotherapy of the diseases caused by these protozoa remains unsatisfactory, as 
currently available drugs have limited activity, as well as frequent toxic side effects and 
rising drug resistance. However, these parasites have a strict requirement for specific 
endogenous sterols (ergosterol and analogs) for survival and growth and cannot use the 
abundant supply of cholesterol present in their mammalian host296-297. Further studies 
led to the discovery of E5700 and ER-119884, two novel quinuclidine SQS inhibitors 
under development as cholesterol and triglyceride lowering agents in humans by Eisai 
Company, which have very potent anti-T. cruzi activity in vitro. One of them (E5700) was 
able to provide full protection against death, and it completely arrested development of 
parasitaemia in a murine model of acute disease when given orally. This was the first 
report of an orally-active SQS inhibitor as an anti-infective agent298-299. Although these 
compounds and other aryl-quinuclidines are also potent inhibitors of mammalian SQS, 
their selective antiparasitic activity in vitro and in vivo might be explained by the capacity 
of a host's cells to compensate for the blockage of de novo cholesterol synthesis by up-
regulating the expression of LDL receptors and capturing this sterol from the growth 
medium or serum300-301. In contrast, there is no way for the parasite to compensate in 
this manner for the quinuclidine-induced blockage of ergosterol biosynthesis, since there 
are no appreciable amounts of ergosterol in host cells or growth media. 
 
4.2.8. Squalene Monooxygenase 
Squalene monooxygenase (SM, EC: 1.14.13.132), also known as squalene 
epoxidase, is a 64-kDa flavin adenine dinucleotide (FAD)-containing enzyme that 
catalyses the first oxygenation step in the cholesterol synthesis. The reaction requires 
NADPH and molecular oxygen to oxidize squalene, to 2,3-oxidosqualene (squalene 
epoxide).  
SM is bound to the endoplasmic reticulum of eukaryotic cells and belongs to the 
flavoprotein monooxygenase family, which catalyzes a wide variety of oxidative 
reactions214, 302. However, there are several differences between squalene 
monooxygenase and other known flavin monooxygenases. Firstly, SM catalyzes 
epoxidation but not hydroxylation of substrates. Secondly, it does not contain cytochrome 
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P450 as a prosthetic group and does not bind NADPH directly. Instead, the electrons 
that are required for the reaction are passed from NADPH, via cytochrome P450 
reductase, to the loosely bound FAD group of squalene monooxygenase. These 
differences turn SM into an attractive target to treat hypercholesterolemia, while not 
disturbing other flavin monooxygenases dependent processes. 
SM was first identified in the early 70s, but studies on the human enzyme began 
only in the 90s. The mammalian SM showed limited sequence similarity to that found in 
yeast. Interestingly, it has also been shown that there are substantial differences 
between the mammalian enzymes from different species303-304, revealing that they might 
be specific to each specie. Unfortunately, structural details of these enzymes from their 
X-ray diffraction studies are still not available, which impedes further analysis. 
The reaction catalyzed by squalene monooxygenase is highly specific305. It 
involves insertion of an oxygen atom across a carbon-carbon double bond to form an 
epoxide. Flavoprotein monooxygenases accomplish this oxygenation by forming a flavin 
hydroperoxide at the enzyme active site, which then transfers the terminal oxygen atom 
of the hydroperoxide (OH) to the substrate306 . The remaining "hydroxyflavin" then 
reoxidizes, with the release of a water molecule and the concomitant formation of 2,3-
oxidosqualene. Squalene monooxygenase presumably utilizes this same mechanism, 
but differs from other known flavin monooxygenases in that the oxygen is inserted as an 
epoxide rather than as a hydroxyl group. Another thing that differentiates these enzymes 
is that squalene monooxygenase contains a loosely bound FAD flavin and obtains 
electrons from NADPH-cytochrome P450 reductase, rather than binding the 
nicotinamide cofactor NADPH directly307.  
Although there is a lack of information regarding the structure and biochemistry of 
SM, this enzyme has been extensively exploited for antifungal drug development308-309. 
Currently, several fungal SM inhibitors, such as terbinafine, naftifine and numerous 
related compounds, are currently on the market or under investigation. Some of the best 
compounds are Terbinafine (Lamisil®) and Naftifine (Naftin®), which show good 
specificity for the fungal enzyme without inhibiting human squalene monooxygenase310. 
Both are fungicidal, interfering with cell membrane synthesis and preventing growth.   
Since this enzyme catalyses the second committed (and likely rate-limiting) step in 
cholesterol biosynthesis, it has also become an attractive pharmacotherapeutic target in 
the treatment of hypercholesterolemia and resultant cardiovascular diseases. Several 
preclinical studies suggest an effective hypocholesterolemic activity, comparable or even 
better than that which can be achieved by HMG-CoA-R inhibition. 
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The most effective inhibitor of mammalian SM known to date is NB-598, developed 
at Banyu Pharmaceutical Co311. This fungal-derived natural compound is a competitive 
inhibitor of SM in human HepG2 cells and effectively reduces serum cholesterol in dogs 
with no apparent adverse effects312. In a comparative study in dogs, NB-598 was more 
potent than the HMG-CoA-R inhibitor simvastatin, decreasing total and serum LDL 
cholesterol. NB-598 also decreased triacylglycerol levels, an effect not observed with the 
HMG-CoA-R simvastatin312. No studies have yet been reported in man. 
 
4.2.9. 2,3-Oxidosqualene Cyclase-lanosterol Synthase 
2,3-Oxidosqualene cyclase-lanosterol synthase (OSC, EC 5.4.99.7) is a 78 kDa 
membrane-bound enzyme that catalyses the conversion of the acyclic compound 2,3-
oxidosqualene (OS) to the cyclic lanosterol. Both oxidosqualene and lanosterol are 
mostly hydrocarbons, and thus are not very soluble in water. The enzyme solves this 
problem by sticking to the membrane in peroxisomes. It then can pull oxidosqualene 
directly out of the membrane, and release lanosterol back there. The reaction catalysed 
by this enzyme is considered to be one of the most complex reactions that are catalysed 
in the enzymatic world, as it involves a sequence of cyclization and 1,2-group 
rearrangements of high energy carbocations to lanosterol, with complete structural and 
stereochemical control of seven chiral centers313. 
OSC is almost exclusively found in eukaryotes, apart from a few prokaryotes that 
can produce this enzyme314. Human OSC is a monomeric enzyme that it is located in the 
membrane of the endoplasmic reticulum315. OSC is composed by two α-helix barrel 
domains (domain 1 and domain 2) connected by loops and three smaller β-sheet 
structures. The active site cavity is located in the middle of the protein, between domains 
1 and 2 (Figure 30-A)313. Domain 2 contains a region inserted in the membrane and 
forms a tunnel that allows the substrate to enter the enzyme and reach the active site 
cavity. Although the architecture of the channel is clear in the available X-ray structure, 
its role in enzyme-subtract interaction is still far from being understood. 
The catalytic mechanism of OSC has been a subject of numerous studies in the 
past four decades313, 316. In spite of these efforts, much remains to be learned about how 
OSC mediates the individual cyclization and rearrangement steps. Currently, there is still 
a great speculation about the mechanism of OSC and several contradictory proposals 
are present in the literature. In general, all the authors agree that the catalytic mechanism 
of OSC can be divided in three main stages. The mechanism starts with the adoption of 
a pre-organized conformation by 2,3-monoepoxysqualene, followed by protonation of the 
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epoxide ring. A cascade of reactions is then triggered, resulting in an array of ring-
forming reactions followed by a series of 1,2-hydride and 1,2-methyl group shifts and a 
final deprotonation step, from which results lanosterol (Figure 11-B). All reactions 
proceed with precise stereo- and regiospecificity required for the formation of the multi 
C-C bonds. 
 
 
Figure 30 - A: Structure of the enzyme and of the active site of OSC (pdb code 1w6k). B: catalytic mechanism 
catalyzed by OSC. 
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The first stage of the reaction is assisted by Asp455, which protonates the epoxide 
of the substrate (Figure 30-B step 1). The acidic character of this residue is enhanced 
by the neighboring Cys465 and Cys533 with which it interacts through two hydrogen 
bonds. The second stage of the mechanism was initially thought to involve the sequential 
formation of the four rings (named A, B, C and D) in a concerted manner316-324. Corey et 
al proposed that the formation of the A-ring should be concomitant with the protonation 
of the epoxide, in a concerted SN2 substitution like process. This proposal was confirmed 
very recently by QM/MM calculations325. The same calculations have also suggested that 
the formation of the B-ring is concerted with this step, and that the three concomitant 
reactions are the rate-limiting step of the full catalytic process (Figure 30-B step 2). 
Corey and co-workers also proposed that formation of the rings C and D involved 
discrete carbocation intermediates. In particular, they showed that the formation of ring 
C involves a cyclopentylcarbinyl carbocation intermediate that subsequently undergoes 
a ring expansion to form the six-membered C-ring. It is also proposed that the closure of 
the D-ring is concerted with the formation of the C-ring326-327 (Figure 30-B step 3’, 4’). The 
only drawback of this proposal is the formation of ring C, which does not follow the 
Markovnikov rule and, therefore, does not ensure the formation of a stable carbocation 
during the addition reactions. In 2002, Hess presented another hypothesis for C and D 
ring formation317. The double bond between carbon 18 and 19 of squalene might be 
involved anchimerically in the cyclopentylcarbinylcyclohexyl ring expansion, meaning 
that the expansion of the C-ring and formation of the D-ring are concerted. This 
mechanism avoids the formation of the stable cyclohexyl carbocation intermediate as 
well as the violation of Markovnikov’s rule (Figure 30-B step 3, 4, 5). Although this 
mechanism is more favorable than the previous one, there is still no certainty about which 
one actually occurs. The only detail that seems clear is that the formation of rings C and 
D is controlled by a set of intramolecular forces (cation stabilization and hydrogen-
bonding) that are imposed by some active site residues to the substrate and are located 
along the active site tunnel. Mutagenesis studies have revealed that Tyr704, Tyr707, 
Tyr587 and His234 have an important role in this context328. 
Once the formation of the D-ring is accomplished, a cation intermediate is obtained, 
which undergoes a series of 1,2-methyl and hydride shifts (Figure 30-B step 6, 7, 8, 9). 
The last step of the catalytic cycle involves a proton abstraction which is catalyzed by 
Tyr503 (Figure 30-B step 10). In the end of this step the product of the reaction, 
lanosterol, is obtained and the enzyme is ready for a new turnover (Figure 30-B step 11). 
The interest in OSC has grown in recent years, due mostly to its late position in the 
cholesterol biosynthesis, which means it can be an optimal target to fight 
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hypercholesterolemia. This interest is partially motivated by the adverse effects of statin 
that inhibit HMG-CoA-R and may cause myopathy. However, until the present date, no 
OSC inhibitor has been approved as a clinical drug for the treatment of 
hypercholesterolemia. However, some OSC inhibitors are already been described and 
co-crystalized in the active center of a close homologue of OSC. One in particular, 
named Ro 48-8071, is one of the most popular among OSC inhibitors, being co-
crystalized in both human OSC enzyme (PDB code 1W6J313) and in the homologous 
SHC enzyme (PDB code 3SQC329). It acts on human OSC as competitive inhibitor, 
preventing the binding of the oxidosqualene. 
 
4.2.10. From Lanosterol to Cholesterol 
The conversion of lanosterol into cholesterol is a very complex and multistep 
pathway, which involves several enzymes. After squalene is transformed into lanosterol, 
this molecule can follow two different routes, both of which ends with a cholesterol 
molecule. They are referred to as the Bloch pathway and the Kandutsch-Russell 
pathway. The difference between them is that the first uses Δ24–unsaturated sterols while 
in the second the intermediates have their side chain saturated.  
In order to be transformed into a cholesterol molecule, lanosterol has to undergo a 
series enzymatic reactions (Figure 31). First, C-14 undergoes a two-step demethylation 
process, which is catalyzed by the enzymes C14α-demethylase and Δ14-reductase. This 
is followed by two subsequent demethylations at C-4, mediated by C4-demethylase. The 
next step is the isomerization of the double bond at Δ8 to Δ7, a reaction catalyzed by Δ8-
Δ7-isomerase. Subsequently, a desaturation occurs between C-5 and C-6 (catalyzed by 
Δ5-desaturase) followed by the reduction of two double bonds, the first at Δ7 and the 
second at Δ24. The enzyme Δ 24–reductase can convert any intermediate on the Bloch 
pathway into its unsaturated counterpart, although it as different affinities for them, and 
the conversion will shift to the Kandutsch-Russell pathway. However, after this route is 
chosen, it cannot revert to the previous one. There is a great lack of structural and 
mechanistic information about this final stage of the cholesterol biosynthetic pathway 
and for that reason it was considered premature to explore it in the present review. 
 
4.3. Conclusions and Future Perspectives 
The complexities of the structure and the biosynthesis of cholesterol have spanned 
decades of research and gathered several Nobel prizes. It is perhaps the only molecule 
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whose studies have paved the way for the discovery of several and important biomedical 
benefits. After one century of research, significant advances have taken place, and our 
current knowledge regarding the enzymes involved in steroid hormone biosynthesis has 
increased substantially. This means that we are now closer to deciphering the full 
mechanistic puzzle behind cholesterol biosynthesis.  
 
 
Figure 31 - Enzymes involved in the catalysis of cholesterol from lanosterol. 
 
Currently, all the enzymes involved in the biosynthesis of cholesterol have already 
been identified and the three-dimensional structures of many of them have been 
deciphered and intensively studied. In this review, all the mechanistic knowledge 
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regarding the majority of the enzymes involved in the biosynthesis of the cholesterol 
molecule, starting from acetyl-CoA, was explored and discussed. The structure of each 
enzyme involved in this process and a detailed description of their active site was 
scrutinized. Particular attention was given to the catalytic mechanism of each enzyme, 
and the chemistry behind the transformations from the reactants into the products was 
carefully described. The chemistry of these transformations is extremely challenging, 
involving, in the many cases, molecules that are very hydrophobic. Such a rich chemistry 
is only possible due to the involvement of remarkable enzymes that allow the binding of 
more than one substrate in their active sites, stabilize uncommon intermediates, manage 
the full stereochemical control of chiral centers, among others. The mechanisms through 
which these enzymes achieve the enormous rate enhancements and exquisite specificity 
are also diverse. For instance, the first three enzymes involved in the cholesterol 
biosynthesis, ACAT, HMG-CoA-S, and HMG-CoA-R, follow a ping-pong type of 
mechanism involving the formation of tetrahedral intermediates with active site residues. 
The next three enzymes, MK, PMK, and MDD are ATP dependent and involve the 
exchange of phosphoryl groups. The enzymes FDPS and SQS follow a sequential 
addition of substrates. SM catalyzes the oxygenation of a squalene and OSC isomerizes 
oxidosqualene to lanosterol.  
In the quest of unraveling the catalytic mechanism of the enzymes involved in the 
cholesterol pathway, the theoretical and computational methods are gaining an important 
role, since they can predict and tackle the formation of reaction intermediates that are 
difficult to detect by experimental means, as it has been observed in other biological 
systems330-335. Some of these proposals were validated later on by experimental means, 
while others were used to explore new mechanistic variants317, 325. 
From all the described enzymes in the cholesterol biosynthesis, HMG-CoA-R, SQS 
and OSC are perhaps the most important, from a pharmacological point of view.  HMG-
CoA-R is the target of statins, important drugs that lower blood cholesterol levels and 
treat cardiovascular diseases. However, this enzyme acts very early in the cholesterol 
synthesis pathway, with nearly 20 subsequent enzymes needed to produce cholesterol. 
SM and SQS are enzymes which are downstream from HMG-CoA-R and located in the 
final branching point of the cholesterol biosynthesis. The inhibitors for these enzymes 
are not so well develop as the ones for HMG-CoA-R, but currently available studies show 
very promising results in reducing cholesterol. In fact, preclinical studies suggest that the 
inhibition of SM has hypocholesterolemic activity comparable, or even better, than that 
obtained with HMG-CoA-R inhibition. Studies involving OSC also show direct decrease 
in lanosterol formation and an inherent decrease in HMG-CoA reductase activity. The 
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great advantage of these inhibitors in relation to the ones that target HMG-CoA-R is the 
absence of myopathic side effects, one of the major drawbacks of statins.  
It is also worth mentioning that there are currently other efficient methods that can 
be used to treat hypercholesterolemia. For example, the bile acid binding sequestrant 
cholestyramine has been used for several decades to treat hypercholesterolemia, even 
before statins became available on the market336. The cholesterol absorption inhibitor 
ezetimibe can also be used to the same end, alone or combined with statins337-338. 
Recently, it was also found that inhibitors of proprotein convertase subtilisin/kexin9 
(PCSK9) monoclonal antibody can be used effectively to treat hypercholesterolemia339-
340. The mechanism of action of these drugs is still poorly understood but it is believed 
that they might not interact directly with the enzymes involved in cholesterol biosynthesis. 
All of these new compounds and methods constitute a great promise and may 
become the next generation of drugs that will be used to reduce low-density lipoprotein 
cholesterol levels, possibly in a future not far from today. 
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CHAPTER 5 
UNRAVELING THE ENIGMATIC MECHANISM OF L-
ASPARAGINASE II WITH QM/QM CALCULATIONS 
In this paper, we have studied the catalytic mechanism of L-asparaginase II 
computationally. The reaction mechanism was investigated using the ONIOM 
methodology. For the geometry optimization we used the B3LYP/6-31G(d):AM1 level of 
theory and for the single points M06-2X/6-311++G(2d,2p):M06-2X/6-31G(d) level of 
theory. It was demonstrated that the full mechanism involves three sequential steps and 
requires the nucleophilic attack of a water molecule on the substrate prior to the release 
of ammonia. There are three rate limiting states, which are the reactants, the first 
transition state and the last transition state. The energetic span is 20.2 kcal/mol, which 
is consistent with the experimental value of 16 kcal/mol. The full reaction is almost 
thermoneutral. The proposed catalytic mechanism involves two catalytic triads that play 
different roles in the reaction. The first triad, Thr12-Lys162-Asp90 acts by deprotonating 
a water molecule that subsequently binds to the substrate. The second triad, Thr12-
Ty25-Glu283, acts by stabilizing the tetrahedral intermediate that is formed after the 
nucleophilic attack of the water molecule to the substrate. We have shown that a well-
known Thr12-substrate covalent intermediate is not formed in the wild-type mechanism, 
even though our results suggest that its formation is expectable in the Thr89Val mutant. 
These results have provided a new understanding of the catalytic mechanism of L-
asparaginases that is in agreement with the available experimental data, even though it 
is different from all earlier proposals. This is of particular importance since this enzyme 
is currently used as a chemotherapeutic drug against several types of cancer and in the 
food industry to control the levels of acrylamide in food. 
 
Adapted from reference 341 
For this paper Diana Gesto preformed all the calculations and analyzed the results, 
wrote the entire preliminary draft of the manuscript which was then reviewed by all co-
authors. 
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5.1. Introduction 
Recent studies show that the decrease of the concentration of highly expressed 
amino acids in tumors can retard or even stop tumor growth without affecting the 
metabolism of normal cells.342-343 The starvation of cancer cells through amino acid 
deprivation has thus become an encouraging strategy in cancer therapy. However, 
restricted diet is not enough to control the concentration of these amino acids in the blood 
serum. Therefore, the administration of enzymes specifically addressed to metabolize 
these amino acids is the method currently used. One of the therapies recently approved 
by the FDA to decrease amino acid blood pools is the administration of the enzyme L-
asparaginase.342 
L-asparaginase (L-asparaginase amidohydrolase, EC 3.5.1.1) is an enzyme that 
hydrolyzes L-asparagine to L-aspartate, with the release of one ammonia molecule 
(Figure 32). It is currently used in both cancer therapy and food industry. This enzyme is 
an important chemotherapeutic drug approved by the FDA and with activity against 
several types of cancer, such as acute lymphoblastic leukemia344-345, lymphosarcoma345 
and a few sub-types of non-Hodgkin's lymphoma.346 The mechanism through which L-
asparaginase destroys cancer cells is related to the fact that, in certain types of tumor, 
the production of asparagine synthase is limited. These cells are, therefore, incapable of 
producing enough amounts of asparagine to support their rapid growth, which promotes 
their dependence on external sources of this amino acid. The treatment with L-
asparaginase reduces the levels of asparagine in the blood stream and, since normal 
cells are capable of producing enough quantity of this amino acid to survive, only cancer 
cells will be selectively affected.347 This means that L-asparaginase can be efficiently 
used to control the growth of the tumor, and eventually to destroy it, while leaving the 
normal cells unharmed. Although L-asparaginase has been identified in many 
organisms, only enzymes with bacterial origin are used in cancer therapy, and from 
these, only type II L-asparaginases have anticancer activity. This is due to the fact that 
type II bacterial L-asparaginase has greater affinity to asparagine (Km = 1.15x10-5) when 
compared with type I (Km = 3.5x10-3).348 Since only L-asparaginase II shows anti-cancer 
properties, our study was mainly focused on this enzyme342-343. In food industry, L-
asparaginase is also being used to reduce the formation of acrylamide from starchy 
foods. 
Despite all these current uses of L-asparaginase in medicinal and industrial 
applications, the reaction mechanism of this enzyme is still not known to its full extent. 
Taking this into account, we have studied the mechanism by computational means. 
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Figure 32. Reaction catalysed by L-Asparaginase. 
 
Research on L-asparaginase and related amidohydrolases has been going on for 
over 40 years, but the correct understanding of the catalytic mechanism remains 
enclosed on the available X-ray structures. In this period of time, the detailed 
enzymological study of L-asparaginases has been focused mainly on Escherichia coli 
asparaginase (EcA). However, several studies have shown that the enzymatic 
mechanisms of all type II amidohydrolases are very similar. 
The first crystallographic model of this enzyme was that of Acinetobacter 
gluataminasificans glutaminase-asparaginase, reported in 1988.349 Several crystal 
structures have been reported since then, some containing only the enzyme 350-351, while 
others are complexes of the enzyme with other compounds such as the substrate l-
asparagine, the product l-aspartate 352-353, the alternative products D-aspartate, L-
glutamate and L-succinic acid 354, or even suicide inhibitors such as the L and D-
stereoisomers of 6-diazo-5-oxy-norleucine.355 
Detailed analysis of the active sites of bacterial L-asparaginase II of E.coli, Erwinia 
carotovora and Erwinia chrysanthemi showed a remarkable structural conservation 
among L-asparaginases. The binding pocket of these enzymes involves residues from 
both subunits of the intimate dimer, i.e. Thr12A, Tyr25A, Ser58A, Gln59A, Thr89A, 
Asp90A and Lys162A from one subunit (chain A), and Asn248C and Glu283C from the 
other subunit (chain C), that are interconnected by strong hydrogen bonds. In addition, 
one water molecule is structurally conserved and is part of a well-defined hydrogen-bond 
network (WAT1355 – PDB code 3ECA). This indicates that it is an integral part of the 
active-site architecture and may play a significant role in the catalytic properties of L-
asparaginase. 
The position of the amino acid residues in the active site suggests several possible 
pathways for the catalysis, but the almost symmetric location of two threonine residues, 
Thr12 and Thr89, above and below carbon C2 (please refer to Figure 35 for numbering) 
of the substrate suggests that one of them must be directly involved in the reaction.353 
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In order to decipher the involvement of these two residues in the reaction, Harms, 
Derst and Palm mutated these residues and evaluated the activity of the enzyme. In 
1991 and 1992, Harms356 and Derst357 showed that the activity of the enzyme 
significantly decreased when Thr12 was mutated by an alanine residue (specific activity 
of the mutated enzyme was less than 0.01 U/mg, against 150 U/mg for the wild type 
enzyme).356 However, when it was substituted by a serine residue, no change in the 
enzymatic activity was observed.357 In 1996, Palm et al. revealed that when Thr89 was 
mutated for a valine, the enzymatic turnover was precluded due to the formation of an 
acyl intermediate between Thr12 and the substrate.358 These results seem to indicate 
that Thr12 plays an important role in the reaction, while Thr89 may only be needed on a 
subsequent step. 
Based on these data, many authors propose that in the wild-type enzyme, the 
formation of an acyl-intermediate should exist and would involve the participation of 
Thr12. Nevertheless, the results are somewhat contradictory since, when Thr12 is 
mutated by an alanine, the enzyme remains active, but it is much less efficient (less than 
0.01% of the specific activity of the wild-type enzyme).356 In addition, substrate analogues 
have also been found covalently bound to other active site residues, such as Ser9, which 
is not even a conserved residue in the L-asparaginase structures.359 
Another site-directed mutagenesis study evaluated the role of Tyr25 in the 
reaction. This residue, together with Thr12 and Thr89, is also conserved in all L-
asparaginases and interacts very closely with Thr12 through a hydrogen bond. The idea 
here was to replace Tyr25 with a phenylalanine, in order to evaluate the role of the 
hydroxyl group of this amino acid in the reaction. The final results showed that the 
mutation does not have a high impact in the activity of the enzyme, and only moderately 
affects the Km value. Other Tyr25 mutants (Tyr-25-Ala, Tyr-25-Gly) presented similar 
results, suggesting that Tyr25 may not be directly involved in the reaction, but required 
for the activity of the enzyme, or perhaps it might be important for the specific recognition 
of the native substrate.360 
In spite of the contradictory information that all these results have generated, the 
currently accepted mechanism of L-asparaginases proceeds via a covalently bound 
enzyme intermediate as depicted in Figure 33. This implies the initial nucleophilic attack 
of an active site amino acid (Thr12) to the substrate (asparagine), the subsequent 
release of ammonia, and the formation of an acyl-enzyme intermediate, in which the 
substrate becomes covalently bound to the enzyme. This intermediate is then attacked 
by a second nucleophile, usually water, resulting in the hydrolysis of the acyl-enzyme 
intermediate yielding the acidic product (glutamate) and free enzyme. In this process, 
FCUP 129 
New Therapeutic Strategies to Lower Blood Stream Cholesterol Levels through the Inhibition of HMG-CoA Reductase  
 
Lys162 has been proposed to have an active role and act as an acid and base in a proton 
buffer process with Thr89. 
 
 
Figure 33. Currently proposed catalytic mechanism of L-asparaginase II. 
 
This mechanism was proposed taking into account the current knowledge about 
the mechanism of serine proteases that share a similar catalytic triad (Ser-Ser-Lys, 
instead of a Thr-Thr-Lys). Although many authors point out that the mechanism of serine 
proteases and L-asparaginase should be very similar, there are many other aspects that 
led us into thinking that they can be very different. For instance, in the mechanism of 
serine proteases, it is the serine residue that binds to the substrate, while in L-
asparaginase it is proposed to be a threonine. Although the reactivities of threonine and 
serine are very similar (pKa ~ 13), the presence of a methyl group nearby the hydroxyl 
group of threonine may difficult the formation of the acyl-enzyme intermediate. Secondly, 
even though there is an X-ray structure of L-asparaginase showing the acyl-enzyme 
intermediate, with Thr12 covalently bound to the substrate, this may result from an 
alternative reaction pathway, different from the wild-type, due to the mutation itself. In 
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fact, this intermediate, in which Thr12 is bound to the substrate, was exclusively obtained 
when Thr89 was mutated by a valine. In addition, when Thr12 is mutated by an alanine 
the catalytic process is drastically reduced. However, a decrease of 1000 fold in the rate 
constant357 corresponds to an increase of only 4.2 kcal/mol in the rate-limiting step. 
Therefore, it is not strange that the mutation of a residue at the active site, involved in 
the fundamental h-bond network, destabilizes the TS by 4 kcal/mol. However, that does 
not mean that the residue is participating directly in the reaction but instead that the 
residue is very close to the reactive center. 
All of these results raise many questions regarding the currently accepted 
mechanism of L-asparaginases and therefore require an urgent re-evaluation. To this 
purpose, we built a model of the enzyme containing all the residues of one dimer that 
participate directly or indirectly in the reaction. The model used to study the catalytic 
mechanism of L-asparaginase II from E. coli was based on the x-ray structure that is 
available on the protein databank with the code 3ECA.352 The structure shows that the 
enzyme is a tetramer composed by four identical subunits (A, B, C and D) that interact 
with each other in the form of two intimate pairs of subunits. In this respect the tetramer 
is regarded as a dimer of identical intimate dimers (here called AC and BD), each one 
containing two active sites that are located at the interface between both subunits. With 
this model we have explored many hypotheses for the catalytic mechanism and 
calculated accurate activation and reaction energies. The results altogether point to a 
catalytic pathway that is different from the earlier proposals. 
 
5.2. Methodology 
5.2.1. Building the Model 
The model used in this study was centered in one active site of the enzyme that is 
located between subunit A and C. The model contains the substrate (an asparagine 
molecule) and Gly10, Gly11, Thr12, Ile13, Ala14, Ser23, Asn24, Tyr25, Thr26, Val27, 
Gly57, Ser58, Gln59, Asp60, Gly88, Thr89, Asp90, Thr91, Gly113, Ala114, Met115, 
Arg116, Thr161, Lys162 and Thr163, all from chain A, and Gly248, Asn248, Leu249, 
Ala282, Glu283 and Val284, from chain C. The model also includes one water molecule 
that is conserved in the active site of L-asparaginase and it is located between the 
substrate, Thr89 and Lys162 (Figure 34). 
Hydrogen atoms were added to the model using the software GaussView. 
Conventional protonation states for all amino acids at pH 7.0 were adopted, except for 
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Lys162 whose side chain was kept in the form of NH2. This protonation state was 
deliberately chosen because earlier experimental results have shown that Lys162 is 
deprotonated at neutral pH358. The truncation of the model was done in the terminus of 
each part included in the model, i.e in the carboxylate and the amino groups, which were 
modeled as neutral, to avoid introducing artificial charges due to the truncation process. 
Also, some of the residues at the terminus of each part, which did not seem to interfere 
with the active site, were mutated to alanine, in order to diminish the number of atoms in 
the model. These residues include: Val27, Arg116, Thr161, Thr163, Leu249 and Val284. 
The final model spans a total of 416 atoms, including all those that interact directly with 
the substrate and are required to maintain the main scaffold of the surrounding region of 
the active site as it is observed in the X-ray structure 3ECA. 
 
 
Figure 34. Left: cartoon representation of the L-Asparaginase II dimer (PDB ID: 3ECA), with both active sites 
shown in sticks. Right: QM/QM model. The high layer is illustrated in sticks (77 atoms) and the low layer in lines 
(339 atoms). The frozen atoms are depicted as spheres. Carbons are colored differently for residues that belong 
to different subunits: green for subunit A, cyan for subunit C and orange for the substrate. 
 
Since the geometry optimizations can lead to a conformational reorganization of 
the terminal amino acids, and this may lead to localized unfolding in the model, we have 
chosen to freeze some atoms in the model in order to maintain it close to the X-ray 
structure. The Cα atoms that were frozen are represented in Figure 34 as spheres. 
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5.2.2. Theoretical Methods 
Given that the model system is very large (over 400 atoms) and geometry 
optimizations are very time-consuming, we have resorted to the ONIOM methodology to 
perform geometry optimizations.64, 361 This method allows the division of a system in 
several regions, each one studied with a different theoretical level. The accuracy of the 
method depends on the chosen regions, the theoretical level used in each of them and 
the coupling scheme between the methods. According to the ONIOM methodology, we 
have divided the system into two overlapping layers, designated as the high-level and 
low-level layers. The high-level layer includes all the atoms from the substrate 
(asparagine) and all the residues that are directly or indirectly involved in the reaction, 
i.e. Thr12, Tyr25, Thr89, Asp90 and Lys162 from chain A and Asn248 and Glu283 from 
chain C. Details about the exact atoms included (beyond the whole side chains) can be 
seen in Figure 34. This layer accounts for a total of 77 atoms. The low-level layer contains 
all the remaining atoms of the model and has a total of 339 atoms. The atoms described 
at the low-level of theory do not undergo significant geometry changes during the studied 
reactions, but it is still important to take them into account to get the correct orientation 
of the active site residues and to include the medium/long range interactions between 
the enzyme and the substrate. We used hydrogen atoms as link atoms to complete the 
valences of the bonds spanning between the two layers. 
The geometry of the high-level layer was optimized with the higher theoretical level 
(DFT). The B3LYP functional was chosen, since it is known to give very good results for 
organic molecules.362-365 The 6-31G(d) basis set was employed, as implemented in 
Gaussian 09.366 The inclusion of diffuse functions in the basis set for geometry 
optimizations was investigated before.367 The conclusion was that the corrections to the 
geometry were very small, and corrections in energy differences (such as energy barriers 
or energies of reaction) were negligible upon the calculation of single point energies with 
a more complete basis set. Therefore, it seems inadequate from a computational point 
of view to include diffuse functions in geometry optimizations, considering the inherent 
increase in computing time that they would cause. The low-level layer was treated with 
the semi-empirical method AM1.368 
The model, with the aforementioned constrains, was fully optimized with the 
Gaussian 09 standard parameters. Subsequently, several hypotheses for the reaction 
mechanism were explored through linear transit scans along the reaction coordinates 
implicated in each studied reaction. The transition states were subsequently fully 
geometry-optimized, starting from the structure of the higher energy point of the scans. 
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The reactants and the products, associated with it, were determined through internal 
reaction coordinate (IRC) calculations. The transition state structures were all verified by 
vibrational frequency calculations, having exactly one imaginary frequency with the 
correct transition vector, even using frozen atoms, which shows that the frozen atoms 
were almost free from steric strain. 
The energies of the minima and transition states were additionally calculated at the 
M06-2X/6-311++G(2d,2p) level in the high layer and M06-2X/6-31G(d) level in the low 
layer.369 These single point calculations also accounted for the long-range contribution 
of the remaining enzyme through the inclusion of dielectric continuum (IEF-PCM), as 
implemented in Gaussian 09.370 This feature is of particular importance to the study of 
enzymatic catalysis because the use of a continuum model is normally taken as an 
approximation to the effect of the long-range global enzyme environment in a reaction. 
A dielectric constant of ε=4 was chosen to describe the protein environment of the active 
site in agreement with previous suggestions.371-372 Anyway, the effect of the continuum 
is quite insensitive to the precise choice of the value for the dielectric constant. 
The atomic charges distributions were calculated at the B3LYP level employing a 
Mulliken population analysis scheme, using the 6-31G(d) basis set. 
 
5.3. Results and Discussion 
In order to study the catalytic mechanism of the L-asparaginases by computational 
means, we based our study on the X-ray structure that is available in the protein 
databank with the code 3ECA.352 In the active site of this structure we have the final 
product of the reaction, and we believe that such configuration should not be very 
different from the one of the reactants. Therefore, we substituted the carboxylic group of 
the side chain of the acidic glutamate (product of the reaction) by an amide group in 
order to obtain the substrate, asparagine (the reactant of the reaction). The full enzyme 
structure was then minimized by molecular mechanics in order to improve the geometry 
of the substrate in the active site and to remove any steric hindrance that may occur after 
the addition of the hydrogen atoms. 
The optimized geometry revealed that the substrate is wrapped in a net of 
hydrogen bonds provided by several residues of the active site (Figure 35). In such state, 
the amide group of the substrate becomes constrained between Thr89 (1.93 Å) and 
Thr12 (3.08 Å), forcing it to acquire a planar shape, perpendicular to the side-chains of 
those amino acids. Such configuration is reinforced by the presence of a conserved 
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water molecule (WAT) that interacts very closely with the carbonyl of the amide group 
(2.15 Å). The position adopted by WAT and Thr89 is very important to this end and it is 
ensured by the conserved Lys162 that interacts very closely with both of them by two 
hydrogen bonds (Lys162-Thr89: 2.22 Å, Lys162- WAT: 1.87 Å). The central role of 
Lys162 in these interactions is only possible due to the neighbor Asp90 (2.06 Å) that 
behaves almost as an anchor to Lys162 and maintains its position in the active site. 
Asp90 also interacts with the amino group of the substrate (1.64 Å), and with Asn248 
(1.96 Å) reinforcing the net of hydrogen bonds in the active site. 
 
 
Figure 35. Optimized structure of the reactants of the reaction. (For clarity, only some of the high level atoms are 
shown.) 
 
Thr12 lies in the bottom part of the active site and, together with Thr89 and WAT, 
interacts very closely with the amide group of the substrate. However, contrarily to what 
happens with Thr89, Thr12 does not establish a hydrogen bond with the atoms of the 
amide group. Instead the oxygen from the hydroxyl group points towards carbon C2, 
which has been proposed to be involved in the formation of the acyl-enzyme intermediate 
(3.08 Å). This configuration is favored by the proximity of the conserved Tyr25 that 
orients the hydroxyl group in its direction (1.92 Å) and by Glu283 that forces Tyr25 to 
occupy such position (1.70 Å). In the same way to what happens with Asp90, Glu283 
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also interacts with the amino group of the substrate (1.93 Å) and with Asn248 (2.02 Å). 
These interactions seem to be important for the correct alignment of all the residues of 
the active site and, at the same time, to force the substrate to acquire a specific 
conformation that might be required to start the reaction. 
In our first attempts to study the catalytic mechanism of L-asparaginase, we tried 
to follow all the possible pathways that could lead to the formation of the acyl-enzyme 
intermediate involving Thr12 as it is found in the mutated X-ray structure 4ECA.358 We 
have located such intermediate 11 kcal/mol above the initial reactants of the wild type 
enzyme. The overall barrier to reach the acyl-enzyme intermediate was 25 kcal/mol in 
the wild-type enzyme, obtained using B3LYP/6-31G(d):AM1. However, any attempt to 
progress further from the intermediate always involved barriers over 50 kcal/mol. This 
means that this pathway is definitely not viable in the wild type enzyme. In any case it is 
important to note that these results do not contradict the experimental findings. 
Contrarily, they give us a plausible explanation for the experimental trapping of the 
covalently-bound intermediate in the Thr89Val mutant structure because they show us 
that it is possible to form the covalent intermediate (assuming that its formation would 
have a comparable activation energy in the mutant and a smaller reaction energy) but 
that it is not possible to progress further from the covalent intermediate towards the final 
products. 
Facing these results, we move forward in exploring other pathways that could be 
more feasible from the energetic point of view. In this process, we found that the most 
favorable pathway involves the nucleophilic attack of the substrate by a water molecule, 
and this occurs prior to the release of ammonia, contrarily to what has been proposed 
so far in the literature. 
 
5.3.1. Step 1 − Nucleophilic Attack of the Water Molecule 
The water molecule that attacks the substrate in our proposal is conserved in many 
X-ray structures that are available in the protein databank.352 In those structures, this 
molecule is trapped between Lys162, Asp90 and the substrate. In the optimized 
geometry of the complex that was built for this study, the water molecule is deviated by 
about 2 Å from the one seen in the X-ray structure 3ECA. This position was chosen 
based on a 5 ns molecular dynamics simulation, where we have seen that, after 
transforming the product present in the crystal into the substrate, the water molecule 
moves to a position close to the one shown in Figure 35, and moves further to that 
position upon geometry optimization. In this new position it makes a hydrogen bond with 
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Lys162 (1.87 Å) and is particularly close to carbon C2 of the substrate that has been 
proposed to be involved in the formation of the acyl-enzyme intermediate (3.06 Å) (Figure 
36). Such interaction is favored by the position of the amide group of the substrate that 
is stabilized by the network of hydrogen bonds that are available on the active site and 
provides a close contact, almost free of steric hindrance. 
 
 
Figure 36. First step of the catalytic mechanism of L-asparaginase II. 
 
As the reaction moves from the reactants to the products, carbon C2 changes the 
hybridization from sp2 to sp3, as the water molecule approaches it. Simultaneously, 
Lys162 becomes positively charged (-0.01 a.u. in the reactants and 0.70 a.u. in the 
products, for the –NH3 group). At the transition state, the OH bond of the water molecule 
is elongated to 1.31 Å, the proton-nitrogen distance is 1.22 Å and the water oxygen-C2 
distance is 1.97 Å. Additionally, the bond between oxygen O4 and carbon C2 elongates 
(1.25 Å), as it changes from a double to a single bond and the oxygen becomes 
negatively charged. Thr12 starts moving away from Tyr25 towards this oxygen, in order 
to stabilize this charge (Figure 37). The transition state of this reaction is characterized 
by one imaginary frequency at 749 icm-1 and reveals that the proton transfer from the 
water to Lys162 occurs simultaneously with the nucleophilic attack of the water molecule 
to carbon C2 of the substrate. 
At the end of this reaction, carbon C2 adopts a tetrahedral configuration and the 
hydroxyl group of the water molecule becomes covalently bound to it (Figure 36). The 
double bond between C2 and O4 changes to a partial single bond (distance changes 
from 1.22 Å in the reactants to 1.31 Å in the products) and oxygen O4 becomes 
negatively charged (-0.72 a.u.). This charge is promptly stabilized by Thr12, which makes 
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a hydrogen bond with it (1.55 Å). In the course of this reaction, the distance between 
carbon C2 and the amino group increases from 1.39 Å to 1.50 Å and the hydrogen bond 
between the latter and Thr89 decreases from 1.93 Å to 1.71 Å. The same pattern is also 
observed with the hydrogen bond between Thr89 and Lys162, which decreases from 
2.22 Å to 1.83 Å due to the strengthening of the Lys162-Thr89 H bond that changes from 
dipolar to ionic. All of these patterns clearly indicate that the active site is ready to 
catalyze the proton transfer from the positively charged Lys162 to the amino group that 
is attached to carbon C2 of the substrate in the next step. 
 
 
Figure 37. Transition state from the first step of the reaction mechanism of L-asparaginase II. The main vectors 
are represented with yellow arrows (749.3018i). (For clarity, only some of the high level atoms are shown.) 
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It should be emphasized that the role of Lys162 in step 1 is very important. Apart 
from being directly involved in the reaction, it guarantees the correct orientation and 
alignment of the water molecule as well as that of Thr89, which will be required for the 
next step. In addition, at the end of this reaction Lys162 becomes positively charged and 
interacts very closely with the anionic Asp90 (1.70 Å). 
The reaction involved in step 1 has an activation energy of 20.2 kcal/mol and the 
reaction is endothermic (11.0 kcal/mol). In spite of high, the activation energy is still 
acceptable when compared with the experimental value regarding the kinetics of L-
asparaginases (around 16 kcal/mol). The relatively high activation energy of this reaction 
may be explained, at least partially, by sub-optimal position of the water molecule to 
perform the nucleophilic attack, as well as by the position of Thr12 which must break its 
hydrogen bond with Tyr25 in order to stabilize the nascent oxoanion in the substrate. 
The inclusion of a water molecule between Tyr25 and Thr12 might lower the barrier 
significantly. We have seen that such water molecule makes a hydrogen bond with the 
carbonyl oxygen of the substrate already in the reactants. However, we decided not to 
include it in the final calculations because we are unsure if that water should be present 
in physical conditions. The position, and particularly, the orientation of the water molecule 
is very important for the success of the reaction, as well as for the stabilization provided 
by Thr12 to oxygen O4. Other factors such as long-range interactions from the missing 
part of the enzyme or conformational/dynamic effects, as well as the limited accuracy of 
DFT, may be responsible for the small difference of 4 kcal/mol between theory and 
experiments. 
 
5.3.2. Step 2 – Formation of Ammonia 
As mentioned before, all the active site residues are pre-organized to facilitate the 
formation of ammonia. Thr89 makes two hydrogen bonds, one with the amino group of 
the substrate (1.71 Å) and another with Lys162 (1.83 Å), favoring in this way the 
concomitant transfer of both protons (from Thr89 to the amide group and from Lys162 to 
Thr89) that ultimately leads to the protonation and release of the amino group attached 
to carbon C2 of the substrate (Figure 38). Thr12 performs a hydrogen bond with oxygen 
O4 and Lys162 interacts in the same way with oxygen O1, which belonged to the water 
molecule and is now covalently bound to carbon C2. 
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Figure 38. Second step of the catalytic mechanism of L-asparaginase. 
 
As the reaction proceeds, the hydrogen from Thr89 moves to the nitrogen N3 of 
the amide group of the substrate in order to form the ammonia molecule. At the same 
time, the hydrogen from Lys162 draws closer to the oxygen from Thr89. In the transition 
state (Figure 39), it is possible to observe that the proton of Lys162 is half-way through 
to Thr89 (the distance from nitrogen N6 to the hydrogen is 1.21 Å while that of the 
hydrogen to the oxygen O5 is 1.31 Å). In the same way, the distance between the 
hydrogen from Thr89 and O5 has increased from 1.02 Å in the reactants to 1.56 Å in the 
transition state, while the distance between this hydrogen to nitrogen N3 has decreased 
to 1.08 Å. The transition state of this double proton transfer is characterized by an 
imaginary frequency at 515 icm-1, and reveals that both protons are transferred 
simultaneously with a relatively low activation barrier (3.5 kcal/mol), as it was proposed 
before. 
In the product of the reaction, one ammonia molecule is obtained but it does not 
unbind from the substrate, as it was expected. Instead, this group remains very weakly 
bound to carbon C2 of the substrate (1.62 Å). This may explain why the reaction is 
endothermic by 4.9 kcal/mol. The total charge of the NH3 group is 0.33 a.u. and not zero 
because it is still bound to the substrate. One cause for such behavior may be related to 
the ionic bond between oxygen O4 and Thr12 (1.59 Å) that helps stabilize the tetrahedral 
intermediate centered on carbon C2, and will be transformed into a weaker dipolar 
hydrogen bond upon release of ammonia. It is also observable that the proton from 
Lys162 is now bound to Thr89 (distance between N6 and the proton in the products is 
1.65 Å and the distance between the same proton and O5 is 1.03 Å). 
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Figure 39. Transition state from the second step of the reaction mechanism of L-asparaginase II. The main vectors 
are represented with yellow arrows (515.8669i). (For clarity, only some of the high level atoms are shown.) 
 
It is also interesting to note that the structure of the reactants, transition state and 
products can be almost superimposed with a root means square deviation of 0.3 Å, 
considering only the QM region. This means that the active-site is extremely well pre-
organized to move from the reactants to the transition state and to the products, with 
minimal reorganization energetic cost. In this regard, the positions occupied by Thr89 
and Lys162 are very important but also that of Thr12, which continues to stabilize the 
negatively charged oxygen O4 (-0.69 a.u.), and consequently the tetrahedral 
intermediate. 
 
5.3.3. Step 3 – Enzymatic Turnover 
The last step of the reaction involves the formation of the product of the reaction 
(glutamate) and the release of one ammonium molecule (Figure 40). 
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Figure 40. Third step of the catalytic mechanism of L-asparaginase. 
 
In the optimized geometry of the reactants, it is clear that the interaction between 
the NH3 group and carbon C2 of the substrate remains very stable (1.62 Å). The NH3 
and the hydroxyl groups of the substrate side chain interact very closely with two active 
site residues, Thr89 (1.74 Å) and Lys162 (2.15 Å) respectively, through two hydrogen 
bonds. In addition, these two residues interact with each other very closely (1.65 Å) 
through a hydrogen bond, creating a net of hydrogen bonds through which the positive 
charge of the NH3 group of the intermediate can spread. Thr12 continues to interact very 
closely with oxygen O4 of the substrate (1.59 Å) supporting the stability of the tetrahedral 
intermediate. 
In order to trigger the release of ammonia, we scanned the distance between the 
NH3 group and carbon C2 of the substrate. The resulting dissociation of an ammonia 
molecule is very favorable and only has an activation energy of 3.8 kcal/mol. At the 
transition state it is possible to see that there are two changes occurring simultaneously 
(Figure 41). As the NH3 group dissociates from carbon C2 (distance changes from 1.62 
Å to 1.92 Å) forming the aspartate molecule, the distance between oxygen O4 and 
carbon C2 decreases (1.25 Å), implying the formation of a double bond between both 
atoms. The hydrogen bonds between Thr89 and Lys162 and between O4 and Thr12 are 
preserved during the reaction. The transition state structure of this reaction is 
characterized by an imaginary frequency of 179 icm-1. 
At the end of this reaction, the aspartate molecule is generated and the ammonia 
molecule dissociates from the intermediate. After optimization of the products, the NH3 
molecule is found 4.86 Å away from carbon C2 of the substrate. Carbon C2 and oxygen 
O4 of the substrate are now connected through a double bond (1.27 Å). The hydroxyl 
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group of Thr12 continues to make a hydrogen bond with oxygen O4 (1.76 Å) as well as 
Tyr25 (1.70 Å), which turned away from Glu283 in order to interact with it. The full 
reaction is rather exothermic (-25 kcal/mol), which favors the formation of glutamate. 
 
 
Figure 41. Transition state from the Third and last step of the reaction mechanism of L-asparaginase II. The main 
vectors are represented with yellow arrows (-179.4042i). (For clarity, only some of the high level atoms are 
shown.) 
 
In the end of these three steps, the reaction is completed and asparaginase can 
release the aspartate molecule from the active site to the solvent. Subsequently, the 
protein is ready to take another molecule of asparaginase and start the reaction all over. 
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5.4. Conclusion 
The computational results addressed to the study of the catalytic mechanism of L-
asparaginase II have shown that the full mechanism involves three sequential steps and 
requires the nucleophilic attack of a water molecule to the substrate prior to the release 
of ammonia (Figure 42). The first step of the mechanism involves the formation of a 
tetrahedral intermediate that results from the nucleophilic attack of the water molecule to 
carbon C2 of the substrate. In the course of this reaction, Lys162 receives the proton 
from the water molecule and becomes positively charged. The second step of the 
reaction involves a concerted double proton transfer from Lys162 to Thr89 and from 
Thr89 to the substrate, which results in the formation of ammonia. However, the 
ammonia molecule is still weakly bound to the substrate at this stage. This reaction 
requires the direct participation of Thr89, which serves as an intermediate in the proton 
transfer between Lys162 and the substrate. Such configuration is believed to be a result 
of the stabilization of the tetrahedral intermediate, in which Thr12 and Tyr25 play an 
active role. The last step of the reaction is very straightforward and involves the 
dissociation of the ammonia molecule. This reaction is very exothermic, and once it is 
complete and the product of the reaction leaves the active site, the enzyme is ready for 
the next turnover. These results also show that the full reaction is almost thermoneutral, 
a condition that is in agreement with the available experimental results, which show that 
this enzyme is capable of catalyzing the reaction in both directions (Figure 43). 
Another conclusion that the results provide regards the importance of the extensive 
network of hydrogen bonds between the residues of the active site and the substrate. 
Two specific regions can be highlighted. One region interacts with the top of the 
substrate, and involves the catalytic triad Thr89, Lys162 and Glu90. These residues were 
shown to be important for the catalytic activity of the enzyme, but also to orient the water 
molecule in relation to the substrate. The second group of residues involves Thr12, Tyr25 
and Glu283. These residues are not directly involved in the reaction, but are very 
important for the stabilization of the tetrahedral intermediate of the substrate that is 
essential for the reaction. This might explain why the mutation of Thr12 to an Ala makes 
the enzyme almost inactive, but if it mutated by a Ser residue the normal pathway is 
maintained373. Although these two triads of active site residues are often regarded as 
independent regions, they are in fact associated with each other by two hydrogen bonds 
promoted by Asn248. Since both Thr12 and Tyr25 are included in the mobile loop, which 
allows the substrate to enter and leave the active site, we can conclude that the presence 
of these residues is also very important since they allow the enzyme to enclosure and 
hold tight the substrate in the binding pocket, by approaching the previous indicated 
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regions close together374. The results obtained with this study show that the formation of 
the acyl-intermediate with Thr12 is not energetically favored, and therefore should not 
be present in the natural pathway of the wild-type enzyme. However, there has been a 
great debate about this intermediate in the literature. In many instances, it has been 
proposed to be a crucial intermediate in the catalytic mechanism of this enzyme. We 
must stress that this acyl-enzyme intermediate was obtained only when Thr89 was 
mutated by a valine. In this study we have shown that Thr89 is an active player on the 
reaction (Figure 42) and it is fundamental for the network of hydrogen bonds that forces 
the substrate to acquire a productive conformation, as well as for the correct orientation 
of the water molecule that is essential for the reaction. This means that, when Thr89 is 
mutated by a valine, the network of hydrogen bonds is completely disrupted, and the 
proton transfer from the water molecule to the amino group of the substrate is precluded. 
Consequently, the formation of the tetrahedral intermediate is prevented and the reaction 
moves toward a different direction and ends up with the formation of the acyl-
intermediate with Thr12. Comparing the X-ray structures 3ECA (wild type enzyme) and 
4ECA (Thr89Val mutant), we can see this trend and, in particular, the different position 
and conformation that is adopted by Lys162, which moves outwards from the active site. 
Together with Thr89, Lys162 is another active player in this reaction and, therefore, when 
Thr89 is mutated by a valine, the catalytic triad formed by Thr89, Lys162 and Asp90 is 
disrupted, another condition that changes the normal pathway of the reaction. These 
facts altogether show that the formation of the acyl-intermediate with Thr12 may be a 
cause of the mutation rather than a true intermediate in the wild-type mechanism. 
Another piece of evidence that supports this concept is the fact that, when Thr12 
is mutated by an alanine, the enzyme becomes less efficient, but remains active (the Kcat 
of the Thr12Ala mutant is approximately 1000 times less than that of the wild-type). Even 
though one may think that a 1000 fold decrease in the rate constant will render the 
enzyme completely inactive, in reality this translates in an increase of only 4.2 kcal/mol 
in the rate-limiting step. It is not strange that the mutation of a residue at the active site, 
involved in the fundamental H-bond network, destabilizes the TS by 4 kcal/mol and it 
does not necessarily means that the residue is participating directly in the reaction but 
instead that the residue is very close to the reactive center. This suggests that this 
residue is not an active player on the reaction, as it has been proposed and as it was 
corroborated by our results.356 In fact, Thr12, together with Tyr25, is very important for 
the stabilization of the tetrahedral intermediate that allows the binding of the water 
molecule to the substrate. If the function of one of these residues is disturbed, as with 
the mutation of Thr12 by an alanine, it will slow down the formation of the tetrahedral 
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intermediate. The last condition is perhaps what is observed when Thr12 is mutated by 
an alanine. Our conclusions are also supported by the fact that when Thr12 is mutated 
by a serine, the catalytic activity is not changed. This is completely in line with the 
catalytic mechanism that we propose. As the role of Thr12 is to stabilize the tetrahedral 
intermediate and position the substrate through H-bonding with its side-chain hydroxyl, 
it becomes obvious that a serine should be able to fulfill the same role with its equivalent 
hydroxyl group. This is the reason why the catalytic activity is undisturbed in the 
Thr12Ser mutant. 
 
 
Figure 42. New proposal for the catalytic mechanism of L-asparaginase II. 
 
We believe that the new mechanistic portrait of the catalytic mechanism of L-
asparaginase II provides a new, but at the same time complementary, understanding of 
the catalytic mechanism of L-asparaginases that fully respects all experimental data on 
this subject. This knowledge is not only important in order to gather an atomistic portrait 
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about the catalytic activity of this enzyme, but also to acquire additional information about 
the transition state structures that are useful to develop new compounds capable of 
controlling its activity, which is of extreme importance in cancer therapy. As a 
chemotherapeutic drug, this enzyme can also be harmful to the normal cells in the body 
if it is active in the blood stream for a large period of time. For this reason, L-asparaginase 
therapy is accompanied by the administration of an inhibitor some time after the uptake 
of the enzyme. With the results we have obtained, new and improved L-asparaginase II 
inhibitors can be studied. 
 
 
Figure 43. Energetic profile of the catalytic mechanism of L-asparaginase II. 
 
We believe that the new mechanistic portrait of the catalytic mechanism of L-
asparaginase II provides a new, but at the same time complementary, understanding of 
the catalytic mechanism of L-asparaginases that fully respects all experimental data on 
this subject. This knowledge is not only important in order to gather an atomistic portrait 
about the catalytic activity of this enzyme, but also to acquire additional information about 
the transition state structures that are useful to develop new compounds capable of 
controlling its activity, which is of extreme importance in cancer therapy. As a 
chemotherapeutic drug, this enzyme can also be harmful to the normal cells in the body 
if it is active in the blood stream for a large period of time. For this reason, L-asparaginase 
therapy is accompanied by the administration of an inhibitor some time after the uptake 
of the enzyme. With the results we have obtained, new and improved L-asparaginase II 
inhibitors can be studied. 
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This knowledge also provides important clues to understand the source of the 
catalytic activity of the enzyme, which can also be used to enhance its efficiency or 
modify the type of substrates, or even the reactions that can be catalyzed by these 
enzymes. 
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CHAPTER 6 
DISCOVERY OF NEW DRUGGABLE SITES IN THE ANTI-
CHOLESTEROL TARGET HMG-COA REDUCTASE BY 
COMPUTATIONAL ALANINE SCANNING MUTAGENESIS 
The enzyme 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA-R) is the 
fundamental target for the treatment of hypercholesterolemia nowadays. The HMG-CoA-
R clinical active site inhibitors (statins) are among the most widespread and profitable 
drugs ever sold but their side effects (myopathies, sometimes severe) still limit their use, 
which makes the finding of alternatives to statins a field of intense research. In this line, 
we address here a new strategy for inhibiting the homotetrameric HMG-CoA-R. The 
enzyme consists in a "dimer of dimers”, each dimer having two active sites. We pursue 
here the inhibition of enzyme oligomerization, through drug binding to the dimer interface. 
We have mutated computationally 232 interfacial residues by alanine and calculated the 
lost in binding free energy among the monomers that build up each dimer of the 
homotetramer. This led to the identification of the (ten) key residues for the formation of 
the active dimer (Glu528, Ile531, Met534, Tyr644, Glu665, Asn686, Lys692, Lys735, 
Met742 and Val863). The results show that these residues are located in two specific 
spots of the protein with a cleft shape, whose shape and size is favorable for small drug 
binding. It is expectable that small molecules specifically bound to these druggable 
pockets will have a major effect in the oligomerization of the protein or/and in active site 
formation. This paves the way for the discovery of new families of inhibitors of HMG-
CoA-R. 
 
Adapted from reference 375 
For this paper Diana Gesto preformed all the calculations and analyzed the results, 
wrote the entire preliminary draft of the manuscript which was then reviewed by all co-
authors. 
 
6.1. Introduction 
Cholesterol is a molecule of most importance in the biological world, and especially 
important for animals, where it is a key player in several biological processes, including 
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membrane fluidity and the biosynthesis of hormones. However, cholesterol has currently 
gained a bad reputation next to the great majority of people, especially because of its 
association with cardiovascular diseases, the number one cause of death in the 
developed world376. 
In humans, cholesterol can derive from different sources, the most important of 
which is the de novo synthesis, which starts with the mevalonate pathway10. In this 
pathway, two molecules of acetyl-CoA are condensed forming acetoacetyl-CoA and 
afterwards a new molecule of acetyl-CoA is used to create HMG-CoA. HMG-CoA is then 
reduced by NADPH, in a reaction catalyzed by the enzyme 3-hydroxy-3-methyl-glutaryl-
CoA reductase (HMG-CoA-R), in order to form mevalonate, an important intermediate in 
the formation of many compounds, including cholesterol. This last step is not only the 
committed step of the entire pathway, but it is also the rate limiting one38. 
Statins are currently the most used drugs to decrease the levels of cholesterol in 
the blood through the inhibition of HMG-CoA-R. The different types of statins differ in the 
structure apart from the HMG-like moiety that is common to all of them. These structural 
differences result in different binding characteristics in the HMG-CoA-R active site that 
confer them different inhibitory potencies377. In spite of the great success of statins in 
decreasing blood cholesterol levels, there are significant side effects associated with 
their use. While some of these can cause beneficial (pleiotropic) effects (plaque 
stabilizing, anti-inflammatory and antithrombotic effects, etc.) others can be adverse and 
even lethal like rhabdomyolysis and myalgia378. In 2001, a statin called cerivastatin was 
withdrawn from the market because of several cases of rhabdomyolysis associated with 
it379. Still, in spite of all the possible side effects, it did not preclude atorvastatin from 
being the most profitable drug in the world over the last 8 consecutive years, which 
demonstrates the great demand for drugs that lower the blood concentration of 
cholesterol.  
Until now the competitive inhibition of HMG-CoA reductase by statins has proven 
to be the most efficient way of decreasing the biosynthesis of cholesterol and, therefore, 
it will continue to be the main approach to treat hypercholesterolemia in a near future. 
However, it is clear that new drugs targeting this enzyme, and consequently capable of 
lowering blood cholesterol levels, are needed. At the same time new ways of inhibiting 
HMG-CoA-R are also being sought and, in this context, the dimerization inhibitors are 
very promising. 
As it is known, each of the four active sites of HMG-CoA-R is composed of residues 
from two identical monomers (the whole enzyme is a tetramer, organized as a dimer or 
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dimers). This means that unless the dimer is formed, the enzyme cannot work properly. 
Inhibitors that interfere with the formation of the dimer will inhibit the biosynthesis of 
mevalonate, and consequently, that of cholesterol. However, in order to achieve this, we 
would first need to discover which residues contribute the most for the 
monomer:monomer  association. As the monomer:monomer interfaces of the protein are 
very large, and bioavailable drugs should be small molecules, the drugs will only 
preclude a small set of interactions among the protein dimers. Therefore the drugs must 
specifically bind to the regions of the protein that are more important for 
monomer:monomer binding. To find this out, we propose the use a method called 
computational Computational Alanine Scanning Mutagenesis (cASM)380. The theory 
behind the cASM method is that if a residue at the dimer interface is mutated by an 
alanine and if we calculate the difference between the binding energy before and after 
the mutation was introduced, we can assess whether that residue is important or not for 
the formation of the interface by calculating precisely the quantitative contribution of each 
residue for the monomer:monomer binding free energy380-381. 
In this paper we conducted a systematic application of the cASM method to a total 
of 232 residues (58 in each monomer) present at the interface of the four subunits of this 
HMG-CoA-R, and identified the ones that have a higher contribution to the formation of 
the dimer. The collected data provides important clues about the association 
determinants for the two subunits and can serve as a basis for the development of a new 
class of HMG-CoA-R inhibitors designed to block the association of the two subunits, 
and therefore the biosynthesis of mevalonate, and that of cholesterol. 
 
6.2. Methodology 
6.2.1. Model and Molecular Dynamics Simulation 
The HMG-CoA reductase model used in this study was based on the tridimensional 
structure of the human enzyme. In the Protein Data Bank there are over 20 structures 
for human HMG-CoA reductase and we have chosen the one with the PDB code 1DQA 
(resolution 2.00 Å)220. Even though there were other structures with better resolution, we 
preferred this one because it is complexed with the natural substrate and the CoA and 
NADP cofactors. This guarantees that the interface between both proteins has not been 
distorted and maintains the main interactions and symmetry of the wild type enzyme. In 
addition, from all the X-ray structures available on the PDB databank this is the only 
structure that has a less number of missing residues of the N-terminal region of protein. 
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While constructing our model we removed all atoms from the HMG, CoA and NADP 
molecules. We also removed all solvent molecules, except structural waters. Since it is 
know that the protonation states of some residues may vary depending on the 
environment in which they are found, we conduct a preliminary study using PROPKA382-
383. This software predicts the pKa (and therefore the probable protonation state) for each 
residue in the enzyme. For our model, the results obtained showed that His672, Cys688 
and Lys735 would not have the standard protonation states once inside the folded 
enzyme, and therefore, in our final model we changed the charges of these residues so 
that they would match the prediction. The hydrogen atoms were added afterwards using 
the LEAP program which belongs to the AMBER 9.0 software package384. Since the total 
charge of the protein was +9 we also added Cl- ions to counterbalance it. We also added 
a water box (TIP3P model) with sides at least 15 Å away from any protein atom, to 
solvate our system, which also enables us to use periodic boundary conditions. 
We used the FF03 force field in all calculations. Before the Molecular Dynamics 
(MD) simulation, we performed a three-stage energy minimization protocol using the 
SANDER module of AMBER 9.05, in which constraints applied to the model were 
progressively removed. During first stage (500 steps) the positions of all atoms of the 
model, except those of the water molecules, were restrained using 50 kcal mol-1 Å-2 
harmonic forces. For the second stage (500 steps), the same constraints were applied 
to all atoms except hydrogens and for the last stage (500 step) no constraints were used. 
Then we did a 20 ps equilibration process, in which the system was gradually warmed 
up until 310.0 K, using the NVT ensemble. Afterwards, a 10 ns simulation was performed 
on the model using NTP conditions. The SHAKE algorithm was used in order to restrain 
bonds involving hydrogen atoms385. The equations of motion were integrated at each 2 
fs and a non-bonded interaction cut-off radius of 12 Å was employed with a Particle-
Mesh Ewald scheme. To maintain a steady temperature of 310 K the Langevin 
thermostat was applied. For the posterior analysis we used only the last 4 ns of the 
simulation. 
 
6.2.2. Computational Alanine Scanning Mutagenesis 
The Computational Alanine Scanning Mutagenesis (cASM) combines a continuum 
approach to model solvent interactions with an MM-based approach to atomistically 
model protein–protein interactions. This methodology has been successfully applied to 
several complexes to predict accurately differences in binding free energies in solution 
between the wild-type and alanine mutated complexes (Gbind)386-389. 
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∆∆𝐺𝑏𝑖𝑛𝑑 =  ∆𝐺𝑚𝑢𝑡,𝑎𝑞
𝑏𝑖𝑛𝑑 − ∆𝐺𝑤𝑖𝑙𝑑𝑡,𝑎𝑞
𝑏𝑖𝑛𝑑  
(31) 
The corresponding binding free energy for mutant and wild type complexes in 
solution (∆𝐺𝑎𝑞
𝑏𝑖𝑛𝑑) were calculated using the thermodynamic cycle shown at Scheme 1 in 
which ∆𝐺𝑔
𝑏𝑖𝑛𝑑 is the binding free energy of the dimer in the gas , ∆𝐺𝑠𝑜𝑙𝑣
𝑚𝑜𝑛𝑜𝑚𝑒𝑟(𝐴)
, 
∆𝐺𝑠𝑜𝑙𝑣
𝑚𝑜𝑛𝑜𝑚𝑒𝑟(𝐵)
 and ∆𝐺𝑠𝑜𝑙𝑣
𝑐𝑜𝑚𝑝𝑙𝑒𝑥
 are the solvation free energy of the monomer A, monomer 
B, and the dimer, respectively. 
 
 
Scheme 1: Thermodynamic cycle used to calculate the binding free energy for mutant and wild type complexes 
in solution (∆𝐺𝑎𝑞
𝑏𝑖𝑛𝑑
) in the CompASM protocol. 
 
The binding free energy of two molecules in a complex (∆∆𝐺𝑎𝑞
𝑏𝑖𝑛𝑑) is defined here 
as the difference between the free energy of the complex and those of the respective 
monomers.  
∆𝐺𝑏𝑖𝑛𝑑 =  𝐺𝑐𝑜𝑚𝑝𝑙𝑒𝑥 − (𝐺𝑚𝑜𝑛𝑜𝑚𝑒𝑟(𝐴) + 𝐺𝑚𝑜𝑛𝑜𝑚𝑒𝑟(𝐵)) 
(32) 
The free energy of a dimer protein and its respective monomers 
(𝐺𝑐𝑜𝑚𝑝𝑙𝑒𝑥, 𝐺𝑚𝑜𝑛𝑜𝑚𝑒𝑟(𝐴) and  𝐺𝑚𝑜𝑛𝑜𝑚𝑒𝑟(𝐵))can be calculated accordingly to equation (33, 
summing the internal energy (𝐸𝑖𝑛𝑡𝑒𝑟𝑛𝑎𝑙), the electrostatic and the van der Waals 
interactions (𝐸𝑒𝑙𝑒𝑐𝑡𝑟𝑜𝑠𝑡𝑎𝑡𝑖𝑐 and 𝐸𝑣𝑑𝑊), the free energy of polar solvation (𝐺𝑝𝑜𝑙𝑎𝑟 𝑠𝑜𝑙𝑣𝑎𝑡𝑖𝑜𝑛), 
the free energy of nonpolar solvation (𝐺𝑛𝑜𝑛𝑝𝑜𝑙𝑎𝑟 𝑠𝑜𝑙𝑣𝑎𝑡𝑖𝑜𝑛) and, the entropic (TS) 
contribution for the molecule free energy. 
𝐺𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒 =  𝐸𝑖𝑛𝑡𝑒𝑟𝑛𝑎𝑙 + 𝐸𝑒𝑙𝑒𝑐𝑡𝑟𝑜𝑠𝑡𝑎𝑐𝑡𝑖𝑐 +  𝐸𝑣𝐷𝑊 + 𝐺𝑝𝑜𝑙𝑎𝑟 𝑠𝑜𝑙𝑣𝑎𝑡𝑖𝑜𝑛 +  𝐺𝑛𝑜𝑛𝑝𝑜𝑙𝑎𝑟 𝑠𝑜𝑙𝑣𝑎𝑡𝑖𝑜𝑛 − 𝑇𝑆 
(33) 
The first three terms in equation 33 are calculated using the Cornell force field with 
no cutoff. The electrostatic solvation free energy is calculated resorting to the MM-PBSA 
(Molecular Mechanics Poisson–Boltzmann Surface Area) approach first developed by 
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Massova et al.380, 390 and that was later one adapted by Moreira et al.391. To this end we 
use the original MM-PBSA script integrated into the AMBER9 package but with different 
internal dielectric constants, which depend exclusively on the type of amino acid that is 
mutated. For the charged amino acids (aspartic acid, glutamic acid, lysine, arginine, and 
histidine), a constant of 4 is used. For the remaining polar residues (asparagine, 
glutamine, cysteine, tyrosine, serine, and threonine) not ionized at physiological pH, the 
internal dielectric constant should be set to 3 and for the nonpolar amino acids (valine, 
leucine, isoleucine, phenylalanine, methionine, and tryptophan), the internal dielectric 
constant is set to 2. The different internal dielectric constants account for the different 
degree of relaxation of the interface when different types of amino acids are mutated for 
alanine. This means that the stronger the interactions these amino acids establish, the 
more extensive the relaxation should be, and the greater the internal dielectric constant 
value must be to mimic these effects. 
The nonpolar contribution to solvation free energy due to van der Waals 
interactions between the solute and the solvent and cavity formation was modeled as a 
term that is dependent on the solvent-accessible surface area of the molecule. It was 
estimated using the following empirical relation381, 
∆𝐺𝑛𝑜𝑛𝑝𝑜𝑙𝑎𝑟 =  𝛼𝐴 + 𝛽 
(34) 
where, A is the solvent-accessible surface area that was estimated using the 
molsurf program (based on the idea primarily developed by Michael Connolly) and α and 
β are empirical constants for which the values of 0.00542 kcal Å-2 mol-2 and 0.92 kcal 
mol-1 were used.  
The entropy term (TS) can be obtained as the sum of translational, rotational, and 
vibrational components. However, it was not calculated here because it was assumed, 
on the basis of previous work that its contribution to ∆𝐺𝑎𝑞
𝑏𝑖𝑛𝑑is similar for the wild type 
protein and for the mutants, and thus its contribution for ∆∆𝐺𝑏𝑖𝑛𝑑 is neglectable380, 392. 
In the present work, the full cASM protocol was done using the compASM plug-in 
that was developed in our group and it is available at: 
(http://compbiochem.org/Software/compasm/Home.html)393. The full process was 
applied to 350 snapshots of the last 4 ns of the molecular dynamic simulation. Since the 
quaternary structure of HMG-CoA-R is a homotetramer compose by two active dimers, 
the cASM protocol was applied to both dimers interfaces. 
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6.2.2.1. Mutant Selection 
As the dimeric interfaces of HMG-CoA-R are quite large, we restricted the residues 
that were tested to the ones that had the possibility of being important for binding. It was 
found in an earlier work393 that any residue whose contribution for the binding energy 
was important (defined as contributing by more than -4 kcal/mol, or 3 orders of magnitude 
for the binding constant) needed to be deeply buried on the protein interface, with a 
buried surface area larger than 40 Å2. Therefore, only the residues that had buried areas 
larger than 40 Å2 were studied. All the others would necessarily give small contributions 
for the binding energy and would never be efficient drug targets. Using this cutoff we 
identified a total of 232 residues, 58 for each subunit (The results can be found at table 
2 of the discussion section). 
The mutant complexes are generated by a single truncation of the mutated side 
chain, replacing Cα with a hydrogen atom and setting the Cα-H direction to that of the 
former Cα-Cβ. The glycine residues present in the interface were not mutated, because 
their side-chain is smaller and their substitution would probably affect the structure 
tridimensional arrangement of the enzyme. Proline residues pose a similar challenge as 
well, and its substitution for alanine could also severely alter the structure of the protein. 
 
6.2.2.2. SASA Analysis 
The solvent accessible surface area (SASA) for all residues mutated was 
calculated using the Visual Molecular Dynamics (VMD) program394 and the VolArea plug-
in395. The standard value for the probe radius of water (1.4 Å) was used. The SASA 
values were calculated for the last 4 ns of the MD simulation, from a total of 2000 
snapshots. We calculated the SASA for each residue considering different 
configurations, i.e. considering residue was free (not integrated in the protein – SASAfree), 
considering only the monomer in which it belongs (and disregarding the shielding effect 
of the other monomer of the dimer – SASAmonomer) and considering the whole dimer 
(SASAdimer). The results were also expressed as a percentage of the maximum possible 
SASA, i.e. the SASA of the free residue. 
 
6.3. Results and Discussion 
Our purpose is to find ways of avoiding the formation of functional HMG-CoA-R, 
by precluding its dimerization or, at least, impairing the formation of native-fold dimmers. 
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As the active site is at the dimer interface, any perturbation in the quaternary structure 
will have severe consequences on the enzyme activity. However, it is difficult to interfere 
with large-molecules association using a (comparatively) very small bioavailable drug. 
For that purpose we need to identify the regions of the protein interface that are 
determinant for binding (to bind the small molecule there), and evaluate if their shape 
makes them are druggable.  
The structure of the human HMG-CoA-R is formed by four identical monomers, 
which forms two dimers that coil around each other in an intricate way. The enzyme 
contains four active sites, two in each dimer, and they are made up of residues from both 
subunits. Based on this information we have analyzed by cASM both dimer interfaces of 
the human HMG-CoA-R that are denominated here as dimer A/B and dimer C/D (Figure 
44). 
 
 
Figure 44 - Tridimensional structure for the catalytic domain of human HMG-CoA reductase (PDB code: 1DQA) 
 
6.3.1. General Analysis of the MD Simulation 
Prior to the cASM study, a general analysis of the MD trajectories generated was 
performed to evaluate the convergence and stability of the most relevant properties 
within the 10 ns simulation times considered. Properties evaluated included the potential 
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and energy, the temperature, the pressure, the volume, the root-mean-square deviation 
in the atomic positions (RMSd), etc. From these general properties, the RMSd is normally 
the most difficult to converge and is usually taken as a reference to assess if the MD 
simulation has reached equilibrium. 
Figure 45 illustrates the RMSd values for the backbone Cα atoms in the MD 
simulations of the full tetramer and for each of the dimers. In addition, this figure also 
shows the RMSd values for the subset of backbone Cα atoms of the 58 interface 
residues that will be the subject of more detail in this study. The results show that all are 
well equilibrated after the initial 6 ns of simulation. The interfacial residues are perfectly 
stabilized. After this observation, the remaining 4 ns of simulation (from 6 to 10 ns) were 
taken into consideration for the ASM calculations and subsequent analysis. 
 
 
Figure 45 - RMSd analysis of the backbone Cα atoms for the tetramer, for the dimers AB and CD, and for the 
studied residues of the interface. 
 
6.3.2. Analysis of the Interfaces of each Dimer of HMG-
CoA-R 
The interfaces of each dimer of HMG-CoA-R are quite large since all domains of 
the monomer participate in the interactions that join both subunits together (Figure 44). 
Taking this into account, we have chosen to restrict the number of residues that were 
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studied. This was done having in mind that the hot-spots are usually deeply buried on 
the protein interface and therefore only the residues whose buried surface area was 
larger than 40 Å² were selected and mutated. In the end of this procedure, a total of 232 
residues were selected (58 of each subunit).  
The energetic contribution for the dimer association was then analyzed using the 
cASM methodology. The calculated binding free energy difference between the wild-type 
and alanine mutated complexes (Gbind) is summarized at Table 3. These values 
correspond to the binding affinity lost when a side chain is changed for an alanine, and 
can be considered as the contribution of the side chain for binding (note that the “energy 
zero” here is the binding provided by an alanine, which is minimal in fact). 
The free energy lost upon mutation allows to classify the residues as hot-spots 
(Gbind ≥ 4 kcal/mol), warm spots (4 kcal/mol > Gbind ≥ 2 kcal/mol), and null spots 
(Gbind < 2 kcal/mol). For the sake of finding the regions determinant for binding only 
the hot-spots really matter. Each hot spot decreases the equilibrium binding constant for 
3 orders of magnitude at least. Warm spots are interesting as well if they are in the vicinity 
of hot spots and can be occluded by a drug altogether. 
The calculated Gbind values are very similar for the equivalent residues of each 
chain, with only very few exceptions. In more than 83% of the cases, this difference is 
less than 1.5 kcal/mol, underlining the accuracy of the method.  
The residues classified by cASm protocol as hot- and warm-spots are not located 
in a specific area, but rather evenly distributed along the contact surface of the dimer 
(Figure 46). From all the 58 residues considered for each dimer of HMG-CoA-R, only 10 
residues have an energetic contribution higher than 4 kcal/mol to the formation of the 
dimer and therefore classified as hot-spots. These are Glu528, Ile531, Met534, Tyr644, 
Glu665, Asn686, Lys692, Lys735, Met742 and Val863. They are the ones that are 
determinant to the dimerization process and therefore they are of most importance for 
the development of drugs that are able to prevent or disrupt dimer formation, and hence 
inhibiting HMG-CoA-R enzymatic activity. The residues that have a Gbind value 
between 2 and 4 kcal/mol are less important but still vital to the binding process and are 
designated as warm-spots. In this work a total of 25 residues were classified as warm-
spots (Lys499, Leu503, Tyr511, Leu512, Tyr517, Cys527, Tyr533, Ile536, Val538, 
Val540, Thr558, Glu559, Arg595, Leu681, Val683, Tyr687, Lys691, Glu730, Ile746, 
Ile762, Asp767, Asn771, Val772, Gln819 and Met820). The remaining residues are 
classified as null-spots and their contribution for the dimer formation/stabilization is very 
small (below 2 kcal/mol). The large number of warm spots that were obtained in this work 
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may seem odd when compared to that of null spots, but we have to remember that this 
analysis was done only to a subset of the residues present on the dimer interface of 
HMG-CoA-R and the selection these residues was made in order to decrease the 
number of null spots as much as possible without excluding the warm and in particularly 
the hot spots residues. It is worth to note that the location of the hot and warm spots are 
in agreement with previous studies that indicate those same regions as important for the 
dimerization process17. 
Even though, for the great majority of the case, the four Gbind energies obtained 
for the four corresponding residues in each subunit is equivalent, there are five that 
present some variability. Those residues are Tyr479, Glu528, Glu665, Ile746, and 
Val772. 
In the case of Glu528 the Gbind values calculated for chain B, C and D vary from 
12.2 to 17.8 kcal/mol. Even though it seems a huge discrepancy, they are nonetheless 
much higher than the 4 kcal/mol needed for a residue to be considered a hot-spot. The 
problem is in the result obtained for the residue located in chain A, which has a value of 
3.0 kcal/mol. This is much lower than the other values, and below the limit of energy to 
be considered a hot-spot. However, looking in detail to the tridimensional structure of the 
model, we can easily see that Glu528 of chain A is a lot more exposed to the solvent 
than those of the other subunits. The SASAdimer values reflects this issue and shows that 
area exposed to the solvent is much smaller in monomer A than in the other monomers 
(73.1 Å² versus at chain 107.2 Å² in chain B, 117.2 Å² in chain C and Å² 133.0 Å² in chain 
D). This happens because Glu528 from monomer A interact with the C-terminus of 
monomer B that is incomplete in the x-ray structure and lacks more residues in that 
region than those of the other monomers. This renders Glu528 from monomer A to be 
less shielded from the solvent, and therefore it presents lower Gbind values. Taking this 
into account, we opt to exclude the Gbind value of Glu528 from monomer A and 
classified it as an hot-spot taking into account the average of the Gbind values of 
monomer B, C and D.  
A similar case happens with Tyr479 from monomer D. For monomers A, B and C 
we got a Gbind of 2.7, 2.1, and 2.4 kcal/mol, respectively, which classifies this residue 
as a warm-spot. However, for Tyr479 from monomer D the result was 0.4 kcal/mol that 
is a value characteristic of null-spots. Looking again to the amino acid sequence of the 
enzyme, we can see that C-terminal of monomer D starts only on residue 477, while 
monomers A, B and C start on residues 462 (for both A and B) and 468 (for C). 
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Table 3 - Differences in the ΔΔGbinding for each of the 232 mutated residues. The hot-spots (Gbind ≥ 4 kcal/mol) 
are marked red, the warm-spots (Gbind between 2 and 4 kcal/mol) are marked yellow, and the null spots (Gbind 
< 2 kcal/mol) are marked white. 
Mutated 
Residue 
Gbinding 
Subunit A 
(kcal/mol) 
Gbinding 
Subunit B 
(kcal/mol) 
Gbinding 
Subunit C 
(kcal/mol) 
Gbinding 
Subunit D 
(kcal/mol) 
Average 
Gbinding 
(kcal/mol) 
Range* 
(kcal/mol) 
Tyr479 2.7±0.9 2.1±0.9 2.4±0.9 0.4±0.9** 2.4 0.3 
Lys480 -0.9±0.9 -1.0±0.9 -1.2±0.9 -0.8±0.9 -1.0 0.1 
Leu499 2.4±0.9 2.7±0.9 2.6±0.9 2.8±0.9 2.6 0.1 
Lys502 0.8±0.9 -0.1±0.9 -0.4±0.9 0.7±0.9 0.3 0.6 
Leu503 2.2±0.9 2.3±0.9 2.2±0.9 2.3±0.9 2.3 0.1 
Ser508 0.8±0.9 -0.1±0.9 0.9±0.9 0.4±0.9 0.5 0.4 
Tyr511 2.8±0.9 2.1±0.9 2.2±0.9 2.2±0.9 2.3 0.3 
Leu512 2.7±0.9 2.6±0.9 2.4±0.9 2.6±0.9 2.6 0.1 
Tyr517 2.0±0.9 1.8±0.9 2.3±0.9 2.0±0.9 2.0 0.2 
Cys526 0.3±0.9 0.6±0.9 1.4±0.9 0.5±0.9 0.7 0.4 
Cys527 3.1±0.9 3.0±0.9 3.2±0.9 2.7±0.9 3.0 0.2 
Glu528 3.0±0.9** 12.2±0.9 17.8±0.9 14.0±0.9 14.7 5.6 
Asn529 0.4±0.9 0.0±0.9 0.5±0.9 1.4±0.9 0.6 0.6 
Ile531 5.3±0.9 4.7±0.9 4.5±0.9 5.2±0.9 4.9 0.3 
Tyr533 3.0±0.9 2.9±0.9 3.0±0.9 2.9±0.9 3.0 0.1 
Met534 5.3±0.9 6.3±0.9 5.9±0.9 5.1±0.9 5.6 0.5 
Ile536 3.8±0.9 3.6±0.9 3.8±0.9 3.9±0.9 3.8 0.1 
Val538 3.3±0.9 4.1±0.9 3.1±0.9 3.4±0.9 3.5 0.4 
Val540 2.9±0.9 4.0±0.9 3.6±0.9 3.3±0.9 3.4 0.6 
Gln552 1.6±0.9 1.5±0.9 1.8±0.9 1.8±0.9 1.7 0.1 
Thr558 1.6±0.9 2.3±0.9 1.7±0.9 3.2±0.9 2.2 0.6 
Glu559 2.8±0.9 3.8±0.9 3.3±0.9 5.5±0.9 3.9 1.0 
Arg571 -0.7±0.9 1.09±0.9 -0.7±0.9 -1.5±0.9 -0.4 1.1 
Arg595 1.9±0.9 1.5±0.9 4.7±0.9 2.3±0.9 2.6 1.1 
Tyr644 4.5±0.9 3.9±0.9 3.9±0.9 4.6±0.9 4.2 0.4 
Asn658 0.3±0.9 0.6±0.9 2.1±0.9 1.1±0.9 1.0 0.7 
Lys662 0.4±0.9 -0.6±0.9 0.1±0.9 0.0±0.9 0,0 0.4 
Glu665 2.6±0.9** 3.8±0.9** 2.9±0.9** 8.7±0.9 8.7 - 
Leu681 2.0±0.9 1.9±0.9 3.0±0.9 1.4±0.9 2.1 0.6 
Val683 1.8±0.9 2.1±0.9 2.0±0.9 3.6±0.9 2.4 0.5 
Ser684 0.3±0.9 0.1±0.9 0.1±0.9 -0.1±0.9 0.1 0.2 
Asn686 4.7±0.9 5.5±0.9 5.4±0.9 4.6±0.9 5.0 0.5 
Tyr687 2.2±0.9 2.0±0.9 1.9±0.9 2.2±0.9 2.1 0.1 
Lys691 2.9±0.9 2.5±0.9 4.1±0.9 2.4±0.9 3.0 0.6 
Lys692 5.5±0.9 5.6±0.9 7.8±0.9 4.4±0.9 5.8 1.4 
Glu730 1.6±0.9 2.1±0.9 2.4±0.9 3.3±0.9 2.3 0.8 
Val731 0.5±0.9 0.4±0.9 0.1±0.9 0.6±0.9 0.4 0.2 
Asn734 0.7±0.9 0.8±0.9 1.0±0.9 2.0±0.9 1.1 0.4 
Lys735 3.9±0.9 4.4±0.9 4.1±0.9 3.9±0.9 4.0 0.2 
Val738 1.0±0.9 1.2±0.9 1.4±0.9 1.2±0.9 1.2 0.2 
Met742 4.0±0.9 4.6±0.9 4.5±0.9 3.7±0.9 4.2 0.4 
Ser745 0.4±0.9 -0.1±0.9 0.2±0.9 0.2±0.9 0.2 0.2 
Ile746 0.9±0.9 3.7±0.9 3.7±0.9 0.9±0.9 2.3 1.4 
Asn755 0.2±0.9 1.0±0.9 0.3±0.9 0.4±0.9 0.5 0.3 
Thr758 1.0±0.9 2.0±0.9 1.9±0.9 1.6±0.9 1.6 0.4 
Ile762 2.5±0.9 2.7±0.9 3.1±0.9 2.4±0.9 2.7 0.3 
Asp767 3.2±0.9 3.2±0.9 3.0±0.9 3.1±0.9 3.1 0.1 
Asn771 1.6±0.9 2.4±0.9 2.7±0.9 1.3±0.9 2.0 0.7 
Val772 4.1±0.9 2.0±0.9 2.1±0.9 4.0±0.9 3.0 1.0 
Ser775 0.4±0.9 0.9±0.9 0.3±0.9 0.1±0.9 0.4 0.3 
Leu812 1.3±0.9 1.4±0.9 1.6±0.9 1.1±0.9 1.3 0.2 
Gln814 1.4±0.9 0.6±0.9 1.0±0.9 1.3±0.9 1.1 0.3 
Gln819 1.5±0.9 2.3±0.9 2.1±0.9 2.3±0.9 2.0 0.3 
Met820 3.5±0.9 4.2±0.9 4.8±0.9 3.3±0.9 3.9 0.6 
Leu857 2.4±0.9 2.1±0.9 0.9±0.9 1.8±0.9 1.8 0.6 
Leu862 1.5±0.9 1.2±0.9 2.6±0.9 1.1±0.9 1.6 0.5 
Val863 4.0±0.9 4.5±0.9 9.3±0.9 4.4±0.9 5.5 1.6 
Lys864 -0.5±0.9 -0.2±0.9 -0.5±0.9 -0.9±0.9 -0.5 0.3 
*The range of a given set of values is defined as the difference between the higher and the lower values of the 
set.  
**This residue was not taken into account in the calculation of the average Gbind as explained in the text. 
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Figure 46 – “Open book” representation of the two monomers with the location of the warm and hot-spots in the 
monomer in the dimer CD. Hot-spots are represented in red and warm-spots in yellow. Each residue are classified 
as either a hot or warm spot by taking into account the average values of the Gbind. 
 
Accordingly, Tyr479 from monomer D is not so well shielded from the solvent as its 
counterparts from the other monomers. The SASAdimer values reflect this trend 71.5 Å² 
for chain A, 70.5 Å² in monomer B, 60.2 Å² in monomer C and 53.0 Å² in monomer D). 
This means that the Gbind of Tyr479 from monomer D can be excluded since it is a 
result by the lack of the full sequence of monomer in that region. We have therefore 
classified Tyr479 as a warm-spot taking into account the average value of the Gbind 
values of monomer A, B and C. 
The Gbind values of Glu665 from monomer D are also different from the ones 
obtained for the other monomers. The value from monomer D classifies this residue as 
a hot-spot and the other three as warm-spots. Looking at the three-dimensional structure 
of the full protein it is evident that these differences come from the location of the Glu665 
in each monomer. In all cases this amino acid residue is located very close to the N-
teminus and, as it was described before, this part of the monomer finishes at different 
residues. Indeed, Glu665 from chain D is more deeply buried in monomer C than its 
counterparts of the other subunits, which lack more residues in that region. The 
calculated SASAdimer values upon dimerization reflect this trend. In monomer D, Glu665 
has a SASAdimer value of 79.2 Å², while in chains A, B and C this values are from 62.1 
Å², 51.4 Å² and 45.6 Å², respectively. Based on this information, we only took in account 
the result that was obtained with chain D and therefore classify this residue as a hot-
spot. 
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Ile746 and Val772 are two other residues that also show different Gbind values 
on the four monomers. These residues are located in the center of the tetramer in the 
only region where the four monomers interact with each other. The calculated Gbind 
values reveal that these values seem to be counterbalancing each other in order to 
maintain the full complex in a minimum. Therefore the higher Gbind values of Ile746 in 
monomer B and C are compensated by the lower Gbind values observed for the same 
residue in monomer A and D. MD simulation also emphasizes this, showing that the 
results are dependent on the stabilization of each residue in two different minima.  In 
order to classify this residue as a null- or warm-spot we have made an average of the 
four Gbind values. The final results classified these residues as a warm spots.  
 
Table 4 - Properties calculated for null, warm and hot spots. Percentages were based on the total SASA for the 
free residue. The average hydrophilic contribution corresponds to the sum of ΔΔEelectrostatic and ΔΔGPolarSolv. The 
average hydrophobic contribution corresponds to the sum of ΔΔvdW and ΔΔGNonPolarSolv. 
 Hot Spots Warm Spots Null Spots 
Residues identified in each monomer 10 25 23 
Average ΔΔGBind 
(kcal/mol) 
6.3 2.7 0.7 
Average ΔΔEelectrostatic 
(kcal/mol) 
8.6 3.3 -1.7 
Average ΔΔEvdW 
(kcal/mol) 
5.0 3.0 1.6 
Average ΔΔGPolarSolv 
(kcal/mol) 
-7.4 -3.7 0.7 
Average ΔΔGNonPolarSolv 
(kcal/mol) 
0.2 0.1 0.1 
Average hydrophilic contribution 
(kcal/mol) 
1.2 -0.4 -1.0 
Average hydrophobic contribution 
(kcal/mol) 
5.1 3.1 1.7 
Average SASA in Monomer 
(Å2 and %) 
102.6 (35.6) 86.6 (30.4) 82.4(30.3) 
Average SASA in Dimer in 
(Å2 and%) 
8.5 (3.0) 16.7(5.9) 29.6(10.8) 
Average SASA lost upon Dimeration 
(Å2 and %) 
94.0(33.1) 69.9(25.0) 52.8 (19.5) 
 
Table 4 displays the values of a set of relevant properties calculated for null, warm 
and hot spots. These results show that the hydrophilic interactions that stabilize these 
residues in the dimer interface (ΔΔEelectrostatic) are similar to the ones that stabilize the 
monomer alone in the aqueous solvent (ΔΔGPolarSolv). The hydrophobic contributions are, 
however, quite different. The hydrophobic interaction of these residues on the dimer 
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interface (ΔΔEvdW) is much higher than of the monomer alone with the solvent 
(ΔΔGNonPolarSolv). These results show that the hydrophobic interactions are the major 
contributor for the binding energy, and therefore the main driving force for the 
dimerization of HMG CoA-R.  
 
6.3.3. SASA Analysis 
Besides the Gbind results, we have also calculated the values of SASA (Solvent 
Accessible Surface Area) for each residue, considering the full dimer (SASAdimer) and 
considering only the residues in the same subunit (SASAmonomer). Given the large 
difference in size that characterizes the different residues present at the interface, the 
values are presented as a percentage of the potential SASA for the free residue as well. 
This means that a high SASAmonomer indicates that a given residue is poorly shielded by 
residues from its own subunit and exposed to the solvent and/or to residues from the 
other subunit, while a low SASAmonomer indicates a residue that is highly protected from 
other interactions by residues of its own subunit. Similarly, a high SASAdimer illustrates 
that, in the dimer, a given residue is a high exposition to the solvent, while a low SASAdimer 
indicates it is extremely protected by residues from the two subunits. From the difference 
between SASAdimer and SASAmonomer (described as SASA lost upon dimerization), it is 
possible to assess how buried a given amino acid is in the surface of the other subunit. 
The percentage of buried area (in relation to the free residue) is also interesting because 
it shows how much of the “potential for interaction” is effectively used in the dimer (i.e. 
how much optimized is the interaction).  
The results expressed in Table 4 show that all the hot-spots that were identified in 
this study have a very low SASA in the dimer. Upon dimerization these residues have in 
average only 8.5 Å² of their area exposed to the solvent, which corresponds in to only 
3.0% of the total of the available area of the residue. These values contrast markedly 
with the estimated SASAmonomer values for these residues that in average are around 
102.6 Å² and correspond to a mean of 35.6% of the total area of the residue. Considering 
the SASAdimer and SASAmonomer values, it becomes evident that dimerization leads to a 
major decrease in the SASA of these residues (in average 94.0 Å²) which, in turn, 
accounts for a decrease of 32.6% of the available area of the residue that now interacts 
with the other monomer. 
The warm-spots are slightly less exposed than the hot-spots when considering only 
the monomer (in average 86.6 Å2 versus 102.6 Å² in the hot-spots). Upon dimer formation 
the corresponding SASA decreases to 16.7 Å2 (compared to 8.5 Å2 in the hot spots), 
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which represents an average decrease of 69.9 Å2 per amino acid residue (25.0% of the 
total area of the residue). 
The null spots interact preferentially with their own subunit, exhibiting small 
SASAmonomer values, which decrease slightly when considering the dimer (the 
SASAmonomer values for the null-spots are similar values to the ones of the warm spots). 
Their values for the SASAmonomer and the SASAdimer are 82.4 Å2 and 29.6 Å2, with an 
average decrease of 52.8 Å2 on the SASA upon dimerization (versus 69.9 Å2 in the warm-
spots). Note than many null-spots were eliminated in the initial stage of this study, when 
the threshold of 40 Å2 for the SASAmonomer was applied. This is also explains why the 
number of null-spots is very small when compared with the number of warm- and hot- 
spots. 
The results of the SASA analysis of this work are in line with previous proposals, 
which dictate that there is a correlation between the buried surface area and the free 
energy of binding388, 391, 393, 396-397. 
 
6.3.4. Druggable Sites for Dimerization Inhibitors 
Two regions (region A and B in Figure 47) that have been identified as optimal to 
drug and preclude the formation of an active dimer of HMG-CoA-R are located in distinct 
regions of the monomers. 
Region A is located in one extreme of each dimer and opposite to the dimer:dimer 
interface. This means that the hot- and warm-spots that were identified in this region are 
not important for the formation of the tetramer, but instead for the dimer formation. This 
region is also the one where a higher concentration of hot and warm spots is found, and 
therefore the one that might be more important for the dimerization process.  
Figure 48 shows in greater detail the surface area of that region. It is very wide and 
shows a distinct cleft in the center where the hot spots from the neighbor monomer fit 
and bind. Such cleft should be an optimal druggable site for dimerization inhibitors 
capable of blocking the binding of the other monomer and therefore impair the formation 
of an active HMG-CoA-R. 
This druggable pocket has a truncated cone shape with an internal volume of 
around 194 Å3 and dimensions of around 7.6 Å X 6.3 Å X 4.9 Å (Figure 48). Such 
dimensions are very convenient as they can fit a molecule with 3-4 fused rings inside, or 
even greater if a part of the drug protrudes outside the pocket. 
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Figure 47 - Schematic representation of the interface of each dimer constitutive of HMG-CoA-R, illustrating the 
relative position of all the hot- and warm-spots identified by cASM protocol. 
 
The other region that can also be used to preclude the formation of an active dimer 
(Region B) is located very near to the active site of the enzyme. The active site of HMG-
CoA-R is composed by residues of both monomers and has a V-shape due to the 
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presence of two tunnels that are occupied by the two cofactors that are required for the 
catalytic process, i.e., CoA and NADPH. The binding pocket of HMG is located in the 
part where both tunnels join and it is formed by residues Ser684, Asp690, Lys691, 
Lys692 and Asp767 from one subunit and Glu559, Lys735, Asn755, Leu853 and His866 
from the other. 
 
 
Figure 48 - A) Druggable cavity in the interface between monomers A and B of HMG-CoA-R, where the most 
important hot and warm spots are located.  B) Top view of the druggable site. In red are represented the portions 
of chain B that interact with the cavity. C) Side view of the druggable cavity highlighting its shape, dimensions, 
and polar residues present in that region. The pockets can fit a drug of 194 Å3 totally inside the pocket. 
 
Taking as reference one of the active sites formed between monomers A and B 
(Figure 49), the hot-spots that were identified in region B are only located in monomer B 
and close to the binding position of CoA and HMG. One of the identified hot-spots, 
Lys692, is also one of the residues that is required for the catalytic process. Note that 
this region does not present a pocket, is mostly flat. Therefore, even being so important 
for dimerization, this region should be much more difficult to drug than region A above, 
where a perfect pocket accommodates drugs of moderate size. 
The statins that are commercially available on the market to inhibit HMG-CoA, as 
it is for example the case of atorvastatin, bind exactly in the same region of acetyl-CoA 
and HMG and interact with one hot-spot that belong to region B. In addition taking as 
reference Figure 49, these compounds interact preferentially with just one of the 
monomers, in this case monomer B. These results suggests that besides the competitive 
inhibition of these compounds, modified versions of these inhibitors could also be used 
to impair the dimerization of HMG-CoA-R (by occluding the hot-spots of region B) or, at 
least, deviate the residues of the active site from its the correct alignment, in order to 
form an active HMG-CoA.  
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Figure 49 - Left: One of the active sites of HMG-CoA-R present at dimer interface of monomers A and B (pdb 
code: 1dqa). The NADPH, acetyl-CoA and the product of the catalytic process are represented in sticks in yellow, 
green and red respectively. The hot spots of region B are represented in van der Waals style and colored in red. 
Right: Binding position of one of the statins commercially available in the market, atorvastatin (pdb code: 1hwk). 
 
6.4. Conclusions 
In this study, we presented a detailed atomistic analysis of each monomer interface 
in the HMG-CoA-R enzyme, an important target to control the levels of cholesterol in the 
blood. In particular, we have evaluated the energetic contribution of all the residues at 
the monomer interface of this tetrameric enzyme, in an attempt to identify the most 
important determinants for dimer formation. This analysis was further complemented with 
a solvent accessible surface areas study for all interfacial residues and the 
decomposition of the binding energy into hydrophilic and hydrophobic contributions, 
where we have shown that the driving force for oligomerization is essentially 
hydrophobic. The outcome provides relevant clues for the development of new inhibitors 
of HMG-CoA-R designed to block the association of the monomers, thereby preventing 
the formation of the fully active dimer enzyme. 
Ten residues (Glu528, Ile531, Met534, Tyr644, Glu665, Asn686, Lys692, Lys735, 
Met742 and Val863) were shown to be fundamental for dimer formation. Mutating one of 
these residues by alanine leads to a destabilization of the resulting dimer formed of more 
than 4 kcal/mol when comparing with the wild-type HMHG-CoA. These residues were 
also the largest contributors, in terms of area, to the subunit interface of the dimer (94 
Å2 each, in average). Three other pairs of residues also make a significant energetic 
contribution (albeit more modest than the latter) to dimer formation. These residues, 
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identified as warm spots, are Val538, Thr558 and Ile536, and have also an intermediate 
contribution in terms of area to the subunit interface.  
Based on the location of the hot and warm spots, these residues have been 
grouped in two distinct areas of the protein, that are proposed as two promising 
druggable targets to develop new dimerization inhibitors of HMG-Co-A-R. One of these 
regions is very close to the active site and closely resembles the one that is occupied by 
the statins that are currently commercially available to inhibit HMG-CoA.  The other 
region is where a higher concentration of hot and warm spots has been identified in this 
study, has a deep pocket that fits drugs of moderate size (a volume of 194 A3), and 
therefore should be the one that is most easily druggable.  
The inhibitors targeting these two regions should be capable of interfering or 
disrupting the more relevant and persistent dimerization contacts, blocking the formation 
of the fully active HMG-CoA-R  
These features should be taken into account in future drug design and 
development studies targeting HMGCoA-R. 
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CHAPTER 7 
STUDYING THE MAMMALIAN ENZYMATIC COMPLEX 
FAS 
7.1. Fatty Acid Synthase 
As stated previously, FAS is an enzymatic complex responsible for de novo 
synthesis of fatty acids. The discovery of FAS and how fatty acids are synthesized goes 
back more than one century ago, when Henry Stanley Raper determined in 1907 that 
fatty acids were likely derived from a C2 precursor 398. Still, at that time Raper was not 
able to ascertain whether this precursor was ethanol, acetaldehyde or acetic acid. It was 
not until almost half a decade later, in 1953, that it was found that this precursor was an 
activated form of acetate, acetyl-CoA 399. A few years later, however, in 1958, two 
different groups 400-401 independently arrived to the same conclusion; prior to being used 
in the synthesis of fatty acids, acetyl-CoA was carboxylated to malonyl-CoA, which was 
then decarboxylated during the condensation step of the reaction. 
By the late 1960s scientists were able to purify FAS from yeast and animal tissues 
and determined that these were different from those present in bacteria and plants402. At 
this point it was established that there should be made a difference between these two 
types of FAS, and so the following terminology was used: 
 Type I FAS (FAS I) refers to the large multidomain enzymes that catalyze 
fatty acid synthesis in its entirety, disposing of the complete product only 
when it is complete. They are present in non-plant eukaryotes 
 Type II FAS (FAS II) refers to the enzymes present in plant, prokaryotes 
and algae. They are expressed as individual domains and not a single 
protein. These domains are found on the cytosol of cells and each of them 
catalyzes one part of the reaction. They are encoded by several genes. 
FAS I contains FAS enzymes from both animals and fungi. However it should be 
noted that despite belonging to the same type, these enzymes are very different is terms 
of structural organizations403. They both include the same functional domains 
responsible for the synthesis of fatty acids, but their disposition is quite distinctive. Fungi 
FAS I is a heterododecamer of 2.6 MDa, which is considerably larger than animal FAS, 
and is encoded by two different genes. Since there will be no further discussion about 
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FAS I from fungi in the remaining of this work, all subsequent mentions of FAS I will refer 
solely to that of animals. 
Another interesting fact is, though there are many differences between FAS I and 
FAS II, the reactions catalyzed by the analogous domains are quite identical, since the 
mechanism for fatty acid synthesis has been greatly conserved throughout evolution. 
Also, if one compares the structural arrangement of each FAS II domain with its 
counterpart on the FAS II enzyme, one could easily observe that these share a great 
deal of resemblance (Figure 50). It is thought that FAS I is derived from an ancient gene 
fusion event of type I proteins. This would in part explain the similarities that exist 
between both types. 
 
 
Figure 50 – FAS domains from both type one and two aligned in a way that is easy to see that the structures are 
quite conserved. Each type I FAS domain is colored, whereas the type II FAS domains are in grey. The numbers 
show the RMSd between both structures. 
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Mammalian FAS I (mFAS) is a multidomain homodimeric protein of approximately 
540 kDa. mFAS comprises all the necessary domains to produce a single molecule of 
fatty acid from its building blocks (malonyl and acetyl). In total, mFAS is composed by 
eight different domains: 
 Six catalytic domains: 
o β-Ketoacyl Synthase (KS) 
o Malonyl/acetyltransferase (MAT) 
o β-Hydroxyacyl Dehydratase (DH) 
o Enoyl Reductase (ER) 
o β-Ketoacyl Reductase (KR) 
o Thioesterase (TE) 
 One carrier domain: 
o Acyl Carrier Protein (ACP) 
 One structural domain: 
o Pseudo-methyltransferase (ΨME) 
 
ACP is perhaps one of the most interesting modules in this whole complex. It is a 
very small, heat stable protein with a structure that is rather conserved throughout 
different organisms404. It consists of a four helix bundle which is stabilized by hydrophobic 
interactions that form between different helixes. In Figure 50 the RMSd between mFAS 
and FAS II from E. coli appears to be rather large (2.807 Å) but if one looks at the 
structure it is possible to notice that this difference is due mainly to the fact that ACP is 
very flexible and has several loops capable of adopting varied conformations. In fact, it 
is easy to perceive that the overall secondary structure of ACP is conserved between 
the two structures.  
ACP is responsible for the transport of all the substrates, intermediates and the 
final product since the beginning and until the end of the reaction405-406. It starts by 
carrying the initial acetyl group on the first step of the reaction to the active site of KS 
and finishes by transporting the completed fatty acid to TE, were it is released. ACP’s 
function is dependent on a prosthetic group called phosphopantetheine (PPT), which is 
covalently bound to a conserved serine residue present on helix 2. PPT is a cofactor 
derived from coenzyme A and is added to ACP post-translationally by a transferase 
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enzyme, and only then is it ready to perform its role in FAS. Given that ACP is such a 
mobile and flexible unit, it is difficult to study its structure using crystallography. As of 
now, the only structure available on PDB of ACP was obtain through the co-crystallization 
of it with the phosphopantetheine tranferase enzyme (PDB code: 2CG5407). 
 
 
Figure 51 – Structure of the phosphopantetheine molecule 
 
In the ACP of FAS II, helix 2, where the PPT is bound, is composed of a cluster of 
highly conserved and negatively charged amino acids which are regarded as an 
universal recognition helix responsible for the interaction with other enzymes408. In FAS 
I however the residues in this helix are not as conversed and do not retain the same 
negative character. Nonetheless, there is still evidence that this helix plays an important 
role in the docking of ACP with the other domains409. The internal pocket of the ACP 
lined with apolar residues responsible for interacting and stabilizing the acyl intermediate 
during transport. Since the intermediate can be as big as 16 carbons, it would be difficult 
to carry it through the aqueous medium, so it enters the ACP module and interacts with 
the hydrophobic interior, while the PPT moiety stays on the outside and in contact with 
the solvent. 
 
 
Figure 52 – Overall reaction catalyzed by FAS, with the indication of all modules in which each part occurs. 
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Figure 53 – Type I FAS. A: the overall structure of the type I FAS megacomplex, with all modules represented in 
diferent colors (KS – red, MAT – green, DH – dark blue, ER – light blue, KR – pink, ψME – yellow, ACP – orange 
and TE – brown). B: a schematic representation of all the subunits and how they are connected. C: representation 
of the primary structure of the FAS enzyme. 
 
In order to perform its role, ACP must transport each acyl intermediate to the right 
domain so that the reaction can proceed410 (Figure 52). After PPT is bound to the serine 
residue, ACP goes to the MAT domain, where either an acyl or malonyl moiety is 
attached, depending on whether it is the beginning of a new fatty acid synthesis cycle or 
it is already partially formed. In the case it is the start of a new cycle, acyl is bound to 
ACP, which then proceeds to the KS domain, where it transfers the acyl to a cysteine 
residue. Subsequently, ACP leave KS and returns to MAT so that a malonyl molecule 
can be added to PPT. This malonyl moiety is the fatty acid building block, and will add 
two new carbons to the growing chain. ACP goes then back to the KS domain, where 
the intermediate that is already attached to this domain will condensate with the malonyl 
adding two more carbons to the chain and releasing CO2. Next, ACP leaves KS again 
and is transferred to the active site of the KR domain, where its β-keto group is reduced 
FCUP 174 
New Therapeutic Strategies to Lower Blood Stream Cholesterol Levels through the Inhibition of HMG-CoA Reductase  
 
by a NADPH co-factor. After leaving KR, ACP travels to DH, where the growing fatty acid 
is dehydrated and later follows to the ER domain for the last step in this cycle, which is 
a new reduction. At the end of this cycle the PPT has attached to it a fully saturated acyl 
intermediate, which is then transferred again to the KS domain, so that ACP is free to go 
to MAT and get a new malonyl moiety to condense and a new cycle can then begin. 
Typically, this steps are repeated for a total of 7 turns in order to build a 16 carbon fatty 
acid. When it is finished, ACP travels with the final product to the chain-terminating TE 
domain, where the fatty acid is released from PPT to the cytoplasm and a new formation 
cycle can then commence410. 
In FAS I (Figure 53) it is currently not known exactly how the ACP domain bearing 
a particular acyl intermediate is able to locate the appropriate domain for the reaction to 
continue. During transport, the fatty acid intermediate is carried in the hydrophobic 
pocket of ACP, while PPT, given its polar nature, can easily travel outside of the carrier, 
and stay in contact with the cytosol. It is thought that the way ACP knows it has arrived 
at the right domain for the next step is through the exposure of the acyl thioester bound 
between PPT and the intermediate411. Given that the reactions occur near this bond, it 
could be hypothesized that its presentation to the other domain (maybe accompanied 
with some degree of change in the conformation of ACP) is what signals ACP that it has 
arrived to the correct destination. If the bond presented and/or the conformation of ACP 
is not the correct one for that domain to carry on the reaction, then ACP detaches from 
it and goes in search of the right one. In theory, this approach seems to make it easier 
for ACP to know whether or not it is the correct domain, without having to insert the 
intermediate in the active site, and instead providing cues that facilitate recognition by 
the appropriate enzyme. However, one cannot exclude the hypothesis that the finding of 
the right domain is done through a random search, in which the reaction proceeds only 
when a certain intermediate finds the correct enzyme and the next step can occur. 
 
7.1.1. KS Domain 
The KS domain is where the first step of the synthesis of fatty acids occurs. This is 
where the growing fatty acid chain is elongated, through the condensation of successive 
molecules of malonyl. 
The structure of KS is reminiscent of enzyme belonging to the thiolase superfamily. 
The KS domain is homodimeric, meaning that it is constituted by two identical subunits. 
Each subunit is constituted by two subdomains, each of which exhibits a similar 
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βαβαβαββ topology, which suggests that these subdomains may have evolved through 
an ancestral gene duplication event. 
One interesting fact is that KS is essential for the correct dimerization of FAS412. 
KS has an extensive dimeric interface which is largely stabilized by hydrogen bonds 
formed between the two subunits. Even though domains like ER and DH also contribute 
in the dimerization process, forming dimers between their subunits, it has been found 
that they are sufficient to promote the correct folding of FAS. In fact, FAS engineered 
without KS is unable to form dimers, and is found entirely as a monomer412. On the other 
hand, however, in enzyme analogous to FAS (polyketide synthases) lacking both ER 
and DH domains, it was observed that they can dimerize, and the interface between both 
monomers is constituted mostly by in the interface between the two KS domains and an 
additional N-terminal coiled-coil appendage. 
As stated previously, KS is responsible for the elongation of the fatty acid chain. 
The reaction mechanism proposed for KS is shown in Figure 54413. The residues of the 
enzyme important for the reaction are one conserved cysteine and two histidines that 
help with the stabilization of the intermediates. Before the reaction can even start, an 
ACP module loaded with one of the acyl intermediates (or in the case of this is the very 
first step of the synthesis, an acyl moiety) must enter the active site of KS through Given 
that the intermediate can be a very long hydrophobic chain, the interior of the KS, past 
the active site, forms a tunnel lined with apolar residues, which help accommodate the 
intermediate during the reaction. Once the substrate enters the KS domain, the reaction 
can then start. The first step is the transference of the intermediate from the PNS to the 
cysteine residue. This step is quite straightforward: the negatively charged cysteine 
residue attacks the carbon from the fatty acid intermediate that is connected to the 
Sulphur from PNS, which causes the C-S bond to break and a new bond between 
cysteine and the intermediate to form (Figure 54 – 1a). This in turn renders the ACP free 
to leave the active site and go to the MAT domain, where a new malonyl chain extender 
will be attached to its free end (Figure 54 - 1b). 
Afterwards, ACP travels back to the KS domain, where the PNS with the malonyl 
again enters the active site and the reaction is then able to proceed. In addition to the 
malonyl, a water molecule is also needed for the second step. The water is activated by 
a nearby residue, most likely one of the active site’s histidines, which functions as a base 
and abstracts a proton from the water, and its oxygen reacts with the terminal carbon 
from malonyl, forming bicarbonate (HCO3-), which dissociates from the rest of the 
substrate (Figure 54 - 2). A carbanion is formed in the meantime, and it is easily stabilized 
by the two active site histidines. 
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The final steps comprise the condensation per se. First, the carbanion attacks the 
carbon adjacent to the sulfur from the cysteine, forming a covalent bond between them 
(Figure 54 - 3). Subsequently this carbon dissociates from the cysteine (Figure 54 - 4) 
and what began as a saturated fatty acid intermediate has now grown in two more 
carbons and must endure other significant chemical reactions (two reductions and one 
dehydration) in order to become again a fully saturated moiety. 
 
 
Figure 54 – Proposed reaction mechanism for the KS subunit of FAS. 
 
At the end of all this steps, ACP detaches from KS and proceeds for the next FAS 
domain. To KS all that remains is to stay put until ACP arrives again with a new 
intermediate that needs to be condensed with one more malonyl molecule. 
As one can easily see, FAS is indeed one mysterious and peculiar enzyme. Not 
only are intermediates shifted around in a private carriage (ACP), but also all reactions 
are catalyzed by the same enzyme, in different domains. Such an enigmatic protein 
deserves to be further studied and understood. Still, in order to study all aspects of FAS, 
one must choose to start somewhere and so it was decided that it would start with the 
KS domain, more precisely, with the study of its reaction mechanism using computational 
methods.  
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7.2. Methods 
7.2.1. Making the Model 
The first step in almost any computational study of an enzymatic reaction is building 
a model of the object of study that is able to mimic the enzyme in the most accurate way 
possible. In order to achieve this, the tri-dimensional structure of the protein must be 
obtained. 
The PDB website was searched in order to find a good structure from which the 
KS model could be built. Since in a parallel work we had already modeled the substrate 
of KS in its active site, starting from the Sus scrofa (pig) FAS414, and based on the 
similarity that exists between the pig and human forms of the enzyme, it was decided to 
use the KS domain from pig FAS. Meanwhile we found that the human form of FAS was 
also available on PDB. However as we had already a validated enzyme:substrate 
complex of KS, we decided to continue the study with this model, keeping in mind the 
similarity between both forms. 
In order to build an accurate model for the study of the mechanism, the substrate 
had to be inserted in the active site. Given that the complete FAS structure is too big, 
and that the domains work independently from one another, it was decided that instead 
of using the complete structure, it was better to make a model of only the KS domain.  
Since the substrate was not present in the FAS PDB structure, it had to be added 
before to the beginning of the study of the mechanism. In order to achieve that we 
employed a docking procedure, using the VINA software415. The docking was made 
using a rigid protein and flexible substrate. As substrate we decided on using a 10 carbon 
fatty acid chain attached by the carboxylic group to the PPT. We decided on a larger 
chain than the initial substrate (acetyl) so that we could also check how it fit in the cavity 
after the active site. The box where the poses were generate comprised the residues 
from the active site as well as those that formed a tunnel which led the PPT moiety from 
the surface (where it should be bound to the ACP module) to the active site. 
After the docking procedure, we chose the pose with the best score to perform a 
MD simulations. We did a 10 ns MD simulation to see whether the substrate would stay 
in place or move away from the initial position. The protocol used for this simulation was 
similar to the one described in Chapter 6, section 6.2.1. The substrate used in the MD 
simulations was geometry-optimized and its electrostatic surface potential was derived 
at the HF/6-31G* level of theory. Then, it was parameterized with the GAFF force field52, 
and its atomic charges were derived using the RESP method56. 
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Figure 55 – Graphical representation of the RMSd values for the backbone of the model. The measurement is 
presented in Å. 
 
7.2.2. ONIOM Calculations 
The MD simulation showed that the substrate stayed practically in the same spot 
for the duration of the run. We calculated the RMSd for the whole enzyme and the 
substrate and concluded that after about 6 ns the enzyme was stabilized (Figure 55) and 
so was the substrate (in average its RMSd was below 2 Å). For the ONIOM model, we 
extracted a structure from the dynamics after the enzyme was stable and in which the 
substrate seemed in a favorable position for the reaction to occur. The substrate attached 
to PPT was cut so that only a molecule of acyl was in the active site. For the high layer, 
we selected residues His331 and His293, Cys161 and Ala160 from the active site and 
from the PPT-acyl we used all the acyl group, the sulfur atom and some other atoms 
following the sulfur (Figure 56). We did not include all of the PPT group because we 
found that its inclusion created some problems with the calculation and we thought it 
might not make a lot of difference in the final result. We used the link atom approach65, 
416-417 to saturate the valences that resulted from the truncation of bonds across the DFT 
and MM layers. The DFT layer was constituted by a total of 62 atoms and presented an 
overall charge of -1 and singlet spin multiplicity, while the overall model (total of 12233 
atoms) presented a total charge of -17.  
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Figure 56 – High layer of the ONIOM model. 
 
All calculations were performed with the ONIOM methodology and the electrostatic 
embedding scheme67, as implemented in the Gaussian09 package366. Throughout the 
calculations all atoms farther than 12 Å from the high layer were kept frozen. The 
B3LYP/6-31G(d):FF99SB level of theory was used for all geometry optimizations. 
Several works have shown that the 6-31G(d) basis is adequate for the purpose418. 
We performed relaxed geometry optimization calculations for all stationary points 
along the reaction coordinate. Nuclear vibrational frequencies revealed their nature (one 
imaginary frequency in the DFT layer for transition states, and no imaginary frequencies 
in the DFT layer for minima). 
 
7.3. Results: Step 1 
As of today, this work is still in its early stages, however, we have already finished 
the first step of the catalytic mechanism of the KS enzyme. 
FCUP 180 
New Therapeutic Strategies to Lower Blood Stream Cholesterol Levels through the Inhibition of HMG-CoA Reductase  
 
In the optimized geometry we observe that the –NH of both histidine is pointing 
towards the sulfur atom of the Cys161, which is deprotonated. In the proposed 
mechanism for KS, the sulfur (S1) from the cysteine is predicted to bind to the acyl group 
through the carbon (C1) through which it is connected to PPT. in order to test this 
hypothesis we shortened the distance from S1 of the cysteine to the C1 of the acyl group 
and scanned this reaction coordinate. 
We obtained a maximum of energy at the distance of 2.0 Å, and tested this 
geometry to assess whether or not it was a transition state by calculating the nuclear 
vibrational frequencies. This structure showed only one imaginary frequency (i74.5 cm-
1) which corresponded to a large motion of the C1 carbon of the acyl group towards the 
sulfur of Cys161.  
 
 
Figure 57 – Structure of the trastition state for the first step if the reaction, with distances between the significant 
atoms represented (in Å) 
 
Along the reaction coordinate, we could see that as C1 and S1 got closer, the 
distance between C1 and the sulfur of the PPT (S2) moiety began to lengthen. It was 
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also clear that His293 shifted its position to stabilize the increasing negative charge of 
S2 (distance changed from 4.7 Å to 2.7 Å). In the transition state, it is interesting to notice 
that the carbon from the acyl group is midway between both sulfurs (Figure 57) and that 
we have one histidine stabilizing each of the sulfurs as well. After this middle point, the 
bond between C1 and S2 is broken (distance is 4.1 Å in the minimized product), and a 
new bond between C1 and S1 is formed (1.8 Å). Both cysteines are now forming 
hydrogen bonds with the negative sulfur from the PPT moiety (distance from His293 to 
S2 is 2.4 Å and from His331 is 2.3 Å). 
The energy of activation for this step totals 3.26 kcal/mol, which means that the 
barrier is not very large. This is probably due to the fact that both histidines help with the 
stabilization of the negative charged sulfurs and allow for a good charge distribution 
which lower the barrier. The fact that the S1 from the cysteine was deprotonated also 
aids with the attack to the C1 carbon. The reaction is exothermic (-6.46 kcal/mol) which 
means it is favorable (Figure 58). 
 
 
Figure 58 – The first step of the mechanism of the KS module (with representation of the transition state) 
 
7.4. Conclusions 
As of now, we still have a long way to go in order finish this work. We have currently 
completed the first step of the KS module of the FAS enzyme. It comprises the attack of 
the sulfur from Cys161 on the carbon of the acyl group which is connected to the sulfur 
of PPT. This step is rather straightforward and is processed according to the proposed 
mechanism of reaction for KS. While the acyl group travel from the PPT to the Cys161, 
histidines 293 and 331 also stabilize the negative charge of the sulfur atoms. In the 
reactant this negative charge is centered of S1 and both histidines have their hydrogens 
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facing this sulfur, forming two hydrogen bridges. In the transition state, however, the 
charge is distributed equally among both sulfurs, and so we have one histidine binding 
each sulfur. As for the intermediate, both histidines are now binding the same sulfur (from 
PPT) through a hydrogen bridge, since now the negative charge is more centered on 
this atom. The reaction is exothermic and it activation energy is -3.26 kcal/mol. 
For future work we would like to finish this interesting mechanism and complete 
the other steps. The second step is currently underway, and showing promising results 
as well. We had, however, to build a new model based on the intermediary of the first 
step, in which we now have in the active site Cys161 bound to the acyl group and new 
malonyl moiety bound to PPT. 
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